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SUMMARY
Recently it was demonstrated that a number of proteins contain short peptide 
regions allowing the apparent free-movement of these proteins through cell 
membranes. In addition when fused as a chimera with other cargo proteins these 
peptides confer on them the ability to translocate into cells. These peptides have 
been termed protein transduction domains (PTDs), or membrane translocating 
peptides (MTPs).
The ability to deliver active gene products to cells rather than the genes 
themselves offers an attractive alternative to gene therapy approaches, bypassing 
the complications associated with the delivery of oligonucleotides to cells. 
However, with a number of PTDs identified, and the possibility of more being 
isolated in the future, it is necessary to undertake comparative quantification of 
the transduction potential of the sequences to determine those with the most 
favourable delivery attributes, allowing focused research on the lead candidates.
In this study three approaches to quantify protein transduction were explored 
using three different proteins as reporters; the green fluorescent protein (GFP), 
luciferase, and a pro-less variant of caspase-3, PLCasp3. Two peptide sequences, 
the HIV Tat PTD and the penetratin sequence from the Drosophila antennapedia 
protein, and one full length protein, the herpes simplex virus type 1 VP22 protein, 
previously reported to demonstrate protein transduction were used as test MTPs. 
A transfection protocol with de novo synthesis of MTP fusion protein was 
adopted for each approach, eliminating additional procedures associated with 
application of exogenously expressed recombinant proteins.
Confirmation of protein transduction was unsuccessful though three alternative 
methods for visualising protein transduction of MTP-GFP fusion proteins were 
employed. Vectors enabling production of MTP-luciferase fusion proteins were 
generated, it was not possible to develop a system by which separation of 
transfected, expressing cells from non-expressing cells could be accomplished. A 
system enabling potential quantification of protein transduction was developed for 
the PLCasp3 approach, but confirmation of transduction by this method was not
possible as a result of mutations in the DNA sequence arising during generation 
of the expression vectors.
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The development of methods by which genes can be delivered to mammalian 
cells has stimulated great interest in the potential to treat human diseases by 
gene-based therapies. Gene therapy can be described as the introduction of 
nucleic acids into cells for the purpose of altering the course of a medical 
condition or disease. The concept is based on the assumption that definitive 
treatment of genetic diseases should be possible by directing treatment to the 
site of the defect itself, the mutant gene, rather than to secondary effects of the 
mutant gene products. The research reported here focuses on the delivery of 
active gene products to cells, rather than the genes themselves, an approach that 
bypasses the requirement for delivery of oligonucleotides to cells. The vectors 
investigated for the protein delivery were peptide sequences with a reported 
ability to cross cell membranes and enter cells. To demonstrate why such a 
method may be preferable to treatment through gene therapy, a number of the 
underlying problems associated with the delivery of genetic material to cells are 
outlined below.
1.1 The Promise of Gene Therapy
Great promise was held for the use of gene therapy in the treatment of disease 
when trials were initiated in September 1990 (Blaese et al., 1995), but successful 
therapeutic rates and progress have been disappointingly slow due to a number 
of complications that currently limit the effectiveness of gene therapy 
approaches. In an attempt to overcome these complications alternative methods 
for the treatment of a number of diseases have been explored.
1.1.1 Viral Delivery of Oligonucleotides
There is an inherent obstacle that must be overcome in order for gene therapy 
approaches to succeed: evolution over many millennia has led to cells and 
organisms developing powerful mechanisms to protect themselves from the 
onslaught of environmental hazards, including the development of systems to 
avoid the accumulation of extraneous genetic material (Bestor and Tycko,
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1996). However, advancement of these defence systems has necessitated co­
evolution of entities whose survival is dependant on incorporation of their DNA 
into host genomes, resulting in generation of equally powerful counter­
measures. Viruses have been particularly successful in overcoming these 
barriers, and, with the hope of capitalising on this, initial efforts at gene therapy 
were directed towards engineering viruses. There are four main types of 
problem associated with viral-based approaches: obtaining efficient delivery, 
transduction of DNA into quiescent or senescent cells, improving gene 
expression, and manufacturing the vector.
1.1.1.1 Efficient Delivery
When using retrovirus delivery vectors, there are a large number of cells from a 
broad range of cell types expressing cell surface viral receptors. This not only 
limits the target specificity of the system, but also limits the effectiveness of 
delivery. This is in large part due to the relatively low titre at which the 
retrovirus vectors can be generated, and the subsequent limit of particles 
delivered in a suitable dose volume. For example, at a titre of 10 colony- 
forming units (CFU) per millilitre (the maximum for amphotropic vectors such 
as murine leukaemia virus) a delivery volume of 100 ml will result in 
application of only 109 CFU. With around 5 x 1013 cells in the human body, 
even at a delivery efficiency of 100% only 1 in 50,000 cells will be targeted 
(Anderson, 1998).
There are approaches that can be adopted in an attempt to improve target cell 
specificity, increasing delivery efficiency. Altering the natural receptor-binding 
domain on the surface of the delivery particle to a domain that interacts with a 
target cell-specific receptor would increase association with that receptor. 
However, in instigating this change the whole structure of the envelope protein 
is altered, which can prevent fusion of the particles with cells, subsequent core 
entry into the cell, and delivery of the genetic cargo to the cells is unacceptably 
low as a result. An alternative approach is to direct the vector particles to a 
region surrounding target cells, increasing the concentration of retrovirus in the 
local environment of the cells. This can be achieved by inserting a ligand that 
recognises the extracellular matrix local to target cells (fibronectin or collagen
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for example) into a part of the surface protein that does not interfere in the 
natural receptor-binding domain, leaving the viral cell-fusion mechanism 
unaffected.
1.1.1.2 Transduction o f Non-Dividing Cells
Retroviruses are efficient at transduction into cells in culture. However, most 
cells in vivo are quiescent at any point in time, making the vector less useful for 
in vivo therapies, unless the cells in the target organ are stimulated to progress 
through the cell cycle. By using alternative viral vectors, such as lentiviruses 
(e.g. human immunodeficiency virus, HIV), non-dividing cells can be 
successfully infected. Safety concerns are raised, however, by the possibility 
that the vectors could undergo recombination with endogenous human viruses 
and produce a pathogenic virus strain. The likelihood of such an occurrence can 
be limited through the use of hybrid systems. It is possible to use just 22% of the 
HIV genome in a retroviral vector, with all genes responsible for pathogenicity 
removed (Kafri et al., 1997; Zufferey et al., 1997). Use of a non-HIV envelope 
reduces the chances of recombination further still.
1.1.1.3 Improving Gene Expression
If the problems associated with transducing target cells can be overcome the 
challenge of gene expression remains, and it is this that is probably the greatest 
shortcoming of current vectors (Miller and Whelan, 1997). The best approach 
to expressing a gene is to use the cell’s own c/s-regulatory DNA sequence to 
provide stable, long-term expression. However, identifying all of the 
components of a gene’s regulatory system can be difficult, predominantly due to 
the size of the sequence the regulatory elements are spread over (about 100 Kb 
in the case of haemoglobin (p-globin gene)). Coupled with the fact that 
retrovirus vectors can contain only about 6-8 Kb of inserted sequence, 
alternative promoters have been used in place. These include the viral 
promoters from Simian virus 40 (SV40) and the cytomegalovirus (CMV). 
Unfortunately, one self-defence mechanism used by cells is to recognise foreign 
promoters and inactivate them through methylation or some other means 
(reviewed in Antequera et al., 1989, and Hendrich and Bird, 1998). Even where 
the gene remains active the immune system will recognise the therapeutic gene
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product as foreign and eliminate the transgene product and the cells producing 
it. This is the case even where the product is a ‘normal’ protein, as the immune 
system will not have been exposed to it previously causing it to appear foreign.
The site of integration of the transgene into the target cells’ genome, which will 
result in the sustained expression of the gene product, can also be problematic. 
The vector might insert itself into the genome at the site of a tumour suppressor 
gene, thereby increasing the propensity of the cell to become cancerous. 
Insertion of the transgene at different loci on the genome of cells within a target 
organ will have an effect on the level of expression within the transduced 
population, as the location of genes within the genome can affect their activity 
(Lercher et al., 2002).
Even when these obstacles have been overcome, regulation of the expression 
remains an issue. Many of the primary target genes for treatment through gene 
therapy are not expressed at the same level all of the time, but rather respond to 
physiological stimuli within the body (insulin, for example). It may not be 
necessary for the transduced cells to respond to such signals, but if this is the 
case, regulation must be provided by some other means, such as the 
administration of a drug to control the level of gene activity.
1.1.1.4 Manufacturing the Vector
It is necessary to use a biological system to produce the viral vectors. There are 
always quality control issues when using such systems for the obvious reason of 
natural variation. Such systems will also invariably give a low yield of product. 
However, there are other problems specifically associated with the production of 
viral vectors for use in gene therapy.
Retroviral vectors are produced in packaging cells that contain a packaging- 
defective viral genome, and because retroviruses have a high propensity for 
recombination, there is the possibility that a replication-competent retrovirus 
(RCR) could arise during the manufacturing process. This complication is 
compounded as every mammalian cell contains endogenous retroviruses. 
Incorporation of additional viral sequences into a RCR could replace those viral
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elements removed in the generation of the vector, resulting in the formation of a 
pathogenic virus (Anderson et al., 1993b).
The organism of choice for manufacturing of vectors also needs to be 
considered. For example, mouse packaging cells produce retroviral vectors that 
are destroyed by human complement. Though this does make the vector 
particles ‘safer’, it does substantially reduce their half-life in vivo, and 
subsequently the delivery efficiency.
1.1.2 Oligonucleotide Delivery by Liposomes
Other, non-viral gene therapy approaches have been examined, in particular the 
use of cationic lipid-based delivery systems. These have a number of 
advantages over viral delivery systems: complexes are easy to prepare and there 
is no limit to the size of DNA molecule packaged. As there are no proteins 
involved there is less of an immune response evoked upon their administration. 
The genes delivered have low integration frequency and so cannot replicate or 
recombine, resulting in much less risk of generating an infectious form, or 
inducing tumourigenic mutations. A low integration frequency, however, means 
that sustained expression of the gene product is unlikely, and activity will 
decrease, probably as a result of degradation of the transgene. Another obstacle 
with such an approach is that, even though the complexes are easy to prepare, it 
is technically difficult to prepare the DNA/lipid complexes at concentrations 
where the injection volume into the animals is not too large, and large 
aggregates will not form.
1.2 Protein Therapy
Many of the obstacles discussed above result from specific aspects of the 
desired outcome, namely the sustained and regulated expression of the 
transgene. For a number of genetic disorders, including enzyme deficiencies or 
diseases such as cystic fibrosis and Duchenne’s muscular dystrophy, such long­
term and appropriately controlled expression is an absolute requirement. 
However, there are circumstances where such stringent criteria do not have to be 
met. A gene therapy approach for the treatment of cancer, for example, would 
result either in the direct induction of tumour cell death, or the induction or
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enhancement of an immune-mediated response to the tumour. With the 
eradication of the tumour the requirement for the therapeutic gene product also 
ends. This short term requirement for the presence of a therapeutic gene product 
raises the possibility of achieving the same objective by the direct delivery of an 
active gene product itself, rather than the transgene; protein therapy. Using this 
approach, a number of the previously described complications associated with 
the administration of oligonucleotides to a patient can be circumvented.
1.2.1 Protein Delivery Methods
Proteins are generally unstable, have high molecular weights and are large in 
size, are hydrophilic and have low permeability. This makes delivery of 
polypeptides into the cytoplasmic and/or nuclear compartments of living cells 
without disrupting the plasma membrane and compromising a cell’s integrity a 
significant obstacle. A number of approaches have been investigated whereby 
delivery of gene products to cells can be achieved. The successful introduction 
of these macromolecules into cells depends largely on the development of a 
delivery system that can overcome the limited chemical and physical stability 
associated with proteins, making them susceptible to proteolysis, chemical 
modification and denaturation (Cleland et al., 1993; Manning et al., 1989). 
Furthermore proteins usually have short half-lives in body fluids (Anderson and 
Sorenson, 1994).
Encapsulation of proteins within a protective barrier has been adopted to prevent 
premature degradation of the therapeutic molecule. Incorporation of cargo 
protein into polymer matrices, forming structures known as microspheres, is a 
popular approach for delivery where prolonged release of the therapeutic agent 
is required (recently reviewed in Sinha and Trehan, 2003). In addition to the 
delivery of oligonucleotides in gene therapy approaches, the use of small lipid 
vesicles, known as liposomes, is already widely used as a drug delivery system 
(Chonn and Cullis, 1995; Gregoriadis, 1995; Lasic, 1998). For protein delivery 
such a delivery vector is attractive as the encapsulated proteins are able to 
remain in their preferred aqueous environment within the vesicles while the 
liposomal membrane protects them against proteolysis and other destabilising 
factors. Liposomal preparations complexed with DNA vectors are regularly
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used to transfect cells in culture, demonstrating their ability to convey cargo to 
the cytosol. This approach has been used by a number of groups to deliver 
proteins to both cultured cells and the cells in vivo (Chonn and Cullis, 1995; 
Lidgate et al., 1988; Ramjeesingh et al., 1998). Similarly, liposomes formed 
from cationic phospholipids have been used the deliver protein to cells in vitro 
(Debs et al., 1990; Sells et al., 1995) and in vivo (Guillaume et al., 2000). With 
these approaches, however, formation of the protein transfection complexes 
gives rise to a number of challenges. Interactions between the encapsulating 
‘coat’ and the cargo protein will vary with the electrochemical nature of the 
cargo. The formation of each delivery complex will, therefore, have to be 
optimised for each cargo molecule. Similarly the fabrication process of the 
delivery systems may damage the proteins, due to their relatively fragile nature, 
reducing the biological activity within a sample.
Recent developments suggest that an alternative approach may address these 
problems - the use of “protein transduction”. In this method full-length fusion 
proteins are generated that contain the transgene product and one of a number of 
peptide sequences from the membrane translocating peptide (MTP) family. 
These peptides have the unusual ability to enter cells freely, independent of 
receptors and transporters (Derossi et al., 1996; Derossi et al., 1994; Elliott and 
O'Hare, 1997; Mann and Frankel, 1991; Vives et al., 1997a). In this way the 
MTP is able to transport the therapeutic peptide across cell membranes and 
deliver it to the cytoplasm or nucleus where it is able to exhibit its biological 
effect (see Leifert and Whitton, 2003, for review). Where a gene therapy 
approach may be a more feasible option, due to long-term expression 
requirements, the importance of this technology is still evident. By generating a 
chimeric gene containing the protein of choice fused in frame to an MTP 
distribution of the gene product following expression in cells could be 
improved. This may go some way to overcoming problems associated with poor 
delivery efficiencies associated with DNA therapy approaches as discussed 
above.
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1.2.2 Membrane Translocating Peptides and Protein Transduction
Over a decade ago, two research groups independently showed that the human 
immunodeficiency virus (HIV) Tat protein could enter cells when added to the 
culture media and retain its /raws-activating ability (Frankel and Pabo, 1988), 
(Green and Loewenstein, 1988). Unlike growth factors or steroid hormones 
there appeared to be no receptor for this process, and there was no transient pore 
formed as occurs with some toxins. Since these initial observations a number of 
other proteins with this same unusual property of apparent energy-free cellular 
uptake have been identified (see Hawiger, 1999, and Lindgren et al., 2000, for 
reviews). The translocating abilities of the proteins HIV Tat, Drosophila 
antennapedia, and Herpes Simplex Virus type I (HSV-1) VP22 are the most 
widely studied of the cell permeable peptides and will be discussed in more 
depth presently.
The ability to freely enter cells is termed membrane translocation, and a protein 
capable of such an action is termed a cell permeable protein (CPP) or a 
membrane translocating peptide (MTP). Very little is known about the 
mechanism by which MTPs are able to target and to traverse lipid membranes. 
However, studies on proteins with such translocating properties have led authors 
to suggest that the mechanism of uptake does not appear to occur through 
classical receptor-, transporter-, endosome- or adsorptive-endocytosis-mediated 
processes (Derossi et al., 1996; Derossi et al., 1994; Elliott and O'Hare, 1997; 
Mann and Frankel, 1991; Vives et al., 1997a). There has, however, been 
controversy and disagreement in the field, and only recently is a consensus 
emerging. These issues are discussed in more detail below.
For antennapedia and HIV Tat short regions of the proteins, numbering only 11- 
16 amino acids in length, have been shown to be sufficient for membrane 
translocation; these sequences confer the translocation ability to the full length 
protein (Derossi et al., 1994; Schwarze et al., 1999; Vives et al., 1997a) (see 
table 1.1). The regions have been termed minimal protein transduction domains 
(PTDs), and these regions in the antennapedia protein and the Tat protein have 
been called penetratin and the Tat PTD, or TAT, respectively (Becker-Hapak et
al., 2001; Derossi et al., 1994; Schwarze et al., 1999). For VP22 the majority of 
the publications have used the full-length protein. Those that have used 
truncated peptide sequences derived from the full-length protein have focused 
on the C-terminus using peptides of varying lengths, which also exhibit the same 
translocatory attributes of VP22. These studies demonstrated that deletion of 
the 34 C-terminal amino-acids of VP22 is sufficient to abrogate the 
translocatory activity (Elliott and O'Hare, 1997). Therefore, by deduction, this 
domain can tentatively be termed a PTD, though no reports have been published 
to date using this short sequence alone (see table 1.1). Fusions of an MTP or 
PTD with other peptide or protein sequences can be achieved by chemical 
means, or by the preparation of a vector containing a cDNA sequence coding for 
the fusion protein. Work with such fusion proteins has demonstrated that VP22, 
the antennapedia homeodomain, and the Tat PTD, at least, are able to transport 
large cargoes (e.g. transport of the 116 kDa enzyme P-galactosidase) from an 
extracellular environment to the cytoplasm of cells, even targeting them to the 
nucleus, whilst the cargoes retained their biological activity ((Schwarze et al., 
2000; Watson and Edwards, 1999) for reviews).
MTP Amino Acid Sequence





Table 1.1. Amino acid sequences of the MTPs. The amino acid sequences of 
the MTPs used for the investigation. * Sequence for the test peptide, Drome, t  
The putative PTD of VP22 derived from results that analogues lacking the C- 
terminal 34 residues fail to translocate (Elliott and O'Hare, 1997).
Recently, intraperitoneal injection of Tat PTD peptide labelled with fluorescein 
into mice resulted in the delivery of significant amounts of fluorescein to all 
tissues examined by confocal microscopy, including the brain (Rousselle et al.,
2000). This highlights the potential of PTDs to deliver small molecules,
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previously with no bioavailability, to tissues in vivo. A potential application 
would be to deliver therapeutic chemicals, such as anticancer agents, through the 
blood-brain barrier (BBB) for the treatment of tumours in the brain, an area that 
drugs have a very limited access to, resulting in the failure of brain tumour 
chemotherapy. A report on the delivery of doxorubicin, an antineoplastic agent 
widely used in the treatment of several cancers, through the BBB by a peptide 
vector-mediated mechanism is very encouraging (Rousselle et al., 2000). In 
addition, work by Dowdy and his colleagues also showed that the intraperitoneal 
injection of a fusion protein of p-galactosidase (P-gal) with the Tat PTD in mice 
resulted in readily detectable p-gal enzymic activity in all tissues assayed, again 
including the brain (Schwarze et al., 1999). The delivery of an active enzyme 
into such an organism holds a tremendous amount of potential for protein 
therapy.
1.2.2.1 The HIV Tat Protein Transduction Domain
In addition to the traditional retroviral structural proteins gag, pol and env, 
human immunodeficiency virus type-1 (HIV-1), the cause of AIDS, encodes at 
least five novel proteins that appear to serve regulatory functions. One of these, 
the HIV-1 trans-activator gene, encodes Tat. The Tat protein £ra«s-activates 
genes that are expressed from the HIV long terminal repeat (LTR) (Sodroski et 
al., 1985b) and Tat is essential for viral replication in vitro (Fisher et al., 1986). 
Tat is an 86 amino acid protein made from two exons of 72 and 14 amino acids, 
respectively. The N-terminal 72 amino acids, coded for by the first exon, are 
sufficient and necessary for full Tat activity (Mann and Frankel, 1991). This 
region contains a cysteine-rich region (with seven cysteines in 16 residues) 
(Arya et al., 1985; Sodroski et al., 1985a) that is important for metal-linked 
dimerisation in vitro (Frankel and Pabo, 1988), and a highly basic region (with 2 
lysines and 6 arginines in 9 residues), which is involved in nuclear localisation 
(Dang and Lee, 1989). In 1988, independent studies using bacterially expressed 
(Frankel and Pabo, 1988) and chemically synthesised (Green and Loewenstein,
1988) Tat protein, respectively, showed that Tat, when added exogenously in 
culture, was taken up rapidly by cells. Through analysis of mutant Tat peptides
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this protein transduction property was also shown to reside in the region 
encoded by the first exon, in amino acids 37-72 (Frankel and Pabo, 1988).
Since these initial observations much work has focused on the transduction 
property of Tat. In 1991, Mann and Frankel demonstrated that the domain 
encompassing amino acids 38-58 (the basic domain of Tat) retained the 
transduction capability, enabling both its nuclear and cytoplasmic accumulation 
(Mann and Frankel, 1991). A truncated version of the Tat protein, residues 35- 
62, was first found to be capable of transporting an antibody fragment into 
tumour cells in 1993 (Anderson et al., 1993a). A year later studies by Fawell 
and his colleagues demonstrated that a number of large molecules were taken up 
by cells in vitro when they were chemically cross-linked to either the amino 
acids encoded on the first exon, or by the residues 37-72 alone (Fawell et al., 
1994). Using a p-galactosidase-Tat model they went on to show that uptake 
took place in vivo following intravenous injection of the chimeric protein in 
mice. Enzyme activity was found in most major tissues only 20 minutes after 
injection, though the protein was almost absent from the brain.
Work by Dowdy and his colleagues investigated Tat-mediated delivery by 
constructing fusion proteins between several polypeptides and proteins and a 
short region of Tat, residues 47-57 (Ezhevsky et al., 1997; Schwarze et al., 
1999; Vocero-Akbani et al., 1999). This work culminated in success after 
undertaking similar in vivo experiments to Fawell et al. The group demonstrated 
the presence of P-galactosidase activity in several tissues 4 hours after 
intraperitoneal injection of the fusion protein into mice. In contrast with the 
earlier work, however, P-gal activity was also detected in the brain, though the 
blood-brain-barrier remained intact as demonstrated by Evans’ blue exclusion 
test (Schwarze et al., 1999). This peptide has been determined as the minimal 
transduction domain of HIV Tat, and has been termed the Tat protein 
transduction domain (Tat PTD) (Schwarze et al., 1999), or TAT (Becker-Hapak 
et al., 2001) (see table 1).
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Though there is much evidence for the uptake of Tat and its peptide derivatives, 
very little is known of the mechanism by which membrane translocation occurs. 
Physicochemical studies involving circular dichroism and energy minimisation 
on the Tat sequence including residues 38-60 indicated that this domain adopted 
a a-helical structure under certain conditions. The residues 38-45 within this 
region had a helix with amphipathic characteristics. The region encompassing 
the basic sequence 49-57 was unstructured under the same conditions (Loret et 
al., 1991). Biological data and physiochemical studies at this time were in 
keeping with a a-helix forming domain crucial in Tat uptake. A detailed study 
by Vives and his colleagues in 1997 demonstrated that a shorter peptide still, 
encompassing only residues 48-60, which appears unstructured in solution, 
rapidly translocated through the plasma membrane and accumulated in the 
nucleus (Vives et al., 1997a). In undertaking this work it was also revealed that 
the region covering the Tat- (38-49) domain did not appear to be required for 
efficient and fast cell uptake, abrogating the role of an amphipathic helix in the 
translocation of Tat and its associated peptides.
Recent molecular modelling studies using protein structure and molecular 
surface predictive programs on the region of HIV Tat encompassing amino acids 
47-57 revealed the structure to be that of a strong amphipathic helix (Ho et al.,
2001). The structure of the Tat PTD, and its relative importance in membrane 
translocation, remains a matter for debate. However, a physicochemical 
property of this region that does appear to be of importance is the presence of 
the eight positive charges, six arginine and two lysine residues, within the short 
amino acids regions studied by either the Lebleu group, residues 48-60 (Vives et 
al., 1997a), or the Dowdy group, residues 47-57 (Schwarze et al., 1999). 
Studies have revealed a significant reduction in the membrane penetration 
ability when these positive residues are removed sequentially from either 
terminus (Vives et al., 1997b; Wender et al., 2000). Results from these studies 
indicate that at least seven positive charges are necessary for high efficiency 
delivery properties (Vives et al., 1997a), with a decrease in translocation ability 
of 50% and 75% following removal of one or two arginine residues, respectively 
(Wender et al., 2000).
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It therefore appears that the Tat fragment encompassing the highly basic 
residues 49-57 alone may be responsible for the translocatory attributes 
exhibited by the peptides derived from Tat. Due to the transduction successes 
experienced by a number of groups in vitro and in vivo using the 11 amino acid 
sequence corresponding to the Tat PTD (Chen et al., 1999; Ezhevsky et al., 
1997; Gius et al., 1999; Kim et al., 1997; Schwarze et al., 1999; Vocero-Akbani 
et al., 1999) it was this sequence that was selected to represent the Tat-derived 
peptides in this study. Since the start of this investigation a number of report 
citing transduction by the Tat PTD have been published (Eum et al., 2002; 
Gustafsson et al., 2002; Harada et al., 2002; Li et al., 2002; Nori et al., 2003; 
Ribeiro et al., 2003; Shibagaki and Udey, 2003; Tasciotti et al., 2003; Xia et al., 
2001).
1.2.2.2 The Antennapedia Peptide, Penetratin
The antennapedia protein is a member of the Drosophila homeoprotein family. 
Homeoproteins belong to a class of £raws-activating factors, first discovered in 
Drosophila, involved in several important biological processes occurring 
primarily, but not exclusively, during development (Gehring, 1987). The 
regulatory effect of homeotic proteins on genes depends on the proteins 
recognising and binding to consensus DNA sequences found in the promoter or 
enhancers of the genes through a highly conserved 60 amino acid C-terminal 
region (Biggin and Tjian, 1989). This region, the homeodomain, is structured in 
three a-helices with one p-tum between helices two and three (Qian et al.,
1989).
In 1991, Joliot et al. reported that the 60 amino acid homeodomain of the 
antennapedia protein was able to enter nerve cells in culture when added to the 
culture media and to accumulate in the cells’ nuclei. The internalised 
homeodomain remained capable of exerting biological effects on cultured 
neurons, resulting in morphological differentiation of the nerve cells. Studies at 
37 °C and 4 °C showed this internalisation did not appear to involve classical 
receptor-mediated endocytosis (Joliot et al., 1991a), though there did appear to
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be involvement of a polysialic acid on the neuronal surface (Joliot et al., 1991b). 
The influence on neuronal morphology, but not on cellular internalisation, was 
disrupted by generation of a mutant peptide with abolished DNA-binding 
properties (Bloch-Gallego et al., 1993). The mutation corresponded to a 
replacement of two residues with two proline residues (leucine 40 and threonine 
41) within the turn between helices 2 and 3, which established that this region 
did not affect translocation of the homeodomain.
Subsequent work demonstrated that the homeodomain was capable of mediating 
the internalisation of foreign polypeptides, in the form of chimeras, and that it 
would convey such cargo to the nuclei of the cells (Perez et al., 1992). The 
region of the peptide responsible for its internalisation has been mapped to its 
third helix (residues 42 to 58) through studies using site directed mutagenesis 
(Le Roux et al., 1993). This finding has enabled work to establish that a 16 
amino acid long peptide (see table 1) translocates at 37 °C and 4 °C across 
biological membranes, reaches the cytoplasm, and is eventually conveyed to the 
nucleus of cells in culture (Derossi et al., 1994). This peptide is known as 
penetratin.
Internalisation studies have been undertaken using a synthetic peptide with a 
primary sequence identical to penetratin but entirely composed of D- 
enantiomers, and with a second where the order of the residues had been 
reversed (Derossi et al., 1996). Both peptides were efficiently internalised by 
cells in culture demonstrating that this process does not require specific 
interactions with a chiral receptor (binding site or transporter). This finding was 
reinforced by the use of a retro-inverso analogue of the same sequence, which 
was internalised with a greater efficiency than the other forms. This increased 
efficiency was probably due to protection from degradation within the cultured 
neurons used for the investigation, as the native sequence contained two sites 
sensitive to neuronal endoproteases (Brugidou et al., 1995).
There have been a number of physicochemical studies undertaken on penetratin 
to evaluate the importance of physicochemical parameters on its cellular uptake, 
and to discern a possible mechanism for membrane translocation. The structure
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of the penetratin region within the homeodomain of antennapedia had 
previously been shown to be that of an a-helix (Qian et al., 1989). However, 
studies of the penetratin sequence in isolation have shown that the nature of the 
medium in which the studies were performed could have a profound effect on 
the conformation adopted (Berlose et al., 1996; Drin et al., 2001; Lindberg and 
Graslund, 2001; Magzoub et al., 2002; Magzoub et al., 2001). It appears that 
the peptide adopts a mainly random coil structure when in an aqueous 
environment, with distinct secondary structures forming only when the peptide 
encounters a hydrophobic medium or synthetic membranes of phospholipids or 
SDS (Berlose et al., 1996; Magzoub et al., 2001). Though a-helical structures 
have been determined through spectroscopic data collected (Berlose et al., 1996; 
Drin et al., 2001; Lindberg and Graslund, 2001) it has been shown that 
penetratin analogues incapable of forming such structures, due to replacement of 
a number of residues with proline residues, are still capable of efficient 
translocation across cell membranes (Derossi et al., 1994). Studies where 
helical structures have been observed have utilised SDS micelles as a membrane 
mimetic, and as such any secondary structures should be extrapolated with 
caution. As membrane models phospholipids are far more realistic, and 
investigations using such negatively charged vesicles have shown penetratin to 
adopt predominantly P-sheet-like structures (Magzoub et al., 2002; Magzoub et 
al., 2001). Common to these and other studies is the finding that it is association 
with the membrane that is important for peptide uptake (Thoren et al., 2000). 
Though the helical amphipathicity may influence binding to some phospholipid 
bilayers it does not appear important for cellular uptake of penetratin (Drin et 
al., 2001). The uptake does, however, require a minimal hydrophobicity and net 
charge (Derossi et al., 1994; Drin et al., 2001), and it may be that affinity of the 
peptide for plasma membranes is the determining factor for cell internalisation.
Though all homeoproteins and homeodomains tested so far are internalised 
(Chatelin et al., 1996), penetratin was used during the course of these 
experiments due to the encouraging results of work previously undertaken on 
this short peptide’s translocating and transduction capabilities (Chen et al., 
1999; Derossi et al., 1996; Derossi et al., 1994). A mutated form of penetratin
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described by Derossi et a l to no longer translocate (W6F, WMF) was also used 
as a control (Derossi et al., 1998).
1.2.2.3 Herpes Simplex Virus Type I  VP22 Protein
VP22 is a 38 kDa, 301 residue protein encoded by the U l49 gene of the herpes 
simplex virus type I (HSV-1) (Elliott and Meredith, 1992), which is expressed 
late in infection (Hall et al., 1982). It is a structural protein forming the major 
component of the nine or more gene products that make up the virus tegument; 
an amorphous region, located between the virion capsid and envelope 
(Pomeranz and Blaho, 1999). VP22 is subject to a large number of post- 
translational modifications including phosphorylation (Elliott et al., 1996) and 
nucleotidylation (Blaho et al., 1994). The localisation of VP22 in infected cells 
changes over the course of HSV-1 infection (Pomeranz and Blaho, 1999). It 
appears that phosphorylation of VP22 during infection cycle progression is 
responsible for translocation from a predominantly cytoplasmic distribution 
early in infection to predominantly nuclear late in infection (Pomeranz and 
Blaho, 1999).
VP22 is exported from cells in which it is synthesised, despite the absence of an 
export signal, by a Golgi-independent mechanism (Elliott and O'Hare, 1997) 
termed non-classical secretion (Kuchler, 1993). In 1997 Elliott and O’Hare 
demonstrated that, upon export, VP22 is able to re-enter surrounding cells with 
high efficiency, where it is targeted to the nucleus, despite lacking a nuclear 
localisation signal (although portions of the protein are highly basic), binds to 
chromatin and segregates to daughter cells (Elliott and O'Hare, 1997). Further 
investigation by this group suggested that this movement of VP22 between cells 
may involve actin microfilaments (Elliott and O'Hare, 1998).
A number of possible roles for VP22 have been proposed. Its ability to co- 
localise with microtubules (Elliott and O'Hare, 1998) and to bind to other 
tegument proteins and direct their localisation (Elliott et al., 1995) suggests that 
VP22 has the ability to redirect both cellular and viral proteins and may play a 
role in the modification of microtubule morphologies (Elliott and O'Hare, 1998). 
An additional study to determine the domain within VP22 responsible for
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microtubule interaction has proposed a model for a bundling of microtubules 
that relies upon cross-linking of VP22 molecules across the space between two 
filaments (Martin et al., 2002). An alternative role suggested for VP22 relies on 
its ability to translocate between cells. By travelling from a newly infected cell 
to uninfected neighbouring cells VP22 may be able to alter cellular functions, 
thereby setting the cells up for subsequent infection (Elliott and O'Hare, 1997; 
Hawiger, 1999). Indeed, Sciortino et al. have shown that VP22 is capable of 
binding to mRNA from HSV-1 infected cells and that this bound RNA is 
delivered to neighbouring cells where it is subsequently translated (Sciortino et 
al., 2002). The delivery of a small number of mRNAs from infected cells to 
uninfected cells in the vicinity would allow the translation of proteins that 
favour viral replication and spread.
In addition to demonstrating the remarkable property of intercellular transport 
exhibited by VP22, Elliott and O’Hare also determined that VP22 was capable 
of transporting other proteins, in the form of fusion proteins, both after 
endogenous synthesis or exogenous application (Elliott and O'Hare, 1997). 
Numerous studies have since confirmed that VP22 is able to ferry large 
covalently linked heterologous protein sequences out of expressing cells and 
into various non-expressing cells. The tumour suppresser protein p53 was 
successfully spread throughout a population of cells when expressed as either a 
C- or N-terminal fusion with VP22 (Phelan et al., 1998). Furthermore, the p53 
fusion proteins retained wild type p53 function and were able to induce 
widespread cytotoxicity in a p53-negative human osteocarcoma cell line. 
Similar demonstrations have been carried out with GFP (Aints et al., 1999; 
Brewis et al., 2000; Elliott and O'Hare, 1999a; Elliott and O'Hare, 1999b; Lai et 
al., 2000; Wybranietz et al., 1999), and HSV-1 thymidine kinase (Dilber et al., 
1999; Liu et al., 2001).
In contrast to the HIV PTD and penetratin it is the full length VP22 gene product 
that is favoured for protein transduction experiments. As a result the approach 
normally employed when working with VP22 fusion proteins is the indirect 
transduction of proteins into cells. This is achieved by first transfecting a 
population of cells with an expression vector in which the cDNA coding for a
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protein is genetically fused to VP22. The transducable fusion protein is made 
by the cellular machinery and is transported from the primary transfected cells 
into the surrounding cells (for an overview of this approach see (Schwarze et al., 
2000)).
There has been some effort towards discerning the region(s) of VP22 that is 
(are) responsible for the translocation function of the protein, with conflicting 
results reported. In the study by Elliott and O’Hare where intercellular 
trafficking of VP22 was initially demonstrated, a VP22 mutant lacking 34 
residues from the C-terminus was shown to localise only in a filamentous 
pattern in transfected cells (Elliott and O'Hare, 1997). As no nuclear 
localisation pattern was observed, the factor used for determination of 
translocation of from transfected cells, this mutant was concluded to lack 
trafficking ability, see table 1. The importance of the C-terminus was confirmed 
in a later study using a C-terminal fragment of VP22 consisting of 143 residues 
(residues 159-301) (Kueltzo et al., 2000). The peptide was found to possess the 
full transport activity of native VP22, both the intrinsic transport ability and the 
ability to carry proteins of significant size. However, by constructing a series of 
deletion constructs of VP22 tagged by GFP Aints et al. mapped the region of 
VP22 necessary for intercellular transport to residues 81-195, with a peptide 
corresponding to the 106 C-terminal residues exhibiting no intercellular 
trafficking (Aints et al., 2001).
Due to the studies reporting successful protein transduction using fusions with 
full-length VP22 it was the full length HSV-1 VP22 gene that was used to 
generate the fusion proteins examined throughout the course of this study.
1.2.2.4 An Experimental ‘MTP ’ -  Drome
To test whether a system developed through the course of this study could be 
utilised to assess novel translocatory sequences a test sequence was generated 
and used alongside the known MTPs. The sequence was generated in the 
laboratory during the preparation of the MTP-GFP fusion proteins, and the 
sequence was retained for rest of the studies detailed here. The sequence was 
taken from the Drosophila regulator of chromosome condensation protein, Bjl.
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The test peptide was derived from the same organism as the antennapedia 
protein, and thus penetratin. Bj 1 is a chromatin-binding protein, and thus bears 
homology to one of the functions VP22. The sequence, as can be seen from 
table 1, also has a high proportion of basic residues, 5 out of the 11 coding 
bases, which appears to be a common feature of MTPs. With this combination 
of features from the known MTPs the sequence, termed Drome, appeared a 
potentially favourable test sequence to study for potential translocatory 
attributes.
1.3 Altering Biological Functions Through Protein Transduction
The MTPs discussed have been shown not only to deliver reporter molecules 
such as (3-gal and EGFP to cells, but also to be capable of transporting 
biologically active molecules through the plasma membrane and into cells 
where they remain capable of imparting a pharmacological effect. It is this, 
rather than a proven ability to translocate into cells, that is of importance when 
the worth of such vectors for the treatment of disease, or the study of 
intracellular functions, is being investigated.
1.3.1 Pharmacological Studies Using Tat PTD as a Peptide Delivery Vector 
Numerous reports have described the delivery of peptides to cells by fusion with 
the Tat PTD. Following delivery these molecules have retained functional 
activity and have elicited the desired pharmacological response within the 
recipient cells (Chellaiah et al., 2000; Dietz et al., 2002; Embury et al., 2001; 
Eum et al., 2002; Ezhevsky et al., 1997; Gius et al., 1999; Harada et al., 2002; 
Nagahara et al., 1998; Ribeiro et al., 2003; Shibagaki and Udey, 2003; Tasciotti 
et al., 2003; Vocero-Akbani et al., 1999; Xia et al., 2001). These reports have 
included both the delivery of exogenously applied fusion proteins as well as 
transport of protein expressed within one population of cells to a second non­
expressing population. Some representative examples of these findings are 
examined below, highlighting the potential application of the Tat PTD as a 
protein delivery vector.
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The introduction into cells of peptides able to interact with cellular machinery, 
thereby altering the cell’s typical function, can provide a valuable method of 
discerning protein function. An example of this is in the study of cell cycle 
progression. In order to understand the timing and duration of cyclin D:Cdk4/6 
complex formation involved in phosphorylating the retinoblastoma tumour 
suppressor pRb, and their requirement for Gi cell cycle progression, a 20 amino- 
acid peptidyl mimetic corresponding to the cyclin-binding domain of the Cdk4/6 
inhibitor plb1^ 4* was transduced into cells using an N-terminal TAT fusion 
(Ezhevsky et al., 1997; Gius et al., 1999). Cdk4/6 activity for a specific early Gi 
phase cell cycle progression was identified, with the transduced mimetic 
arresting the cell cycle here by interrupting interaction with, and subsequent 
inhibition of, Cdk4/6 and plb 1^ 4*.
In 2001 Xia et al demonstrated the mannose-6-phosphate independent uptake in 
vitro of the lysosomal enzyme p-glucuronidase using a recombinant viral vector 
with a Tat PTD C-terminal fusion. The group went on to show a significant 
increase in the enzyme distribution secreted from virally infected cells following 
intravenous or direct brain injection in mice (Xia et al., 2001). An approach 
using gene therapy with a vector engineered to express a Tat-modified 
recombinant lysosomal protein was effective in clearing storage pathology from 
P-glucuronidase-deficient mice.
In addition to rectifying pathological conditions the Tat PTD has also been 
successfully utilised in protection of ‘normal’ cells from various harmful insults. 
Islet cell transplantation during an immunosuppressive regimen (the Edmonton 
protocol) is a feasible means of attaining insulin independence in the treatment 
of diabetes (Shapiro et al., 2000). However, islet apoptosis triggered through 
isolation from a donor, and in subsequent in vitro culture, makes production of 
sufficient islets for this approach very difficult, and is a major limitation to such 
an approach. In 2001 Embury et al demonstrated that tumour necrosis factor-a- 
induced apoptosis of a pancreatic p-cell line was prevented by the transduction 
of the anti-apoptotic protein B c1-Xl fused to Tat PTD and applied exogenously 
to cells in vitro (Embury et al., 2001). Ribeiro et al showed protection of islets
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could be equally afforded by the transduction of an active cytoprotective 
protein, heme oxygenase-1, rather than through inhibition of the apoptotic 
pathways (Ribeiro et al., 2003). Similarly, low-potassium-induced apoptosis of 
cerebellar granule cells was also inhibited by transduction of T A T -B cI -X l , 
demonstrating a possible neuroprotective therapy strategy (Dietz et al., 2002). 
The effectiveness of such an approach was later demonstrated in vivo through 
the reversion of hyperglycaemia in diabetic immunodeficient mice (Embury et 
al., 2001) and the protection of mouse retinal ganglion cells from retrograde 
neuronal apoptosis caused by optic nerve lesion (Dietz et al., 2002).
In contrast to such protective approaches, the Tat PTD has been used for the 
transport of molecules into cells with the aim of elimination of those cells 
through apoptosis. Thymidine kinase (TK) is a good candidate to control 
cellular proliferation in gene therapy, with obvious interest in the arrest of 
proliferation of tumour cells. Cells expressing TK convert the nucleoside 
analogues acyclovir and ganciclovir into their phosphorylated forms, which are 
in turn incorporated into replicating DNA where they block further chain 
elongation and consequently induce cell death (Miller and Miller, 1980). 
However, results using TK pro-drug therapy have shown only marginal clinical 
benefit, mainly due to the poor rate of delivery of the HVS-TK gene to tumours 
(Rainov, 2000; Shand et al., 1999). In vitro Tasciotti et a l showed that cells 
expressing TAT-TK would release the fusion protein into the cell culture 
medium, from where it was internalised by neighbouring, non-expressing cells. 
When treated with acyclovir this second population of cells then became 
susceptible to cell death (Tasciotti et al., 2003). The research shows that a 
possible method for the optimisation of TK suicide gene therapy approach may 
be to modify TK with the Tat PTD, or some other transduction domain, 
improving the bystander effect
Protein transduction has also been investigated as a means of killing HIV- 
infected cells through induction of apoptosis, using a fusion of a modified 
caspase-3 protein with the Tat PTD (Vocero-Akbani et al., 1999). The caspase-3 
zymogen requires processing by upstream caspases at two recognition sites to 
remove a pro-domain and to cleave caspase-3 into a large and a small subunit,
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allowing the formation of the active heterotetramer (Woo et al., 1998). Vocero- 
Akbani et al altered the recognition sites of caspase-3 from caspase recognition 
sites to sequences that would be specifically recognised by the HIV protease, 
identified through the sequencing of the AIDS vims, HTLV-III (Ratner et al., 
1985). Transduction of the fusion protein was evident in about 100% of cells, 
irrelevant of their being HIV-infected or not. However, caspase-3 was only 
activated in infected cells containing the HIV protease, resulting in apoptosis. 
The zymogen remained inactive in the uninfected population. This strategy 
neatly circumvents the problems associated with the emergence of HIV strains 
resistant to the small inhibitory molecules currently employed as clinical 
treatments to prevent processing of HIV polyproteins by HIV protease, and thus 
maturation of infectious virions (Condra et al., 1995; Kohl et al., 1988). The 
work also suggests the possibility of substituting the proteolytic cleavage sites 
for those specific for other pathogens encoding specific proteases, such as 
malaria (Francis et al., 1997).
1.3.2 Pharmacological Studies Using Penetratin as a Peptide Delivery Vector 
Though penetratin has also been extensively studied as a translocatory peptide 
there are fewer reports of full-length proteins in fusion with this PTD 
transducing cells and exhibiting a pharmacological activity (Han et al., 2000; 
Kato et al., 1998). This is a possible consequence of an apparent limitation of 
transportable cargo size exhibited by the peptide (Derossi et al., 1998). 
Penetratin has preferentially been utilised for the transport of short peptide 
sequences and has been involved in the study of regulation of cell proliferation 
(Ball et al., 1997; Bandara et al., 1997; Bonfanti et al., 1997; Chen et al., 1999; 
Cussac et al., 1999; Fahraeus et al., 1998; Fahraeus et al., 1996; Giorello et al., 
1998; Hall et al., 1996; Herbert et al., 2000; Holinger et al., 1999; Kardinal et 
al., 2000; Kato et al., 1998; Kim et al., 1999; Lin et al., 2000; Mutoh et al., 
1999; Riedel et al., 2000; Wang et al., 1999), cell migration (Fahraeus and Lane, 
1999; Peck and Isacke, 1998), cellular immune responses (Schutze-Redelmeier 
et al., 1996), together with a number of other modulators of cellular processes 
(Hildt and Oess, 1999; Liu et al., 1999; May et al., 2000; Theodore et al., 1995; 
Troy et al., 1996). Some of these studies, which featured prospective 
therapeutic applications for penetratin, are discussed below.
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The use of peptides, in place of whole proteins, in cytotoxic T lymphocyte 
(CTL) production is limited as exogenous antigens are generally internalised by 
receptor-mediated endocytosis and presented by the class II pathway to 
stimulate helper T cells. It is necessary for such peptides to reach the 
cytoplasmic compartment for processing, loading into class I molecules and 
subsequent presentation on the surface of antigen presenting cells (APCs) if 
induction of CD8+ CTLs is to occur, in a manner analogous to presentation of 
endogenous antigens (Watts, 1997). Pietersz et al demonstrated that the uptake 
of the 9-mer OVA-Kb CTL epitope into APCs was facilitated by penetratin 
linked to either the C- or N-terminus of the peptide. The synthetic peptides were 
also shown to protect vaccinated mice against growth of an ovalbumin 
expressing tumour cell line through the induction of CTLs (Pietersz et al., 2001). 
Using this system other epitopes may also be used for priming CTLs both in 
vitro and in vivo.
In order to prevent cells from undergoing inappropriate apoptosis there is in 
place a tightly-regulated, intricate control system with levels of inhibitory and 
counter inhibitory molecules (for an introduction to this complexity see 
Salvesen and Duckett’s review of the ‘inhibitor of apoptosis’ gene family 
(Salvesen and Duckett, 2002)). The delivery of short (4-8 amino acids) N- 
terminal peptides of the pro-apoptotic protein Smac/DLABLO fused to 
penetratin to a number of immortalised cell lines was shown to enhance the 
induction of apoptosis and long term anti-proliferative effects of a diverse range 
of antineoplastic agents (Amt et al., 2002). Displacement of caspase-3 from 
cytoplasmic aggregates with its inhibitors by the peptide was responsible for 
this, and so demonstrates that modulation of such inhibitors by this approach can 
positively adjust the efficacy of antineoplastic agents. Such modulation may 
limit patient exposure to chemotherapeutic agents, and therefore reduce 
associated side effects.
Penetratin has also been used to transport a plb1^ 43 peptide to investigate the 
effect on cell proliferation (Hosotani et al., 2002). This study, in contrast to 
those using the Tat PTD (Ezhevsky et al., 1997; Gius et al., 1999), examined the
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influence of the peptide on murine tumour models in vivo. Daily intraperitoneal 
injections of penetratin conjugated with the 21-mer peptide were shown to 
significantly inhibit tumour growth in mice, and to increase the survival of 
treated mice compared to controls. These results are of obvious interest for 
therapeutic approaches to treating the large numbers of cancers where p i6™*^ 
is inactivated (Yang et al., 1995).
1.3.3 Pharmacological Studies Using VP22 as a Peptide Delivery 
Unlike TAT and penetratin, the transduction attributes of VP22 are usually 
employed using fusions with the full-length protein. A number of studies have 
been undertaken to explore the potential of VP22 to deliver both full-length 
proteins capable of eliciting a therapeutic effect within recipient cells (Derer et 
al., 2001; Dilber et al., 1999; Liu et al., 2001; Phelan et al., 1998) and also with 
regard to enhancing immune responses through the priming of cells (Cheng et 
al., 2001b; Hung et al., 2001; Michel et al., 2002).
As with p lb 1^ 4*, the product of the tumour suppressor gene p53 is mutated in a 
wide range of human malignancies (Levine, 1997). Failure to synthesise p53, or 
more commonly, synthesis of a mutated form of the protein results in 
uncontrolled proliferation and tumour formation. In 1998, Phelan et al 
demonstrated the p53-VP22 chimeric protein was able to spread from 
transfected COS-1 cells expressing the fusion protein to untransfected /755- 
negative human osteosarcoma cells (Phelan et al., 1998). The work showed 
apoptosis induction in recipient cells, indicating recovery of p53 regulation of 
cell cycle arrest, and subsequent controlled cell death.
As with the Tat PTD, the potential of VP22 to transport thymidine kinase has 
been explored (Dilber et al., 1999; Liu et al., 2001). In co-cultured monolayers, 
cell death in response to ganciclovir treatment was observed in neuroblastoma 
cells when the sole source of TK was transfected COS cells (Dilber et al., 1999). 
As the neuroblastoma cells were gap junction-negative this effect was proof of 
direct transport of the enzyme to these cells rather than a bystander effect 
elicited by spread of the activated pro-drug generated in the expressing cells. 
Through a characterisation of the increase of cytotoxicity of this TK/GCV
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suicide strategy, Liu et al showed lower concentrations of GCV were necessary 
when the fusion protein was employed in preference to TK alone (Liu et al.,
2001). This may alleviate the toxic side effects associated with high 
concentrations of GCV necessary in vivo (Engelmann et al., 1999; LeMay et al., 
1998).
Because of their association with most cervical cancers, human 
papillomaviruses (HPVs), and in particular HPV-16, present an attractive target 
for developing a means of treatment and prevention of HPV-associated cancers 
(Bosch et al., 1995). A prime candidate in the development of an 
immunotherapy strategy for cervical cancer is the use of the HPV 16 E7 protein 
as a tumour antigen. HPV 16 E7 is expressed in most HPV-containing cervical 
cancers, and studies have shown E7 to be required for growth of tumour cells in 
vitro (Doeberitz et al., 1988; Schwarz et al., 1985). Expression of a fusion 
protein of VP22 with HPV 16 E7 from a Sindis virus RNA replicon vector 
resulted in enhancement of E7-specific CD8+ T cell activities in vaccinated mice 
(Cheng et al., 2001b). In a DNA vaccination model, VP22 fused to E7 resulted 
in a strong E7-specific CD8+ T cell response, reduction in pulmonary 
metastases, and CD8+ T cell-dependant, and natural killer cell-dependant 
tumour-free survival in immunised mice (Hung et al., 2001). Other studies have 
seen similar effects using VP22-E7 fusion constructs (Michel et al., 2002). 
These investigations indicate that the potency of a DNA/RNA vaccine may be 
dramatically improved through intercellular spreading and enhanced MHC class 
I presentation of antigens that otherwise induce a rather inefficient CTL 
response.
1.4 Are MTPs Delivering?
It is commonly accepted that the internalisation of MTPs does not involve 
receptor-mediated endocytosis or specific protein transporters. The only factor 
common to translocation of MTPs appears to be an absolute dependence on 
basic amino acids within the transport sequences (Wender et al., 2000). There is 
rapid uptake to the cytoplasm and the nucleus, taking place in less than 15 
minutes, which occurs in an ATP- and temperature-independent manner (Vives 
et al., 1997a; Derossi et al., 1996). This transfer through lipid membranes has
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been attributed to a direct penetration-driven model (Vives et al., 1997a; Derossi 
et al., 1996). Energy may be provided from the refolding of partially denatured 
cargo proteins following transport to the cytoplasm, as such cargos are 
transported with a higher efficiency (Nagahara et al., 1998). For delivery of 
small molecules by hydrophobic peptide carriers, such as penetratin, an inverted 
micelle system has also been proposed, with the formation of unilamellar 
phospholipid bubbles induced by membrane destabilisation by tryptophan 
residues (Derossi et al., 1998).
From the volume of literature detailing novel uses for MTPs, there appears to be 
incontrovertible evidence from a large number of functional studies to show that 
fusions of HIV Tat, antennapedia and VP22 (and their relative PTDs) can have 
biological consequences. While many of the observed outcomes reported are 
consistent with translocatory activity, these promising observations have been 
questioned by some recent studies that have addressed the uptake mechanism 
(Koppelhus et al., 2002; Leifert et al., 2002; Lundberg et al., 2003; Richard et 
al., 2003; Sandgren et al., 2002). The data collected from these studies indicate 
that the effects may instead be explained by well-characterised biophysical 
interactions and recognised cellular transport pathways.
It has been difficult to visualise protein transduction between living cells 
(Brewis et al., 2000; Elliott and O'Hare, 1999a; Fang et al., 1998) and many 
reports of translocation are based on microscopic analysis of fixed cells. 
However, it has been observed that the use of some organic fixation agents 
introduces a profound artefact into subsequent analysis. Translocation studies 
with transfected cells expressing VP22-GFP fusion proteins showed a large 
difference in the number of GFP positive cells before and after permeabilisation 
with methanol (Aints et al., 1999; Brewis et al., 2000). Application of 
exogenously expressed VP22-GFP to cells has resulted in strong fluorescence 
from protein associated with the membrane of living cells, with no apparent 
nuclear fluorescence. However, directly after methanol fixation and rehydration 
of cells in PBS, the cells exhibited nuclear GFP fluorescence (Lundberg and 
Johansson, 2001). VP22 has also been shown to readily associate with the 
nuclei of cells following application of bacterially expressed VP22-GFP fusion
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proteins to methanol-fixed cells (Lundberg and Johansson, 2001; Lundberg and 
Johansson, 2002). Quantification of the translocatory ability of Tat PTD-GFP 
fusion protein in live cells also showed no intercellular transfer. GFP 
fluorescence was, however, observed in cells subjected to methanol fixation 
where no fluorescence was observed in the cells prior to fixation (Leifert et al.,
2002). Under even the mild fixation conditions of paraformaldehyde treatment 
artifactual uptake of TAT and penetratin has been observed (Richard et al.,
2003). Rather than acting to actively transport cargoes across cell membranes it 
has now been hypothesised that the electrostatic interaction of the short, highly 
basic motifs of MTPs with the cell surface allows the labelled proteins to remain 
attached to cells during washing, and that this protein may constitute a 
‘reservoir’ that is released when the membrane is disrupted during fixation 
(Lundberg and Johansson, 2001). Recently, rapid association of the Tat PTD 
with cell membrane components, rather than its uptake, was demonstrated by 
FACS analysis, where a decreased number of live cells exhibiting GFP 
fluorescence are observed following trypsin treatment (Richard et al., 2003).
Such dependence of association of MTPs with components of cell membranes 
for their subsequent uptake has been observed. The original studies on HIV Tat 
implicated heparan sulphates (HS) to be low-affinity binding sites for HIV Tat 
(Frankel and Pabo, 1988). Cells genetically defective in the biosynthesis of 
fully sulfated HS have been shown to be selectively impaired in the 
internalization of recombinant Tat fused to GFP, as evaluated by both flow 
cytometry and functional assays (Tyagi et al., 2001). Polysialic acid appeared to 
act in a similar way for the antennapedia homeodomain (Bloch-Gallego et al., 
1993). It is worth noting that cations that bind to cell-surface heparans may be 
internalised by endocytosis (Fuki et al., 2000).
The redistribution artefact observed following fixation with organic solvents 
could result from subsequent electrostatic interactions between the same basic 
motifs and oligonucleotide molecules within the cell, which are particularly 
concentrated in the nucleus. However, recent investigations of the Tat PTD, 
using both live (Richard et al., 2003) and paraformaldehyde fixed cells 
(Koppelhus et al., 2002; Sandgren et al., 2002), have shown not only intense
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membrane association, but also intercellular localisation almost exclusively 
within endosomal structures. The involvement of endocytosis in uptake of 
exogenous MTPs is also appealing as early experiments showed enhanced 
translocation of HIV Tat when cells were also treated with lysomotropic agents 
(Frankel and Pabo, 1988). Taken together these observations suggest that rapid 
electrostatic interaction with cell membranes, causing enrichment of MTPs at 
the cell surface, followed by uptake through the well-characterised process of 
endocytosis, may be a more plausible mechanism for their uptake than an 
unconventional, energy-independent, non-endocytotic process.
However, despite the compelling studies demonstrating the uptake of fusion 
proteins by these peptides, quantitative analysis shows that this uptake may not 
be as efficient as first stated. For example, Falnes et al undertook studies using 
low-dose VP22 or Tat PTD fused to diphtheria toxin A (dtA) (Falnes et al., 
2001). In the context of a holotoxin with diphtheria toxin B (dtB), dtA is able to 
efficiently translocate to the cytosol where the presence of a single dtA molecule 
is sufficient to kill a cell (Falnes et al., 2000). Though considerable cell- 
associated MTP-conjugated dtA was detected, substantially more so than the 
wild-type toxin itself, no cytotoxicity was detected. With the protein 
concentrations used these results indicated that these carrier proteins were at 
least 4 orders of magnitude less efficient than dtB in translocating dtA to the 
cytosol (Falnes et al., 2001). Though success was reported using a similar 
approach with penetratin as the delivery vector, any cytotoxicity was only 
detected using fusion protein concentrations 1,000 fold above wild-type toxin 
levels, and at these concentrations only a slightly higher toxicity was detected 
than application of dtA alone (Keller et al., 2001). The concentration of MTP 
fusion protein applied to cells in culture before the any biological effect is 
observed is relatively high, at a concentration of around 0.1 pM (Bennett et al., 
2002; Nagahara et al., 1998). This is in contrast with the low ligand 
concentrations needed to trigger responses in other biological pathways such as 
receptor-mediated internalisation (10‘10 to 10'11 M) (Arora and Leppla, 1994; 
Arora et al., 1994; Falnes et al., 2000).
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A single pharmacokinetics study has been carried out to assess delivery efficacy 
of MTPs. This study, undertaken by Lee and Pardridge, explored a number of 
parameters associated with the delivery of TAT and TAT-protein conjugates to 
tissues in vivo (Lee and Pardridge, 2001). The work showed that there was near 
instantaneous clearance from the plasma by all tissues of femoral vein injected 
rats by unconjugated TAT-biotin. TAT-biotin/streptavidin conjugate clearance 
was reduced about 20-fold relative to that of the unconjugated TAT peptide, but 
this was about 20-fold higher than the clearance of unconjugated streptavidin. 
However, pharmacological effects in vivo are measured not by the organ 
clearance parameter, but by the organ uptake (percent injected dose (%ID) per 
gram of tissue), which is a function of both membrane permeability, and of the 
area under plasma concentration curve (AUC). The AUC is a measure of the 
amount of drug available for delivery, within the plasma, over a specified time 
following an injected dose. A point of interest of this study was that the marked 
increase in the rate of removal of the conjugated protein was reflected by a 
reduced plasma AUC. These have offsetting effects on the organ %ID/g, and as 
a result the organ %ID/g of streptavidin is not increased in proportion to the 
increase in the membrane permeation caused by its conjugation to the Tat PTD, 
as may be expected.
However, it is clear from the large number of studies showing biological activity 
attributable to cargo proteins transported to the inside of target cells, by MTPs, 
that some form of transfer is occurring. Rather than belonging to a novel 
family of translocatory proteins, HIV Tat, antennapedia, and VP22, and their 
PTDs may instead be additional members to a family of molecules that have 
been known for many years to enhance the delivery of many different 
molecules, members of which include polyethyleneimine, poly-L-lysine, and 
various lipids -  cationic reagents.
The ability of polylysine to improve the uptake of associated protein was 
demonstrated 25 years ago (Shen and Ryser, 1978), and this process has been 
shown to rely on non-receptor-mediated (i.e., nonsaturable) adsorptive 
endocytosis (Ryser et al., 1982). It may be that in generating fusion proteins 
with membrane translocatory proteins or peptides that cationic activity mediated
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by the PTD is tightly co-localised with the molecule of interest, in a similar 
manner to the generation of complexes during transfection procedures (Leifert 
and Whitton, 2003). Indeed, by simply mixing plasmid DNA with the Tat PTD 
transfer of DNA into cells can be enhanced, albeit less effectively than cationic 
lipids (Futaki et al., 2001).
The current data and understanding of these proteins suggest that the term 
“protein transduction domain” should be reconsidered (Falnes et al., 2001; 
Green et al., 2003; Leifert et al., 2002; Richard et al., 2003). Perhaps a term that 
would more accurately reflect the mode of action upon which the biological 




Internalisation of exogenous macromolecules, in particular proteins, by live cells 
provides a powerful approach for studying cellular functions. More 
significantly, transfer of proteins from the extracellular milieu to the cytoplasm 
and nucleus could also contribute to the development of new therapeutic 
approaches. A number of proteins, and peptides derived from them have shown 
the unexpected properties of membrane translocation and protein transduction, 
allowing such a transfer to take place. Such peptides are known as membrane 
translocating proteins/peptides (MTPs). This study focused on an investigation 
of the most widely studied MTPs; the HIV Tat protein, the Drosophila 
antennapedia protein and the Herpes Simplex Virus type 1 (HSV-1) VP22 
protein, and the peptides derived from them (the Tat protein transduction 
domain (PTD) and penetratin for Tat and antennapedia, respectively).
Though the potential of these peptide sequences to deliver cargo polypeptides 
has been extensively studied following the initial observations of the 
transduction potential of MTPs, 1994 for Tat (Fawell et al., 1994), 1992 for the 
antennapedia homeodomain (Perez et al., 1992), and 1997 for VP22 (Elliott and 
O'Hare, 1997), little work has been carried out to quantify the degree to which 
this protein transduction occurs (Ye et al., 2002). More importantly, for the 
potential of these sequences in therapeutic applications to be realised, direct 
comparisons of transduction efficiency is desirable, to enable the selection of 
favourable candidates for further, focused investigation. The aim of this study 
was to develop a system whereby the protein transduction efficiencies of the Tat 
PTD, penetratin and VP22 could be compared quantitatively.
Throughout the course of this study a reporter has been sought which would 
satisfy the following criterion: the reporter must be a protein capable of
providing a detectable signal. The focus of this research was to develop a 
protocol by which comparative quantification of the transport efficiency of 
MTPs could be undertaken in order to find suitable candidates for use in protein 
therapy approaches. It is possible to use small molecules, or peptides as reporter 
molecules, but such a reporter would tell nothing of the ability of the vectors to
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a transport a target protein, and for that protein to still be capable of eliciting its 
desired effect within the target cells.
Three different proteins were investigated to explore their suitability as reporters 
for quantification of protein transduction in a de novo synthesis system. 
Expression vectors were designed to encode specific reporter proteins in-frame 
with each MTP, enabling expression of MTP-reporter fusion proteins in 
transfected mammalian cells. The ease with which transduction of the reporter 
protein could be detected from transfected to non-transfected cells was then 
investigated.
The three reporters were the green fluorescent protein (GFP), luciferase, and an 
analogue of caspase-3 lacking the pro-domain found in the wild-type protein, 
pro-less caspase-3 (PLCasp3). The reporter proteins GFP and luciferase were 
utilised with the aim of capitalising on the information available for undertaking 
assays with these well-characterised reporters. It was hoped that at least one of 
the two systems would enable rapid development of a protocol to assess the 
protein transduction capabilities of the tested MTPs. There has been little work 
undertaken with the third protein (Meergans et al., 2000; Pop et al., 2001), and 
these have focused on examining the properties of the caspase-3 analogue itself. 
By using such an enzyme the aim was to examine the potential of harnessing an 
endogenous signaling pathway to monitor protein transduction. Such an 
approach has the potential to allow development of a system with sensitivity 




2.1 Large-Scale DNA Preparation
A number of different vectors were used during the course of these studies. The 
method that follows was used to produce milligram quantities of each of the 
plasmids used throughout the course of this work for transfection experiments 
and cloning procedures. Presented here are the steps required to propagate, 
isolate, purify and quantify any of the plasmids.
2.1.1 Plasmid Propagation
Escherichia coli strain JM109 was used for the propagation of all of the 
plasmids. Competent E. coli JM109 cells were prepared as described (appendix 
B) and transformed with the appropriate plasmid using the heat shock technique 
(appendix B). A single colony of E. coli JM109 containing the appropriate 
plasmid was isolated from a LB agar plate supplemented with ampicillin (125 
jug/ml) and inoculated into 250 ml of LB broth containing the same antibiotic. 
This culture was grown overnight at 37 °C on a shaking incubator at 300 rpm.
2.1.2 Plasmid Isolation and Purification
The plasmid was isolated and the cell lysate purified using a modified version of 
the alkaline lysis method described by Sambrook et al (Sambrook et al., 1989). 
Cells were pelleted by centrifugation at 5000 rpm for 15 minutes in a Beckmann 
floor centrifuge. The cell pellet was resuspended in 5 ml ice-cold alkaline lysis 
solution I (20 % glucose, 1 M Tris-HCl pH 8.0, 0.5 M EDTA pH 8.0). The 
suspension was transferred to a 50 ml centrifuge tube (Greiner Labortechnik 
Ltd, Germany) and placed on ice. Ten millilitres alkaline lysis solution II (0.2 M 
NaOH, 1 % SDS) was added and the suspension mixed by inverting the tube 3 
or 4 times. The suspension was incubated on ice for 10 to 15 minutes. Seven 
and a half millilitres alkaline lysis solution III (3 M potassium acetate, 11.5% 
v/v glacial acetic acid) was added, the solution mixed by vortexing, and 
incubated on ice for 15 minutes. Cell debris was removed by centrifugation at 
7500 rpm for 15 minutes and the supernatant decanted into a sterile 50 ml
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centrifuge tube. One hundred microlitres RNAseA solution (10 mg/ml) was 
added to the supernatant prior to incubation in a water bath at 37 °C for 30 to 60 
minutes. Ten millilitres of phenol:chloroform:isopropanol (25:24:1) solution 
was added and the phases mixed by vortexing. The resulting emulsion was 
centrifuged as before. The clear- (upper-) phase was transferred to a clean 50 ml 
centrifuge tube. Twenty-three microlitres 100 % ethanol was added and the 
solution mixed by vortexing. The solution was centrifuged as before following 
incubation at room temperature for 1 to 2 minutes. The supernatant was 
decanted and the pellet washed briefly in 5 ml 70 % ethanol. The tube was 
inverted over paper towels and the pellet left to dry. The pellet was resuspended 
in 555 pi water and transferred to a 1.5 ml microcentrifuge tube (Tyco 
Healthcare Group, MA, USA). One hundred and six microlitres 5 M NaCl (in 
water) and 172 pi 50 % PEG6000 (in water) were added and the solution was 
vortexed. The solution was then incubated on ice for 30 minutes. The plasmid 
was pelleted by centrifugation at 13,000 rpm for 15 minutes in a MicroCentaur 
centrifuge (MSE, UK) and the supernatant was removed with a pipette. The 
DNA pellet was washed with 1 ml 70 % ethanol, which was removed 
immediately, and the pellet air dried for 15 minutes. The isolated DNA was 
dissolved in 300 pi TE buffer (10 mM Tris-Hcl pH 8.0, 1 mM EDTA pH 8.0) 
and stored at -20 °C.
2.1.3 Sample Purity and Quantification
For quantification of plasmid DNA, a 5 pi sample was diluted to 1 ml with 
water and the absorbance of the solution measured at 260 nm (A260) and 280 nm 
(A280) on a GeneQuan II spectrophotometer. Five microlitres TE buffer diluted 
to 1 ml in water was used as a standard reference. The display gave the 
calculated concentration of the original solution. The purity of the sample was 
calculated as follows:
n  . .  A 260Ratio =
A 280





Fresh Milli-Q water was used for the preparation of all culture media and 
solutions and was obtained from a Milli-Q PF Plus system with ultrafiltration 
cartridge (Millipore UK Ltd).
2.2.1.2 Phosphate Buffered Saline
Phosphate buffered saline solution (PBS) tablets without magnesium or calcium 
ions were obtained from Oxoid Ltd, UK. One tablet was dissolved in 100 ml of 
Milli-Q water with a final pH of 7.3. Solutions were sterilised by autoclaving at 
121 °C for 15 minutes.
2.2.1.3 HEPES Buffered Saline
HEPES acid, 0.554 g, was dissolved in 100 ml water and the pH titrated to 7.05 
with 5 M NaOH. The solution was filter sterilised (0.2 pm acrodisc) and 10 ml 
aliquots were stored at -20 °C until required.
2.2.1.4 Trypan Blue
Trypan blue, used for assessing cell viability, was obtained from BDH 
Laboratory Reagents Ltd and was prepared as a 0.1 % (w/v) solution in PBS.
2.2.1.5 Trypsin
Trypsin was obtained at lOx concentrate (2.5 % [v/v]) and was prepared as a 
0.25 % (v/v) solution in PBS and filter sterilised (0.2 pm acrodisc).
2.2.1.6 Polyethyleneimine
Polyethyleneimine (PEI), Mr = 25 kDa, was obtained from Sigma-Aldrich. A 
stock solution of 20 mM PEI in Milli-Q water was prepared, neutralised with 
0.1 M HC1 and filtered (0.2 pm acrodisc). The PEI solution was stored at 4 °C.
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2.2.1.7 Formaldehyde Solution
Paraformaldehyde obtained from Sigma-Aldrich was dissolved in PBS at 70 °C 
to prepare a 4 % (w/v) solution. The solution was allowed to cool to room 
temperature, adjusted to a final pH of 7.4, and stored at 4 °C. A fresh solution 
was prepared monthly.
2.2.2 Casnase-3 Inhibitors
The caspase-3 inhibitor N-Acetyl-Asp-Glu-Val-Asp-al (AC-DEVD-CHO) was 
obtained from Sigma-Aldrich. A 10 mM stock solution was prepared in DMSO 
and stored at -20 °C until required. Further dilutions were performed in 
OptiMEM and used immediately.
The cell permeable caspase-3 inhibitor Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala- 
Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Asp-Glu-Val-Asp-CHO (cp-DEVD-CHO) 
was obtained from BD Biosciences (Abingdon, UK). A 1 mM stock solution 
was prepared in DMSO and stored at -20 °C. Further dilutions were performed 
in OptiMEM and used immediately.
2.2.3 Culture Media and Additives
All solutions used for the preparation of culture media for mammalian cells 
were obtained from Gibco-BRL, Paisley, unless otherwise stated. Dulbecco’s 
Modified Eagle’s Medium (DMEM) and OptiMEM were obtained at lx 
concentrates and were supplied with sodium bicarbonate, GLUTAMAX I (L- 
Alanyl-L-Glutamine, a stable glutamine dipeptide used in place of L- 
Glutamine), and contained phenol red as an indicator. OptiMEM was supplied 
supplemented with trace elements and growth factors. Modified Eagle’s 
Medium non-essential amino acids solution (MEM-NEAA) and penicillin 
(10,000 IU/ml)/streptomycin (10,000 pg/ml) were obtained as lOOx 
concentrates. Heat inactivated foetal bovine serum (FBS) were used in growth 
media.
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Growth media were prepared aseptically according to the formulae shown below 
in table 2.1, stored at 4 °C, and used within 4 weeks of preparation.






Table 2.1. Formulae for the preparation o cell culture media
2.2.4 Additional Antibiotics
Tetracycline (Tc) and doxycycline (dox) were obtained from Sigma-Aldrich. A 
1 mg/ml stock solution of Tet was prepared in ethanol and stored in the dark at 
-20 °C. A 1 mg/ml stock solution of dox was prepared in sterile Milli-Q water 
and stored in the dark at -20 °C. G418 was obtained from Sigma-Aldrich as a 
50 mg/ml solution and was stored in the dark at 4 °C.




All aseptic techniques were carried out in a laminar flow cabinet (MDH, UK) 
designed for vertical re-circulation of air. Cells were cultured in an LEEC PF2 
anhydric incubator. Growing cells were viewed daily under an inverted light 
microscope. For determination of cell concentration in suspension, 
appropriately diluted samples were counted on a standard double grid 
haemocytometer (Neubauer 0.1 mm Dept, Weber, UK).
2.2.5.2 Disposable Items
Sterile 25 cm2, 75 cm2 and 175 cm2 filter top tissue flasks; 96-, 12-, and 6-well 
plates, 60 mm diameter culture dishes and sterile cell scrapers were obtained
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from Helena Biosciences, UK. Ninety millimetre diameter culture dishes were 
obtained from Fisher Scientific, UK. Cryopreservation ampoules used for 
storing frozen cells in liquid nitrogen were obtained from Coming, UK.
2.2.6 Culture Methods
2.2.6.1 Cell Lines
All cell lines were maintained at 37 °C in a humidified atmosphere consisting of 
95 % air/5 % CO2 (v/v). Cells were visualised on a daily basis to assess growth 
and to check for evidence of microbial contamination.
The COS-7 cells, an SV40 transformed African green monkey kidney cell line, 
were obtained from the European Collection of Animal Cell Cultures (ECACC, 
Porton Down, Salisbury, UK). The rat embryo derived Rat-1 cell line and the 
transformed human cervical epithelioid carcinoma derived HeLa Tet-Off cell 
line (Clontech) were already present in the laboratory. All cells were grown in 
DMEM containing 10 % (v/v) FBS. The media was supplemented with 200 
pg/ml G418 for maintenance of HeLa Tet-Off cells. For routine culture, cells 
were subcultured 1 in 8 twice weekly (or 1 in 20 weekly) and the media changed 
every 48 hours.
2.2.6.2 Subculturing
Cell lines were grown as adherent monolayer cultures and subcultured at 80- 
100 % confluence. For subculture, 75 cm flasks were rinsed twice with 3 ml 
aliquots of PBS and then incubated with 2 ml 0.25 % trypsin for approximately 
6 minutes. Detached cells were diluted to 15 ml with complete culture medium 
and transferred to a 50 ml centrifuge tube. The suspension was centrifuged at 
1000 rpm for 8 minutes, and the supernatant discarded. The cells were 
resuspended in 1 ml complete culture medium. Three or 4 ml additional media 
were added and 200 pi or 500 pi of this suspension transferred into a sterile 
75 cm2 flask containing 10 ml fresh culture medium (for 1 in 20 or 1 in 8 
subcultures, respectively) for subsequent culture.
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2.2.6.3 Determination o f Cell Concentration
Following the detachment of cells from a flask and pelleting of the cells, the 
cells were resuspended in 1 ml medium and the cell suspension was briefly 
pipetted to break up clumps of cells. Ten microlitres of suspension was added to 
40 pi of PBS and 50 pi of 0.1 % (w/v) Trypan blue solution. Six microlitres of 
this sample was loaded on to a grid haemocytometer under an overlaying 
coverslip. Viable cells were detected by a bright ‘halo’ light around their cell 
membranes whereas dead cells were permeabilised and stained blue. The viable 
cell numbers in the four squares surrounding the central square were counted 
using an inverted light microscope. The viable cell concentration in the original 
suspension was calculated using the following equation:
Cells per ml = Total cell count in 4 chamber x lOxlO4
4
2.2.6.4 Cell Storage and Recovery
Cells were prepared for storage by the detachment of a near confluent 
monolayer from a 75 cm2 flask according to the standard protocol (see 2.2.4.1) 
followed by centrifugation at 1000 rpm for 8 minutes. The supernatant was then 
discarded and the cells resuspended in 10 ml filter sterilised (0.2 pm acrodisc) 
culture medium supplemented with 10 % (v/v) dimethyl sulphoxide 
(spectrophotometric grade, Aldrich, UK) as a cryopreservative. Cell 
suspensions were then dispensed in 1 ml aliquots into cryopreservation 
ampoules, placed in an insulated freezer box and transferred to a -80 °C freezer 
(Lab Impex research, UK) to cool to -80 °C overnight. The cells were then 
transferred to a Linde liquid nitrogen freezer where they were stored at 
approximately-148 °C.
For cell recovery from frozen stocks, the contents of an ampoule was thawed in 
a 37 °C water bath for five minutes and transferred to a 15 ml centrifuge tube 
(Helena Biosciences, UK). Ten millilitres of fresh medium was added to the 
thawed cells drop wise, with mixing by inversion after addition of every ~2-3 ml 
medium. Cells were centrifuged for 8 minutes at 1000 rpm and the supernatant 
was discarded. The cells were then resuspended in 1 ml fresh medium and
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transferred to a 75 cm flask containing 10 ml fresh medium and subsequently 
incubated under standard conditions. Cells were cultured for at least two 
passages in order to establish them before any experiments were carried out.
Where cells were purchased from the ECACC they were supplied in the form of 
frozen ampoules. These were stored in a liquid nitrogen freezer until required. 
The cells were recovered according to the supplied protocol. This followed the 
standard protocol, but the resuspended cells were transferred to a 25 cm2 flask 
containing 5 ml fresh medium and then incubated under standard conditions. 
Again, cells were cultured for at least two passages in order to establish them 
before any experiments were carried out or stocks were prepared for storage.
2.2.7 Transfection of Mammalian Cells
Mammalian cell transfection was undertaken by use of either polyethyleneimine 
or GeneJuice as a carrier. Protocols for each are outlined below.
2.2.7.1 Preparation o f Polyethyleneimine Transfection Complexes 
Polyethyleneimine (PEI), Mr = 25 kDa, was obtained from Sigma-Aldrich. A 
stock solution of 20 mM PEI in Milli-Q water was prepared, neutralised with 
0.1 M HC1 and filtered (0.2 pm acrodisc). The PEI solution was stored at 4 °C.
A total of 2 pg plasmid DNA was diluted to 50 pi with HBS in a sterile 0.5 ml 
microcentrifuge tube (Tyco Healthcare Group, MA, USA). Separately, 3 p i of 
PEI solution (20 mM) was diluted to 50 p i in HBS. Complexes were prepared 
by adding the 50 pi of PEI solution to the 50 p i of DNA. Gentle mixing of the 
two solutions was achieved by pipetting the solution up and down 5 times with a 
200 pi Gilson pipette. The complex solution was formulated at a total DNA 
concentration of 20 pg/ml.
2.2.7.2 Transfection o f COS-7 Cells with PEI Transfection Complexes 
Transfection using PEI required exponentially growing cultures. Cos-7 cells 
were seeded at a density such that at the time of transfection monolayers were 
40 - 50 % confluent. For both of the cell types studied this density was
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determined to be 1 x 105 cells per 35 mm well on a 6 well plate. Where larger 
transfections were required the number of cells seeded onto the culture surface 
was increased in line with the increase in growth area. One hour prior to 
transfection growth medium was aspirated from monolayers of rapidly dividing 
cells and replaced with 1.9 ml OptiMEM, a serum-free medium specifically 
designed for transfection experiments. One hundred microlitres of transfection 
complex containing a total of 2 fig of DNA was added to each well. 
Transfection was carried out for 4 hours at 37 °C after which time the 
transfection media was replaced with fresh complete media, and cells cultured 
further, as required, before harvesting for analysis.
2.2.7.3 Transfection o f Cells with GeneJuice
The transfection reagent GeneJuice was obtained from Novagen (Merck 
Biosciences Ltd, Nottingham, UK), stored at 4 °C and used within 6 months of 
delivery.
Routinely, cells seeded in 6-well plates were transfected. Cos-7 cells were 
seeded at a density of lx l 05 cells per well and HeLa Tet-Off cells at a density of 
4x105 cells per well 24 hours prior to transfection.
Three microlitres of GeneJuice was added to 9 7  jllI OptiMEM. The solution was 
mixed by gentle vortexing and incubated at room temperature for 5 minutes. A 
total of 1 pi of DNA was added to the solution, mixed as before, and incubated 
for a further 15 minutes at room temperature. The DNA-containing solution 
was then added to the cells and dispersed evenly by gently shaking the growth 
receptacle. Cells were grown as normal until cells were harvested for analysis, 
normally 24-48 hours post-transfection.
2.2.8 Susceptibility of COS-7 Cells to G418
The sensitivity of the COS-7 cells to G418 was examined to determine the 
minimum concentration of the antibiotic necessary for almost 100 % mortality 
over a two week period. Thirty-five millimetre wells were seeded with 5x104 
cells and grown as normal. Twenty-four hours after seeding, various
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concentrations of G418 were applied to each well, and cells again grown as 
normal. At 48 hours intervals following the application of G418 cells from one 
well at each dose concentration were harvested by trypsinisation (incubation 
with 200 pi, 0.25 % trypsin for 8 minutes at 37 °C) and pelleted by 
centrifugation at 1000 rpm for 8 minutes. The medium was discarded and cells 
resuspended in 100 j l l I  fresh medium. The number of viable cells in each 
sample was determined by performing cell count on a haemocytometer as 
outlined above (see 2.2.4.2). Remaining samples had their media changed for 
fresh media supplemented with G418 every 48 hours. Cell counts were 
performed for a total of 15 days from seeding of the wells. The amount of G418 
required for 100 % mortality of Cos-7 cells over this time period was 
determined to be 750 pg/ml.
2.2.9 Generation of a Stable COS-7 Cell Line Expressing EGFP 
Thirty-five millimetre wells were seeded with 5x104 COS-7 cells and grown for 
24 hours. Each well was transfected with 2 jug pEGFP-Nl using PEI as a 
transfection reagent. Twenty-four hours post-transfection, growth media was 
supplemented with 750 pg/ml G418, and cells grown as normal. Media was 
changed for fresh media supplemented with G418 every 72 hours. Eighteen 
days after transfection individual plaques of surviving cells were harvested. 
Media was aspirated from the wells and cells washed in PBS. Plaques were 
detached by application of 15 jul, 0.25 % trypsin to the individual plaques and 
incubation for 3 minutes at room temperature. Cells were gentle agitated from 
the growth surface with a pipette tip and transferred to the individual wells on a 
96-well microtitre plate. Two hundred microlitres of fresh media supplemented 
with G418 was added per well. After 24 hours incubation, media was removed 
and cells detached from the growth surface by trypsinisation and harvested by 
the addition of 200 j l l I  fresh media with G418. Cells were transferred to a new 
well to ensure even growth over well surface. In addition, 30 pi of the cell 
suspensions were transferred to the wells on a multi-well slide (Fisher 
Scientific, UK) contained within 70 mm dishes. The slides were incubated as 
normal and after a 24 hour period to allow adherence of the cells to the slide’s 
surface, slides were covered with fresh medium. After a further 48 hours the
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slides were washed with PBS and the presence of fluorescence within the 
samples confirmed under a fluorescence microscope. Colonies in the 96-well 
plate corresponding to those exhibiting the most consistent and brightest EGFP 
expression were successively grown up to give stable populations. Cell lines 
were harvested and stored as outlined previously.
2.2.10 Regulation of expression in HeLa Tet-Off cells
The antibiotic (tetracycline or doxycycline) was added directly at the start of 
transfection using concentrations as described.
2.2.11 Induction of Anontosis
For routine induction of apoptosis cells were exposed to 1 pM staurosporine for 
3 hours.
2.3 Methods for Quantifying Protein Expression
2.3.1 Detergent Lvsis Method 1
After an appropriate period of incubation post-transfection, the cell monolayer 
was washed twice in 2 ml of PBS. The washed monolayers were treated with 
250 pi of Promega lysis buffer (lx: 25 mM Tris-phosphate, pH 7.8; 2 mM DTT; 
l,2-diaminocyclohexane-N,N,N’,N’-tetraacetic acid; 10 % glycerol, 1 % Triton 
X-100 and BSA 1 mg/ml) and incubated at room temperature for 15 minutes. 
The cell extracts were collected and transferred to sterile micro-centrifuge tubes 
and vortexed for 15 seconds. Cell debris was pelleted by centrifugation at 
13,000 rpm for 15 seconds in a MicroCentaur. The supernatant was transferred 
to a clean microcentrifuge tube and stored on ice for immediate use. For 
prolonged storage before assaying of the lysate, samples were snap frozen in a 
dry-ice/ethanol bath and stored at -80 °C.
2.3.2 Detergent Lvsis Method 2
At the desired time following transfection/induction of apoptosis, media was 
removed from cells and transferred to a 15 ml Falcon tube. Cells were washed 
twice with 1 ml PBS, with washes removed and added to the saved medium.
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Attached cells were incubated in 200 jul 0.25 % trypsin for 8 minutes at 37 °C. 
Cells were harvested by the addition of 1 ml PBS and transferred to the Falcon 
tube. Cells were pelleted from suspension by centrifugation at 1,000 rpm for 8 
minutes, and the supernatant discarded. Cells were resuspended in 1 ml PBS 
and transferred to a 1.5 ml microcentrifuge tube. Cells were pelleted by 
centrifugation at 13,000 rpm for 30 seconds in a MicroCentaur. The supernatant 
was discarded and cells resuspended in the 120 pi NET buffer (150 mM NaCl, 
1 mM EDTA, 50 mM Tris-HCl, 0.1% Igepal CA630, pH 7.6) and incubated on 
ice for 15 minutes. Cell debris was pelleted by centrifugation at 13,000 rpm for 
10 minutes. The supernatant was transferred to a clean microcentrifuge tube and 
stored on ice for immediate use. For prolonged storage before assaying of the 
lysate, samples were snap frozen in a dry-ice/ethanol bath and stored at -80 °C.
2.3.3 Luciferase Activity Assay
Luciferase levels within cells were quantified using the Promega luciferase 
assay system (Promega, UK) according to the manufacturer’s instructions. As 
little as 10' moles (0.001 pg) of firefly luciferase can be measured using this 
kit. The detergent lysis protocol detailed above (see 2.3.1) was followed. After 
centrifugation of the cell lysate, 20 pi of room temperature cell extract 
(supernatant) were mixed with 100 pi of luciferase assay reagent again at room 
temperature. The disposable test tube containing the reaction was vortexed 
briefly and immediately placed in a TD-20/20 luminometer (Turner Designs, 
UK). The instrument settings were as follows: sensitivity 25.1, delay, 5 seconds 
and the integration 10 seconds. The relative activity of the samples was found 
by correcting for the protein content of the samples, determined by Bradford 
assay (see below).
2.3.4 Caspase-3 Activity Assay
Caspase-3 activity within cells was quantified using a colorimetric assay as 
outlined in the Oncogene Research Products apoptosis catalogue and technical 
guide, with alterations as noted.
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To determine caspase-3 activity within the samples 105 pi of cell lysate from 
NET buffer lysis (see 2.3.2) was transferred to a 500 pi microcentrifuge tube. 
Two hundred and ten microlitres of assay buffer (50 mM Hepes, pH 7.4; 100 
mM NaCl; 0.1% w/v CHAPS; 10 mM DTT; 100 pM EDTA; 10% glycerol) and 
35 pi of substrate Ac-DEVD-pNA (100 mM N-acetyl-Asp-Glu-Val-Asp p- 
nitroanilide, CN Biosciences, UK) was added to the cell lysate. The reaction 
mixture was mixed by briefly vortexing. One hundred microlitre aliquots were 
loaded on a 96 well microtitre plate (Fermentas, UK), which had equilibrated to 
37 °C, in triplicate. The absorbance at 405 nm was read at 5 minutes intervals 
for 120 minutes in a Thermomax kinetic microtitre plate reader (Molecular 
Devices, UK) using SoftMax 2.3 software (Molecular Devices Corp., Menlo 
Park, California, USA). One hundred microlitres of 10 mM substrate was used 
as a blank.
The linear portion of the absorbance at 405 nm versus time plot for each sample 
was used to calculate the Vmax using the SoftMax software. The Vmax of the 
replicate samples were averaged, and the value of the slope for the blank sample 
was subtracted from these values. The relative activity of the samples was 
found by correcting for the protein content of the samples, determined by 
Bradford assay (see below).
2.3.4 Protein Assay
The luciferase and caspase-3 activity in each sample was expressed per 
microgram of protein by dividing the activity level per sample by the amount of 
soluble protein (jug) in the sample. The protein content in cell extracts was 
measured using the Sigma Bradford assay according to manufacturer’s 
instructions. Measurements on 1 0  jllI aliquots of room temperature cell extract 
(supernatant) from each sample were taken, and calibration curves were 
constructed using bovine serum albumin as a standard (see appendix A). 
Spectrophotometric measurements were made at 595 nm. Where the protein 
concentration of a sample was above the upper limit of the calibration curve the 
sample was diluted so the protein content of 10 pi of the diluted sample would 
be measurable within the limits of the calibration curve.
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2.4 Fluorescence Microscopy
2.4.1 Sample Preparation for Visualisation of Green Fluorescent Protein 
Coverslips (22 x 22 mm) were cleaned and sterilised by heating at 180 °C 
overnight. A single sterile coverslip was placed into each well of a 6 well plate 
and the wells filled with 2 ml DMEM. NIH 3T3 or COS-7 cells were plated 
onto the coverslips at a density of lx l05 cells per well and allowed to adhere and 
grow overnight. After incubation for 16 to 24 hours the old medium was 
removed and replaced with 1.9 ml OptiMEM. The cells were then ready for the 
addition of the 100 pi of DNA complex (see 2.2.5.3). Following addition of the 
complexes the cells were incubated for an allotted time period. At the end of 
this incubation period the cells were fixed. The transfecting medium was 
aspirated from the cells, and the monolayer washed three times with PBS and 
then fixed in 4 % paraformaldehyde at room temperature for 20 minutes. The 
coverslips were washed twice in PBS and permeabilised in 100 % methanol at -  
20 °C for 5 minutes. If no immunostaining of the cells was to be undertaken the 
coverslips were mounted by inverting them onto a drop of Vectashield (Vector 
Laboratories Inc, CA, USA) on a microscope slide. Vectashield contains an 
anti-oxidant that helps to prevent bleaching of the fluorescence. Excess 
Vectashield was removed from around the upturned coverslip and the edges of 
the coverslip sealed using clear nail polish. The slides were left to dry 
overnight, in the dark, before being cleaned. Mounted samples were stored at 
4 °C.
2.4.2 Co-Culture of COS-7 Cells with Rat-1 cells
Twenty four hours post-transfection with GeneJuice, transfected COS-7 cells, 
and untransfected Rat-1 cells were detached from 35 mm wells by incubation 
with 200 j l l I ,  0.25 % trypsin. Cells were harvested by addition of 2 ml media 
and cell populations were combined in a single 15 ml Falcon tube. Cells were 
pelleted by centrifugation at 1000 rpm for 8 minutes at room temperature. The 
media was discarded and cells resuspended in 1 ml fresh medium. Five hundred 
microlitres of the suspension was used to seed a 35 mm well containing a sterile 
22 mm coverslip. Cells were grown for a further 24 hours before fixing and
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staining. Cells were fixed by PFA and methanol treatment as described above 
(see 2.4.1).
2.4.3 Immunofluorescence
Where antibodies directed against green fluorescent protein or the rat-specific 
TGN38 protein were used additional steps were required, subsequent to 
permeabilisation with methanol and prior to the mounting of the coverslips on 
microscope slides. The cells were washed once with PBS and then blocked with 
PBS supplemented with 0.2 % BSA at room temperature for 5 minutes.
For immunofluorescent staining directed against GFP the coverslip was next 
inverted onto 70 pi of anti-GFP antibody (Santa Cruz Biotechnology, USA), 20 
pg/ml in 0.2 % BSA, and incubated at room temperature for an hour. The 
coverslip was then returned to the 35 mm well and washed twice for 5 minutes 
in 0.2 % BSA. The cells were then washed twice for 5 minutes with PBS and 
the coverslip inverted onto 70 pi of the rhodamine-conjugated, anti-rabbit IgG 
secondary antibody (Molecular Probes, Leiden, Holland), 20 pg/ml in 0.2 % 
BSA. Incubation with the 2° antibody was carried out for 2 hours in the dark to 
prevent photobleaching of the fluorophore, as were all subsequent stages of 
staining and mounting. The coverslip was again returned to the 35 mm well and 
washed as before. Cells were mounted, as above (see 2.4.1), and images 
obtained as described below (see 2.4.3).
For species-specific immunostaining, the coverslip was next inverted onto 70 pi 
rabbit polyclonal antiserum to a member of the trans-Golgi network (TGN), 
TGN38 (a gift from G. Banting, University of Bristol, UK) diluted 1:200 in 
blocking buffer, and incubated at room temperature for 90 minutes. The 
coverslip was washed twice in blocking buffer for 5 minutes, and twice in PBS 
alone. The coverslip was next inverted onto 70 pi, x pg/ml Alexa Fluor 564- 
conjugated goat anti-rabbit IgG secondary antibody (Molecular Probes, Leiden, 
Holland) diluted 1:300 in blocking buffer. Incubation was carried out for 2 
hours in the dark to prevent photobleaching, as were all subsequent stages of
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staining and mounting. The coverslip was washed as before and cells were 
mounted as detailed previously, and images obtained as described below.
2.4.4 Confocal Imaging
Differential-interfaced-contrast (DIC) and fluorescence images of the samples 
were obtained using a Zeiss LSM-510 confocal laser-scanning microscope 
(Zeiss LSM-510 system with inverted Axiovert microscope) equipped with a 
krypton-argon laser. Green fluorescent protein was imaged with excitation at 
488 nm and emission from 515 to 540 nm, Alexa Fluor 564 was imaged with 
excitation at 568 nm and emission at 590 nm.
2.5 Fluorescence Activated Cell Sorting (FACS) Analysis
Monolayers of cells transiently washed twice with 1 ml PBS and cells detached 
by incubation with 200 pi, 0.25 % trypsin for 8 minutes, 37 °C. Cells were 
harvested by the addition of 2 ml media, and transferred to a 15 ml Falcon tube, 
on ice. Cells were pelleted by centrifugation at 1,200 rpm, 4 °C. Media was 
discarded and cells washed twice by resuspending in 1 ml cold PBS and 
pelleting cells by centrifugation for 30 seconds at 13,000 rpm in a 
MicroCentaur. Cells were finally resuspended in 1 ml cold PBS and stored on 
ice until processed.
Fluorescent analysis of cell populations for EGFP fluorescence, and cell sorting 
was performed using a Becton Dickinson FACSVantage instrument at 
excitation and emission wavelengths of 488 nm and 530 nm (±15 nm) using an 
argon laser, and a single band pass FL1-H filter. A minimum of 104 cellular 
events was analysed.
To collect EGFP-expressing cells from a mixed sample of EGFP-expressing and 
non-expressing cells, a non-fluorescent population of cells was analysed. A 
high-fluorescence capture gate was set so that less than 0.5 % of the non­
population fell within the gated region. To sort cells, a minimum of 5xl05 
events was analysed using a gated region, as determined above. Cells collected
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from this high-fluorescence bracket were pelleted and resuspended in a suitable 
volume, routinely 200 pi, cold PBS before the sample was re-analysed.
2.5 SDS-PAGE and Western Blots
2.6.1 Sample Preparation
Following extraction of the cytosolic fraction from cells by detergent lysis, 
protein content was determined by Bradford assay. Samples were diluted to 
0.4 mg/ml in lx SDS sample buffer (10 % w/v SDS; 50 % v/v glycerol; 0.2 M 
Tris, pH 6.8; 5 % v/v 2- p-mercaptoethanol; two grains bromophenol blue), and 
boiled for 3 minutes. Samples were stored on ice (short term), or at -80 °C.
2.6.2 SDS-PAGE
Polymerisation of a 10 % running gel (10% v/v acrylamide (Sigma Aldrich, 
UK); 0.375 M Tris, pH 8.8; 0.15 % w/v SDS) was induced by the addition of 50 
pi, 10 % w/v ammonium persulphate (APS) and 20 pi TEMED, with thorough 
mixing. The running gel was poured into the assembled apparatus (BioRad, 
UK) to about 5 mm below the level the bottom of the wells would descend to 
when the comb was inserted. A layer of water-saturated n-butanol (Sigma, UK) 
was pipetted on top of the gel and the gel allowed to set. The butanol was 
removed, and stacking gel (4 % v/v acrylamide; 0.125 M Tris, pH 6.8; 0.15 % 
w/v SD) poured. Polymerisation induced by the addition of 50 pi, 10 % w/v 
APS and 20 pi TEMED). A comb was carefully inserted ensuring no air was 
trapped within the wells. Once the gel had set the apparatus was transferred to a 
gel tank (BioRad, UK) containing IX running buffer (0.3 % w/v Tris-HCl; 0.2 
M glycine; 0.1 % w/v SDS). Eight micrograms of prepared sample was loaded 
per well together with a positive control, and molecular weight markers. 
Samples were run at 50 V for 25 minutes, until they had reached the bottom of 
the stacking gel, and then at 180 V for a further hour.
Gels were stained in coomassie blue stain (Sigma Aldrich, UK) for 3 hours and 
incubated overnight on a rocker in de-stain buffer (10 % v/v acetic acid; 50 % 
v/v methanol). Stained gels were rinsed in water and dried between two sheets 
of gel drying membrane (Promega, UK) in a gel-drying frame (Promega, UK).
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2.6.3 Western Blots
Following separation of sample proteins by SDS-PAGE the gel was removed 
and equilibrated in IX trans-blot buffer (0.3 % w/v Tris-HCl; 0.2 M glycine; 20 
% v/v methanol) for 15 minutes. All trans-blot equipment (BioRad) was also 
equilibrated in lx trans-blot buffer for 15 minutes prior to apparatus assembly. 
Following assembly the cassette was inserted into a gel tank containinglX 
trans-blot buffer, and protein transferred to the membrane by the application of 
100 V across the gel and membrane for 60 minutes. Protein transfer was 
confirmed by staining the membrane in Ponceau S solution (Sigma Aldrich, 
UK). The stain was removed by briefly rinsing in water.
The membrane was incubated in blocking buffer (5 % Marvel skimmed milk 
powder in PBS) overnight. The membrane was sealed into small plastic 
envelopes containing primary antibody (2 ml, 1:1000 dilution of 1 mg/ml goat 
anti-luciferase antibody (Promega, UK) in blocking buffer, previously 
subtracted against COS-7 cells (see below)), and incubated overnight on a 
rocker, at room temperature. The membrane was then removed from the 
envelope and washed three times in PBS supplemented with 0.1% v/v Tween- 
20, and a further three times in PBS alone. The secondary antibody (25ml, 
1:10,000 dilution rabbit anti-goat IgG horseradish peroxidase-conjugated 
antibody (Sigma Aldrich, UK) in blocking buffer) was applied, and the 
membrane incubated on a rocker for 45 minutes, at room temperature. The 
membrane was washed as before. ECL reagent (Amersham Pharmacia and 
Biotech, UK) was prepared by adding 0.5 ml Solution A to 0.5 ml Solution B 
according to the manufacturers instructions, and incubating for 1 minute. One 
millilitre prepared ECL reagent was applied to the membrane for one minute, 
the excess removed, and the membrane wrapped in Saran wrap. Hyperfilm film 
(Amersham Pharmacia and Biotech, UK) was exposed to the membrane in a 
light-proof cassette for one hour, and developed.
2.6.4 Antibody Subtraction
Following transfer of proteins from lysed COS-7 cells onto nitrocellulose 
membrane, the membrane was incubated in blocking buffer overnight. The
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membrane was next sealed in a small plastic envelope containing primary 
antibody (2 ml, 1:1000 dilution of goat anti-luciferase antibody in blocking 
buffer). The membrane was incubated on a rocker overnight, at room 
temperature. The antibody solution was carefully removed from the membrane 
and transferred to a cryotube (Helena Bioscience, UK). Subtracted antibody 
was stored at -20 °C.
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CHAPTER 3
GREEN FLUORESCENT PROTEIN AS A REPORTER 
FOR PROTEIN TRANSDUCTION
3.1 Introduction
There are a number of reporters that are universally used to confirm the presence 
of a protein in a sample (by use of fusion proteins for example), or to determine 
effect changes to a promoter/enhancer region have on gene expression. Where 
the of study protein transduction is concerned the most common reporter by far 
is the green fluorescent protein (GFP). This is usually a tool for showing that 
the process of transduction has occurred, and to visualise the subcellular 
localisation of the transported protein within the target cell. A similar approach 
has been to use the enzyme P-galactosidase (p-gal). This can be visualised in a 
manner similar to that of GFP, but has an advantage in that, as an enzyme, any 
signal is amplified providing there is sufficient substrate available. However, 
endogenous, ubiquitously expressed proteins within cells and tissues can also act 
on the P-gal substrate, giving rise to background noise and potential false- 
positive results.
The green fluorescent protein (GFP) is coded for by the gfp gene from the 
jellyfish Aequorea victoria. Purified GFP, a protein of 238 amino acids, absorbs 
blue light (maximally at 395 nm) and emits green light (peak emission at 509 
nm). This fluorescence is very stable, has no requirement for exogenous 
substrates or cofactors, and is not destructive to tissues (Chalfie et al., 1994). 
GFP can be visualised at a high resolution using laser-scanning confocal 
microscopy, which allows the precise localisation of the fluorescence. Various 
mutated forms of GFP have been engineered to enhance the wild-type’s 
emission signal, alter the absorption wavelength or the emission spectrum to 
change the colour of the fluorescent signal, or to improve upon the stability of 
the protein for use in model systems. A comprehensive review by Roger Tsien 
(Tsien, 1998) discusses GFP and its isoforms. For the work undertaken here, the 
class 2 GFP mutant F64L, S65T, enhanced GFP (EGFP), was used. This has an
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altered emission spectrum, allowing visualisation with a fluorescence 
microscope using the readily available FITC filter set, and has a fluorescence 
signal with a magnitude over twenty times that of wild-type GFP.
GFP has been used for a number of protein transduction studies of both TAT 
and VP22 (Aints et al., 2001; Brewis et al., 2000; Del Gaizo and Payne, 2003; 
Elliott and O'Hare, 1999a; Elliott and O'Hare, 1999b; Fang et al., 1998; Harms 
et al., 2000; Koshizuka et al., 2001; Lai et al., 2000; Liu et al., 2001; Lundberg 
et al., 2003; Wybranietz et al., 1999), but there has been only one account of 
trafficking of GFP in fusion with penetratin (Han et al., 2000).
Three approaches were examined to explore protein transduction of MTP-EGFP 
fusion proteins. The first approach used indirect immunofluorescence (IF) 
analysis to detect the fusion proteins. The primary antibody was an anti-GFP 
antibody, and the secondary antibody was rhodamine-conjugated. It was hoped 
that an indirect approach would allow visualisation of the fusion proteins in 
situations where diffusion of the proteins following transduction reduced the 
fluorescence of EGFP to levels below those detectable by confocal microscopy. 
The indirect approach would also enable detection of protein that had been 
denatured, possibly as a result of the transduction process. The second approach 
was to utilise IF to differentiate transfected cells expressing the fusion proteins 
from recipient cells that were not transfected. In doing this co-localisation of 
direct EGFP fluorescence and IF would indicate the presence of fusion protein 
in a cell that was not expressing it. The final approach was to examine live cells 
by FACS. This would avoid any possible artefacts introduced during fixation, 
and allow analysis of large samples of cells for variation in the number EGFP- 
positive cells, and the distribution of fluorescence within the samples.
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3.2 Results
3.2.1 Control Transfections with EGFP-N1 Alone
To observe protein translocation of the MTP-EGFP fusion proteins from 
transfected cells to untransfected cells, a level of transfection was required that 
would result in isolated transfected cells on a background ‘carpet’ of 
untransfected cells. By varying the amount of pEGFP-Nl expression vector 
used for a transfection, a suitable amount could be determined for future 
experiments. However, for successful polyethyleneimine (PEI)-mediated 
transfection it is important for the nitrate to phosphate charge ratio of PEI to 
DNA to remain constant at around 9. This requires 2 pg of DNA for 3 pi of PEI 
(20 mM). To ensure the amount of DNA in each transfection remained constant 
at 2 pg, where less than 2 pg of pEGFP-Nl was used, the amount of DNA in 
each transfection was made up to a total of 2 pg with the non-specific DNA. 
The DNA of choice was the expression vector pcDNA3.1(+). To ensure that 
transfection with this DNA would not affect fluorescence images, transfections 
of COS-7 cells were carried out using 2 pg pcDNA3.1(+) alone. Cells were 
fixed 48 h post-transfection by sequential treatment with paraformaldehyde 
(PFA) and methanol, and mounted cells were examined using laser-scanning 
confocal microscopy. Figure 3.1. shows transfected cells imaged at lOx and 40x 
magnifications. No cells exhibited any fluorescence. The fluorescence 
observed at the higher magnification is autofluorescence. The detector gains 
were raised until autofluorescence was visualised to demonstrate that not even 
low levels of GFP fluorescence were present.
COS-7 cells were then transfected with varying amount of pEGFP-Nl by PEI- 
mediated transfection. Cells were fixed 48 hours post-transfection, as before, 
and examined using by laser-scanning confocal microscopy. Figure 3.2 shows 
cells treated with decreasing amounts of pEGFP-Nl at xlO magnification. For 
studies using 2000 ng to 200 ng of pEGFP-Nl the amount of EGFP expression
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Figure 3.1. Transfections with pcDNA3.1(+). COS-7 cells were transfected with 
2000 ng of the vector pcDNA3.1(+) as a control. Images A and B are confocal DIC 
images. Images C and D are confocal images, excitation 488 nm, FTTC filter. Images 
E and F are overlays of panels A and C, and B and D, respectively. Images A, C and 
E are at lOx magnification (bars indicate 100pm) and images B, D and F are at 40x 
magnification (bars indicate 20 pm).
Figure 3.2. COS-7 cells transfected with pEGFP-Nl. Images are confocal images, 
excitation at 488 nm, FITC filter, overlaid onto DIC images of the same cells. 
Transfections were carried out using 200 ng, 100 ng, 50 ng, 10 ng and 5 ng pEGFP-Nl 
per 35 mm well (A to E, respectively). Bars indicate 100 pm.
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vector used in the transfections appeared to have little affect on the number of 
fluorescent cells observed in any one visible frame. Images for transfections 
using more than 200 ng pEGFP-Nl are not shown. An appreciable difference 
was only observed when just 5 ng pEGFP-Nl is used in the transfections. The 
images were captured using setting identical to those for the pcDNA3.1(+) 
transfection experiments, which results in very intense fluorescence preventing 
visualisation of any detail in the transfected cells. The experiment was carried 
out on a minimum of three separate occasions to confirm observations, and the 
images are representative examples from a single set of transfections.
3.2.2 An Immunofluorescence Analysis Approach
Transduction of EGFP from expressing cells by the MTPs could result in 
diffusion of the fusion protein throughout the cultured cells. This could result in 
the recipient cells possessing insufficiently concentrated EGFP to allow 
detection of the fusion protein by direct fluorescence analysis. Similarly, it is 
possible that during the process of translocation the fusion proteins could be 
subjected to some degree of denaturation, resulting in loss of fluorescence. An 
indirect IF approach was adopted that would allow the detection of the EGFP 
fusion proteins. A primary rabbit anti-GFP antibody would bind to each of the 
EGFP fusion proteins. A rhodamine-conjugated mouse anti-rabbit IgG antibody 
would then allow visualisation of the proteins at a different excitation 
wavelength from direct visualisation of EGFP. It was hoped that the sensitivity 
of this approach would be greater than direct EGFP analysis, allowing detection 
of lower levels of the fusion proteins that may result following translocation 
from expressing cells. The primary antibody is also able to bind to denatured 
protein. Figure 3.3 shows the direct and indirect imaging of pEGFP-Nl 
transfected COS-7 cells viewed at 40x magnification. Indirect IF was only 
detected in cells expressing EGFP, demonstrating the specificity of the IF 
approach with no non-specific binding of the anti-GFP antibody to endogenous 
epitopes.
3.2.3 Immunofluorescence Analysis of Transfer of MTP-EGFP Fusion Proteins 
in Transfected Cells
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Fusions at either terminus of EGFP retain the fluorescent properties of the native 
protein, allowing localisation studies of the fusion protein. Vectors encoding N-
W
Figure 3.3. Immunofluorescence analysis of COS-7 cells transfected with 
pEGFP-Nl. (A) Direct visualisation of GFP by excitation at 488 nm, FITC filter. (B) 
Overlay of panel A on DIC image of the same cells. (C) GFP detected by 
immunocytochemistry using rabbit anti-GFP IgG followed by mouse anti-rabbit IgG- 
TRITC, excitation 568 nm, TRITC/rhodamine filter. (D) Merge of Panels A and C. 
Bars indicate 20 pm.
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terminus fusions of TAT, Drome, wild-type penetratin (WTPen) and mutant 
penetratin (mPen) with EGFP were gifts from Dr Amott. The vector encoding 
VP22 in fusion with EGFP was a C-terminus fusion, and was a gift from Dr 
O’Hare. Cells were transfected with vectors coding for MTP-EGFP fusion 
proteins and expressed protein visualised for direct EGFP fluorescence and 
indirect IF by confocal microscopy. Any difference in the localisation of direct 
and indirect fluorescence in transfected samples would be examined as evidence 
of protein transduction, for the reason discussed above. All experiments were 
carried out on a minimum of three separate occasions and images are 
representative of the samples examined.
3.2.3.1 Transfection with pTA T-EGFP
Figure 3.4 shows COS-7 cells transfected with 200 ng pTAT-EGFP. The 
overlay of green fluorescence on the DIC image (Fig. 3.4 B) makes it apparent 
that the number of transfected cells is lower here than when cells were 
transfected with the other EGFP expression vectors (see figures 3.3, 3.5, 3.6, 3.7 
and 3.8), with only two transfected cells captured in the frame. Transfected 
cells stained positive using both the anti-GFP antibody and the indirect IF 
protocol and direct EGFP fluorescence.
3.2.3.2 Transfection with pDrome-EGFP
Figure 3.5 shows COS-7 cells transfected with 200 ng pDrome-EGFP. 
Observation of direct GFP fluorescence shows a majority of the cells within the 
captured frame to contain EGFP. The fusion protein is localised in a diffuse 
pattern throughout the cells, though some regions exhibit brighter direct 
fluorescence than other regions. The differences are less apparent when indirect 
IF is examined, though this approach does generate a staining pattern that is 
generally brighter around the cells’ peripheries. By merging the direct 
fluorescence and indirect IF images, panel D, the fluorescence patterns are 
shown to have considerable similarity when GFP is detected by either the direct 
or indirect methods.
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Figure 3.4. Immunofluorescence analysis of COS-7 cells transfected with 
pTAT-EGFP. (A) Direct visualisation of GFP by excitation at 488 nm, FITC 
filter. (B) Overlay of panel A on the DIC image of the same cells. (C) GFP 
detected by immunocytochemistry using rabbit anti-GFP IgG followed by mouse 
anti-rabbit IgG-TRITC, excitation 568 nm, TRITC/rhodamine filter. (D) Merge of 
panels A and C. Bars indicate 20 pm.
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Figure 3.5. Immunofluorescence analysis of COS-7 cells transfected with pDrome- 
EGFP. (A) Direct visualisation of GFP by excitation at 488 nm, FITC filter. (B) 
Overlay of panel A on the DIC image of the same cells. (C) GFP detected by 
immunocytochemistry using rabbit anti-GFP IgG followed by mouse anti-rabbit IgG- 
TRITC, excitation 568 nm, TRITC/rhodamine filter. (D) Merge of panels A and C. Bars 
indicate 20 pm.
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3.2.3.3 Transfection with pPen-EGFP and pmPen-EGFP
Figures 3.6 and 3.7 show 40x images of COS-7 cells transfected with 200 ng 
pPen-EGFP and pmPen-EGFP, respectively. Detection by both the direct and 
indirect approach (A and C, respectively, in both figures) results in observation 
of a similar distribution of fluorescence for both fusion proteins. This similarity 
is emphasized where the images have been merged (D). All cells positively 
stained for Pen-EGFP and mPen-EGFP by indirect IF also exhibit intrinsic GFP 
fluorescence. However, the intracellular distribution of WTPen-EGFP differs 
when its presence is detected by intrinsic GFP fluorescence compared to indirect 
IF. Figure 3.6 D, a merge of the direct fluorescence and indirect IF, shows the 
fusion protein to be detected predominantly in the cytoplasm of the cells when 
IF is examined compared to brighter nuclear staining detected by direct GFP 
fluorescence alone. The same is not observed for mPen-EGFP (Fig 3.7 D). 
Here the two fluorescent patterns are virtually identical.
3.2.3.4 Transfection withpGE155 (pEGFP-VP22)
The construct pGE155 was a gift from the O’Hare group. This plasmid encoded 
a C-terminal fusion of VP22 to EGFP rather than a N-terminal fusion as is the 
case for the other EGFP constructs. This vector was generated by insertion of 
VP22 into the pEGFP-Cl vector (Clontech), and thus for descriptive simplicity 
and consistency the construct will be referred to as pEGFP-VP22.
Figure 3.8 shows COS-7 cells transfected with 200 ng pEGFP-VP22. The 
intensity of the indirect IF is very low in comparison to that of the intrinsic GFP 
fluorescence. This may be a result of photobleaching from prolonged exposure 
during imaging, or potentially obstruction of the GFP epitope by the full-length 
VP22 protein. GFP fluorescence is observed diffuse throughout the cells, 
though the nuclei exhibit more intense staining than the cytoplasmic regions. A 
very intense region of localised GFP fluorescence was observed in most cells. 
This is thought to be aggregated protein situated at the nuclear periphery. A 
merge of the two images (Fig. 3.8 D) shows cells stained positive by both 
approaches.
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Figure 3.6. Immunofluorescence analysis of COS-7 cells transfected with pWTPen- 
EGFP. (A) Direct visualisation of GFP by excitation at 488 nm, FITC filter. (B) 
Overlay of panel A on the DIC image of the same cells. (C) GFP detected by 
immunocytochemistry using rabbit anti-GFP IgG followed by mouse anti-rabbit IgG- 
TRITC, excitation 568 nm, TRITC/rhodamine filter. (D) Merge of panels A and C. Bars 
indicate 20 pm.
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Figure 3.7. Immunofluorescence analysis of COS-7 cells transfected with pmPen- 
EGFP. (A) Direct visualisation of GFP by excitation at 488 nm, FITC filter. (B) 
Overlay of panel A on the DIC image of the same cells. (C) GFP detected by 
immunocytochemistry using rabbit anti-GFP IgG followed by mouse anti-rabbit IgG- 
TRITC, excitation 568 nm, TRITC/rhodamine filter. (D) Merge of panels A and C. 
Bars indicate 20 pm.
Figure 3.8. Immunofluorescence analysis of COS-7 cells transfected with 
pEGFP-VP22. (A) Direct visualisation of GFP by excitation at 488 nm, FTTC 
filter. (B) Overlay of panel A on the DIC image of the same cells. (C) GFP detected 
by immunocytochemistry using rabbit anti-GFP IgG followed by mouse anti-rabbit 
IgG-TRITC, excitation 568 nm, TRITC/rhodamine filter. (D) Merge of panels A and 
C. Bars indicate 20 pm.
3.2.4 Determination of MTP-EGFP Transfer in Co-Cultured Cells
The indirect IF approach described above had demonstrated the presence of the 
fusion proteins in only those cells exhibiting direct EGFP fluorescence. The 
protocol did not, however, allow for separation of cells expressing the fusion 
proteins from recipient, untransfected cells. Being able to distinguish one group 
of cells from the other would enable detection of direct EGFP fluorescence in 
cells that were not expressing the protein, confirming that protein transduction 
had taken place. An approach was therefore adopted whereby transfected cells 
were co-cultured with untransfected cells from a different species. Through the 
use of indirect IF using a species-specific primary antibody and a red fluorescent 
secondary antibody expressing cells could be distinguished from non-expressing 
cell, and thus allow validation of protein transduction.
The protocol undertaken was as follows. COS-7 cells were transfected with the 
fusion constructs. To ensure that the transfection occurred with high efficiency 
GeneJuice was used as the transfection vector and 1 pg of vector used for each 
transfection. Cells were grown for 24 h following transfection, when they were 
harvested and used to set up co-cultures with untransfected Rat-1 cells. Twenty- 
four hours after plating of co-cultures cells were processed ready for 
examination by confocal microscopy. Subsequent to fixation cells were 
subjected to immunofluorescence using rabbit polyclonal antiserum to a member 
of the trans-Golgi network (TGN), TNG38. The antiserum was species-specific 
and only the TGN of the Rat-1 cells would be stained. Alexa Fluor 564- 
conjugated goat anti-rabbit IgG secondary antibody was used to enable 
visualisation of the stained Rat-1 cells by confocal microscopy.
A control co-culture was set up using pEGFP-Nl transfected COS-7 cells and 
untransfected Rat-1 cells to ensure that there was no cross-reactivity between the 
antiserum and the COS-7 cells that would prevent differentiation of the two cell 
lines. Direct visualisation of EGFP-expressing COS-7 cells showed the 
presence of pEGFP-Nl transfected COS cells, with diffuse staining throughout 
the cells (Fig. 3.9 A). Rat-specific TGN38 IF analysis showed many Rat-1 cells 
in the same frame, identifiable by their stained Golgi (Fig. 3.9 B). As expected 
this staining was predominantly in a crescent pattern around what would be the
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Figure 3.9. Confocal images of COS-7 cells transfected pEGFP-Nlco-cultured 
with non-transfected Rat-1 cells. (A) Direct visualization of GFP by excitation at 
488 nm, FITC narrow band emission filter. (B) Immunostaining against rat-specific 
TGN46, excitation 568 nm, TRITC/rhodamine filter, indicating Rat-1 cells. (C) 
Merge of images A and B. Bars indicate 20 pm.
nucleus of the Rat cells. An overlay of the two images showed that there was no 
cross-reactivity of the antiserum to COS-7 cells, and that it was only the COS-7 
that exhibited GFP-associated fluorescence (Fig. 3.9 C).
Following confirmation that the two cells lines could be differentiated by this IF 
approach, the vectors for the MTP-EGFP fusion proteins were used to transfect 
the COS-7 cells, and these cells then used to seed co-cultures with the Rat-1 
cells. The presence of GFP fluorescence in TGN38-positive cells would offer 
an indication as to spread of the fusion protein from the expressing COS cells to 
non-expressing Rat cells. All experiments were carried out on at least three 
separate occasions and images are representative of each.
3.2.4.1 Transfection with pTA T-EGFP
Direct visualisation of GFP fluorescence (Fig. 10 A) showed the presence of 
pTAT-EGFP transfected COS-7 cells exhibiting a diffuse pattern of staining 
throughout the cells. However, on occasion small, round arrangements of 
punctate staining was also observed. Two such regions are indicated by arrows 
in figure 10 A. A merge of cells exhibiting GFP fluorescence with non-EGFP 
expressing Rat-1 cells in the same frame shows no co-localisation of the 
antiserum with cells displaying diffuse GFP fluorescence (Fig. 3.10 C). 
However, for at least one of the regions of round, punctate GFP fluorescence 
staining of Golgi networks is observed in close proximity (circled in Fig. 3.10 
C). No other areas where both GFP and indirect Golgi IF co-localised were 
discerned.
3.2.4.2 Transfection with pDrome-EGFP
Direct visualisation of GFP fluorescence showed the presence of pDrome-EGFP 
transfected COS-7 cells, which exhibited a diffuse pattern of staining similar to 
that of pEGFP-Nl transfected cell. As with the co-culture studies using
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Figure 3.10. Confocal images of COS-7 cells transfected with pTAT-EGFP co­
cultured with non-transfected Rat-1 cells. (A) Direct visualization of GFP by excitation 
at 488 nm, FTTC narrow band emission filter. (B) Immunostaining against rat-specific 
TGN46, excitation 568 nm, TRITC/rhodamine filter, indicating Rat-1 cells. (C) Merge of 
images A and B. Bars indicate 20 pm.
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pTAT-EGFP transfected COS-7 cells, however, other staining patterns were 
observed on occasion. Two such patterns are visible within the captured frame 
and are marked with arrows (Fig. 3.11 A). One, on the right hand side of the 
image is an area of fluorescence similar to the small, round, punctate regions of 
GFP fluorescence observed in the pTAT-EGFP studies (Fig. 3.10 A and C). 
The other region of GFP fluorescence, at the top left of the image, takes the 
form of a pearls-on-a-string structure. The areas of interest are boxed in figure 
11C, and shown at a higher magnification. The merged image, revealing IF of 
the non-EGFP expressing Rat-1 cells, shows a tight association between these 
two small regions of GFP fluorescence and the stained Golgi networks of the 
Rat-1 cells (Fig. 3.11 C). Such an association is not observed with the cell 
exhibiting the diffuse GFP-fluorescence at the bottom of the image, marking this 
as a transfected COS-7 cell.
3.2.4.3 Transfection with pWTPen-EGFP and pmPen-EGFP
The pWTPen-EGFP transfected cells observed in the co-cultures through direct 
visualisation of GFP fluorescence exhibited fluorescence distributed diffusely 
throughout the cells’ entireties (Fig. 3.12 A). EGFP fluorescence was only 
evident in the large COS-7 cells. These cells have a tendency to expand over 
the growth surface, and are able to spread over neighbouring cells. This is 
evident in the merged image (Fig. 3.12 C) where an arrow indicates an area 
inhabited by both a COS-7 cell and a Rat-1 cell. This can give the appearance 
of co-localisation of EGFP with the Golgi IF, but confocal analysis revealed this 
to be a COS-7 cell overlaid on a Rat-1 cell.
The pmPen-EGFP transfected cells exhibit the same diffuse staining as cells 
expressing the wild-type penetratin-EGFP fusion protein, though the 
fluorescence is less intense (Fig. 3.13 A). An merged image of the co-cultured 
cells shows no direct EGFP fluorescence co-localised with the indirect IF, 
demonstrating that, as expected, translocation has not taken place (Fig. 3.13 C).
3.2.4.4 Transfection withpEGFP-VP22
The predominant distribution of fusion protein within the cells exhibiting GFP 
fluorescence in co-cultures involving pEGFP-VP22 transfected cells was that of
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Figure 3.11. Confocal images of COS-7 cells transfected with pEGFP-Drome co­
cultured with non-transfected Rat-1 cells. (A) Direct visualization of GFP by 
excitation at 488 nm, FTTC narrow band emission filter. (B) Immunostaining against rat- 
specific TGN46, excitation 568 nm, TRITC/rhodamine filter, indicating Rat-1 cells. (C) 
Merge of images A and B, with boxed areas shown at a higher magnification. Bars 
indicate 20 pm or 10 pm for the higher magnification images.
largely nuclear staining, though fainter cytoplasmic fluorescence was apparent, 
with a small, intensely fluorescent region located just outside the nucleus (arrow 
in Fig. 3.14 A), which is probably aggregated protein. However, other 
fluorescence patterns were observed and these are represented, and numbered, in 
figure 3.14 A: Cytoplasmic (1), nuclear (2), and ‘other’ (3). The cytoplasmic 
fusion protein appears largely associated with filamentous structures, which are 
probably actin microfilaments. The ‘other’ fluorescence patterns observed 
varied, but appeared to involve association with chromatin, and segregating 
chromosomes during the formation of daughter cells are clearly visible in figure 
3.14 A.
Though the fusion protein was showing functional similarity to the native VP22 
protein, namely association with actin filaments and microtubules, and 
chromatin binding, there was no evidence that membrane translocation had 
taken place. An overlay image allowing visualisation of both GFP fluorescence 
and immunostaining of Rat-1 cells shows that though in close proximity there is 
no transfer of EGFP-VP22 fusion protein from the transfected COS-7 cells to 
the untransfected Rat-1 cells (Fig. 3.14 C).
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Figure 3.12. Confocal images of COS-7 cells transfected with pWTPen-EGFP co­
cultured with non-transfected Rat-1 cells. (A) Direct visualization of GFP by 
excitation at 488 nm, FTTC narrow band emission filter. (B) Immunostaining against rat- 
specific TGN46, excitation 568 nm, TRITC/rhodamine filter, indicating Rat-1 cells. (C) 
Merge of images A and B. Bars indicate 20 pm.
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Figure 3.13. Confocal images of COS-7 cells transfected with pmPen-EGFP co­
cultured with non-transfected Rat-1 cells. (A) Direct visualization of GFP by 
excitation at 488 nm, FITC narrow band emission filter. (B) Immunostaining against rat- 
specific TGN46, excitation 568nm, TRITC/rhodamine filter, indicating Rat-1 cells. (C) 
Merge of images A and B.
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Figure 3.14. Confocal images of COS-7 cells transfected with pEGFP-VP22 co­
cultured with non-transfected Rat-1 cells. (A) Direct visualization of GFP by 
excitation at 488 nm, FITC narrow band emission filter. (B) Immunostaining against rat- 
specific TGN46, excitation 568 nm, TRITC/rhodamine filter, indicating Rat-1 cells. (C) 
Merge of images A and B. Bars indicate 20 pm.
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3.2.5 Quantification of Membrane Translocation of EGFP-MTP Fusion Proteins 
bv Fluorescence-Activated Cell Sorting Analysis
Fluorescence-activated cell sorting (FACS) analysis allows objective and 
accurate quantification of the number of live cells exhibiting EGFP 
fluorescence, and the intensity of this fluorescence within each cell, in a way 
that is not possible through the confocal microscopy approaches. The number of 
MTP-EGFP-positive cells in a sample would be greater than the number in a 
sample of cells expressing EGFP alone if protein transduction had taken place. 
However, subtle differences in the distribution of the fluorescence throughout 
the MTP-EGFP expressing samples may occur in addition to, or in place of, an 
overall increase in the number of EGFP-positive cells. Protein may be 
transduced from cells exhibiting very intense EGFP fluorescence, indicative of 
cells expressing high levels of the fusion protein, to cells with a lower level. In 
such a scenario there may be no overall increase in the number of EGFP- 
positive cells, but rather a shift in the fluorescence distribution of the sample, 
with fewer cells exhibiting high and low fluorescence intensities and more cells 
with exhibiting moderate fluorescence intensities. To account for this, the 
percentage of cells occupying a number of fluorescence intensity strata would be 
monitored, and changes in the distribution between samples examined
COS-7 cells were transfected with 50 ng of EGFP expression vector 48 hour 
before processing for FACS analysis. The small amount of DNA used ensured 
that only a proportion of the cells would be successfully transfected, allowing a 
proportion to remain available as ‘acceptor’ cells for the transduced fusion 
protein. Cells were co-transfected with 1 pg pcDNA-luc, a luciferase expression 
vector that would allow consistent transfection efficiencies across the samples to 
be confirmed. Transfected cells were detached from the growth surface by 
trypsinisation, which had the additional benefit of removing any fusion protein 
that may be associated with the extracellular surface of the cells, rather than 
inside the cell. An aliquot of each sample was lysed and analysed for luciferase 
activity.
Representative histograms of the transfected samples are shown in Figure 3.15 
B-G, with data from 10,000 events. Because cells exhibit autofluorescence a
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sample of pcDNA-luc transfected cells was used for calibration so > 98% of this 
sample occupied the first log cycle (1-10 AU) of the fluorescence intensity scale 
(arbitrary units covering 4 log cycles describing the fluorescence intensity 
exhibited by the cells). Three regions encompassing cells exhibiting different 
fluorescent intensities above this background level were established (10-100 
AU, 10-1,000 AU, and 10-10,000 AU), as shown on the histograms. 
Assessment of the number of cells within each region would allow 
determination of how any MTP-driven translocation of EGFP affected the 
fluorescence distribution throughout a population of cells. Figure 3.15 A shows 
the mean percent of cells, from three experiments, within each of the regions of 
fluorescence intensity, and error bars indicate standard deviations.
For each sample the percentage of EGFP-positive cells was very similar in each 
of the three strata of fluorescence intensity examined (10-100 AU, 100-1,000 
AU, and 1,000-10,000 AU) demonstrating a large variance in the fluorescence 
intensity of the cells. The result is a trend for a linear increase in the cumulative 
percent of events from 10-10,000 AU for each of the samples, with about 40- 
50% of cells from each transfected sample exhibiting fluorescence intensities 
above auto-fluorescence background (i.e. >10  AU). Expression of EGFP as a 
fusion with the MTPs neither increased the number of fluorescent cells observed 
in the transfected populations, nor greatly altered the distribution of fluorescence 
intensities in the populations. Luciferase activities determined for the samples 
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Figure 3.15. FACS analysis to quantify protein transduction of EGFP-MTPs in 
live cells. (A) COS-7 cells were transfected with pcDNA-luc alone, as a control, or 
co-transfected with each of the EGFP expression vectors as indicated. Forty-eight 
hours post-transfection cells were washed, trypsinised and immediately processed for 
direct FACS analysis. The number of GFP-positive cells was determined by FL1-H 
fluorescence, and the percent events in 3 regions of fluorescence intensity (Ml = 10- 
10,000 AU; M2 = 10-1,000 AU; M3 = 10-100 AU) determined. Data represent 
mean ± S.D. (n = 3). (B-G) Representative histograms of each of the samples trans-
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fected with pEGFP-Nl (B), pTAT-EGFP (C), pDrome-EGFP (D), pWTPen- 
EGFP (E), pmPen-EGFP (F), and pEGFP-VP22 (G), with the bars indicating 
the 3 fluorescence intensity regions studied (M l-M3).
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3.3 Discussion
The green fluorescent protein was used as a reporter due to the success of a 
number of groups in observing protein transduction carried out by MTPs using 
this protein (Aints et al., 1999; Brewis et al., 2000; Elliott and O'Hare, 1999a; 
Han et al., 2000; Harms et al., 2000; Kafri et al., 1997; Lai et al., 2000; 
Wybranietz et al., 1999). The aim of the study was two fold: To confirm 
reports that the Tat PTD, penetratin and VP22 could direct the transport of 
proteins between cells, and to examine whether it would be possible to quantify 
the efficiency of this process using GFP fusion proteins. As a method of 
transduction quantification was sought that could be used to compare the 
relative efficiencies of these and potentially novel MTPs, it was necessary to 
develop a system that could readily accept new sequences for assessment. For 
this reason an approach was adopted whereby transport would be monitored 
from cells expressing the fusion proteins rather than one involving application of 
protein expressed from an exogenous source. In doing this steps involving the 
purification of expressed proteins were removed, creating a less time 
consuming, more cost effective, more accessible system.
3.3.1 Anti-GFP Immunofluorescence Studies of Protein Transduction 
Observations of transfected cells were initially undertaken through an 
immunofluorescence (IF) approach using an antibody to the reporter itself, 
EGFP. The protocol adopted, using a rhodamine-conjugated secondary 
antibody for IF, allowed both direct and indirect visualisation of GFP. 
Observations of direct fluorescence alone were substantiated using an indirect IF 
approach because of a report by Elliott and O’Hare stating that the sensitivity of 
detecting VP22 spread was significantly increased using an IF approach (Elliott 
and O'Hare, 1999a). In addition a recent study had addressed an observation 
that the nature of fixation conditions could influence interpretation of 
translocation results (Brewis et al., 2000). It was suggested that spread of GFP- 
VP22 could be detected by IF after paraformaldehyde (PFA) fixation and 
detergent permeabilisation, though at lower levels than that observed using 
organic solvents. However, the report also demonstrated that a small but 
discemable displacement of VP22 from methanol-fixed cells increased the 
detection of spread observed. As a result, cells examined here were fixed with
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PFA prior to methanol-mediated permeabilisation of cell membranes to cross­
link cellular proteins. This prevented the expressed proteins from being eluted 
from the cells during the washing steps associated with IF.
Observation of monolayers of cells transfected with the MTP-EGFP expression 
constructs by IF showed localisation of the anti-GFP antibody to only those sites 
that also exhibited intrinsic GFP fluorescence. It was hypothesised that there 
were at least two possible outcomes as a result of translocation of the fusion 
proteins from expressing cells to adjacent non-expressing cells. The first was 
that diffusion of GFP as spread occurred from a central expressing cell would 
cause local concentration of GFP to fall below the detectable levels. Other 
groups have reported such a phenomenon, with transduction from transfected 
cells visualised as individual brighter cells surrounded by cells showing less 
intense signal (Elliott and O'Hare, 1997; Hung et al., 2001; Wybranietz et al., 
1999). In IF experiments with an anti-VP22 antibody it was noticed that the 
intensity of transduced cells’ nuclei decreased as their distance from an 
expressing cell increased, as would be consistent with the cell-to-cell transfer of 
VP22 containing fusion proteins (Liu et al., 2001). A similar phenomenon 
would be observed as the EGFP protein was diluted as a result of cell division.
The second outcome was that the fusion proteins might become denatured as 
part of the translocation process, resulting in loss of detectable intrinsic 
fluorescence in transduced cells. Such an occurrence may be expected as 
enhanced delivery has been observed following denaturation of TAT fusion 
proteins prior to administration (Becker-Hapak et al., 2001; Nagahara et al., 
1998; Vocero-Akbani et al., 2000). By using IF with an anti-GFP antibody it 
would be possible to detect partially denatured fusion protein if this were to 
occur. Whether denaturation would transpire following synthesis of a fusion 
protein in vivo, as with the system employed during this investigation, does not 
seem likely, especially in light of work undertaken by Kahn et al demonstrating 
that GFP can be expressed with reasonable efficiency in a cell-free in vitro 
translation system (Kahn et al., 1997). So, if denaturation were to take place as 
a result of protein transduction it is likely that autonomous refolding would 
follow.
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For the MTPs examined there was no obvious evidence that protein transduction 
had taken place. The staining observed for direct GFP fluorescence and IF was 
virtually identical in each case, with only slight variance in fluorescence 
intensities between detection methods. For the short MTP fusion proteins (i.e. 
fusions with TAT, Drome, penetratin and mutated penetratin) staining was 
detected in a pattern very similar to that exhibited by the pEGFP-Nl transfected 
cells. Diffuse fluorescence was detected throughout the cells, in both 
cytoplasmic and nuclear regions. The nuclear intensity was perceived to be 
higher in some of the cells examined for these samples, and this may be a result 
of the propensity for the basic MTP domains to adhere to negatively charged 
structures within the cells (Lundberg et al., 2003).
The staining observed for EGFP-VP22 was very different from that of the short 
MTPs. Again fluorescence was detected throughout the cells, but there were 
small, round regions exhibiting very intense fluorescence. This was only 
observable by direct GFP fluorescence as IF appeared to have suffered 
photobleaching. Association of VP22 with microtubules has been previously 
documented (Elliott and O'Hare, 1998; Harms et al., 2000; Martin et al., 2002), 
and the intense fluorescent regions observed could be the microtubule 
organising centre, or centrosome, situated on the periphery of the nucleus. 
Alternatively these regions of fluorescence may correspond to aggregates of the 
fusion protein within the cells, as protein aggregates are often located to the 
periphery of the nucleus. Groups have reported that VP22 translocation can be 
recognised by a difference in the subcellular localisation of the protein between 
expressing and transduced cells, with expressing cells exhibiting largely 
cytoplasmic localisation and recipient cells demonstrating predominantly 
nuclear fluorescence (Aints et al., 2001; Brewis et al., 2000; Elliott and O'Hare, 
1997; Liu et al., 2001). No distinguishable differences were observed in the 
fusion protein localisation in cells demonstrating GFP fluorescence.
3.3.2 Co-Culture Studies of Protein Transduction
As no transduction had been observed by direct or indirect visualisation of the 
fusion proteins, an alternative approach was undertaken. Separation of
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transfected ‘donor’ cells expressing the fusion protein and non-expressing 
recipient cells was undertaken through species-specific IF staining. 
Transduction does not appear to be a cell-type specific process with studies 
performed on a broad range cell types from different species. Indeed in one 
study alone VP22-mediated transduction of GFP was observed in 15 different 
cell lines (Wybranietz et al., 1999). Though impaired uptake has been observed 
for the native Tat protein and the antennapedia homeodomain in cell lines with 
defective cell-surface proteoglycan biosynthesis machinery (Bloch-Gallego et 
al., 1993; Tyagi et al., 2001), no such requirement has been observed for VP22 
or the short MTPs derived from these peptides.
Control co-cultures using pEGFP-Nl transfected COS-7 cells and untransfected 
Rat-1 cells showed that the two cell lines could be differentiated by IF with 
antiserum specific to rat trans-Golgi network, with no cross reactivity to the 
Golgi network of the COS cells. As expected, when co-cultures were set up 
using the EGFP fusion vectors the transfected cells exhibited the same GFP 
fluorescence as cells observed during the anti-GFP IF studies. However, for the 
TAT-EGFP and Drome-EGFP fusion proteins there was some evidence that 
protein translocation may be taking place. Transfected cells in these samples 
were clearly perceived as large cells exhibiting diffuse GFP fluorescence 
throughout the cell. Also distinguishable were isolated regions of fluorescence, 
which appear to be in the locale of nuclei. In addition, these regions were in 
close proximity to, and in some cases surrounded by, IF staining of Rat-1 cell 
Golgi. A curious observation was that there were no transfected cells in the 
immediate vicinity of these regions, yet there were clearly Rat cells harbouring 
no GFP fusion protein closer to expressing COS cells.
Though early studies exploring the effect that fixation conditions had on 
observable VP22 translocation concluded that permeabilisation with methanol 
could not account for the observed spread of VP22 through a monolayer (Brewis 
et al., 2000), these observations have since been questioned. Lundberg and 
Johansson applied VP22 directly to cells already fixed by treatment with 
methanol and found that the protein could be detected in the nuclei of the cells, 
even after extensive washing, following only a 2 minute incubation (Lundberg
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and Johansson, 2001). In addition, exogenous application of VP22-GFP to live 
cells resulted in detection of the fusion protein associated with the cell 
membrane only. However, directly after methanol fixation and rehydration in 
PBS, the cells exhibited nuclear GFP fluorescence (Lundberg and Johansson, 
2001). Further studies by the group have supported these findings (Lundberg 
and Johansson, 2002; Lundberg et al., 2003). A study using only mild PFA 
fixation condition in place of methanol permeabilisation reported artifactual 
redistribution of TAT into the nucleus of cells following exogenous application, 
giving rise to altered images as compared with the experiments performed on 
unfixed cells (Richard et al., 2003), and photomicrographs of identical fields of 
cells demonstrated the apparent spread of TAT-EGFP from transfected to cells 
to neighbouring cells following fixation with methanol (Leifert et al., 2002). 
The neighbouring cells had exhibited no fluorescence prior to fixation.
The distribution of the TAT-EGFP and Drome-EGFP fusion proteins in small, 
isolated regions can be explained by three possible events. The first is that the 
fluorescence is coming from COS-7 cells expressing low levels of the fusion 
protein, which is predominantly localised within the nucleus. The second is that 
the fixation conditions used have resulted in artefactual redistribution of the 
fusion proteins from expressing cells. The third possible occurrence is that 
protein transduction of the fusion proteins has taken place, resulting in detection 
of GFP-fluorescence in Rat-1 cells. It is unlikely that the GFP fluorescence 
detected is attributable to expressing cells as such distribution had not been 
observed in other transfection experiments. The size of the regions, if they were 
nuclei, was also appreciably smaller than the nuclei of the obviously transfected 
COS-7 cells. Problems are also posed when accounting for fluorescence arising 
from the other two events. It would be expected that redistribution of the fusion 
protein by either translocation, or by a fixation-induced artefact, would be 
marked by spread to cells immediately adjacent to the expressing cells, yet IF 
staining demonstrates the presence of Rat-1 cells occupying the area between 
the expressing cells and the isolated regions of fluorescence.
It is possible that redistribution has occurred, and that the cells exhibiting the 
GFP fluorescence have greater propensity for the fusion proteins than the other
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cells. For the artefactual spread of the fusion protein, increased accessibility of 
the intracellular environment to the extracellular milieu would increase the 
possibility that basic MTPs eluted from expressing cells could interact with 
negatively charged cellular components. It is possible that only some cells have 
had complete permeabilisation of their nuclear membranes, allowing fusion 
proteins eluted from the cytoplasm of the expressing cells access to the highly 
negatively charged oligonucleotide molecules, with which they associate 
through electrostatic interactions. These cells would therefore exhibit nuclear 
localisation of the GFP fusion proteins. If protein transduction has taken place, 
then uptake in these cells must have occurred to a greater extent than in the 
intervening cells. A possibility is that the cells are exhibiting an altered 
expression profile, and are synthesising some component of the extracellular 
matrix, or cell surface which increases the local concentration of the fusion 
proteins following their escape from the COS cells. Such a concentration 
increase would preferentially favour transduction to these cells whilst decreasing 
the protein available to other cells.
An interesting observation, captured in figure 3.14 A, was the variety of GFP 
localisation found within pEGFP-VP22 transfected cells. Cells showing distinct 
cytoplasmic and nuclear staining were frequently observed, and the presence of 
these two localisations has been used as a demonstration of protein transduction 
from expressing cells (cytoplasmic localisation) to recipient cells (nuclear 
localisation) (Aints et al., 2001; Brewis et al., 2000; Elliott and O'Hare, 1997; 
Liu et al., 2001). Also evident was strong association with chromatin in cells 
undergoing mitosis, which has again been observed previously (Elliott and 
O'Hare, 1997; Harms et al., 2000; Martin et al., 2002). Many cells exhibiting 
cytoplasmic staining for GFP also exhibited a localisation of the EGFP-VP22 to 
a region outside of the nucleus as demonstrated by figures 3.8 and 3.14. This is 
thought to be aggregated protein. An alternative explanation to transduction 
being accountable for the different cytoplasmic and nuclear staining would be 
that protein in expressing cells could be predominantly cytoplasmic until 
specific cellular cues prompted association with chromatin. If this were to occur 
when the nuclear envelope began to disassemble the protein would not be 
required to cross this barrier in order to gain access to and bind DNA.
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Following separation of daughter cells, this protein would then be trapped 
within the nucleus as the nuclear envelope reformed.
3.3.3 FACS Studies
As the microscopy approaches had only detected limited, if any, transduction 
FACS was employed to allow an objective and accurate quantitation of 
transduction. Several groups have previously used flow cytometry analysis of 
living cells to determine the uptake of MTPs (Ho et al., 2001; Nagahara et al., 
1998; Schwarze et al., 1999; Vives et al., 1997a; Vocero-Akbani et al., 1999; 
Wybranietz et al., 1999). Analysis was undertaken on live cells, so artefactual 
redistribution through fixation would be ruled out. In addition, a large sample of 
cells could be analysed, with the level of GFP fluorescence detected in each cell 
examined in a manner not possible by the confocal methodology.
Three ranges of fluorescence intensity were examined for each sample, from 
cells exhibiting low fluorescence (above background) to highly fluorescent cells. 
This covered a range of fluorescent intensity over three orders of magnitude. 
Though transduction could result in an overall shift in the number of cells 
exhibiting high levels of fluorescence, it was hoped that by examining the 
different ranges subtle events would be detected. Such an event would include 
transduction from highly fluorescent cells to cells expressing only low levels of 
protein. This would not affect the total number of GFP positive cells but would 
shift cells from both the low and high fluorescent ranges into the mid- 
fluorescent range.
None of the populations of cells expressing MTP-EGFP fusion proteins 
exhibited a higher percentage of cells exhibiting GFP fluorescence than the 
pEGFP-Nl control sample. In addition, the cells detected in each of the three 
fluorescence intensity regions increased in a very similar manner for all of the 
samples, indicating an almost identical distribution of fluorescence intensities 
for the GFP-positive cells in each sample. Such a distribution is similar to that 
FACS analysis of cells expressing TAT-EGFP or EGFP where observations 
were taken of the percentage of cells occupying 9 strata of fluorescence intensity 
(Leifert et al., 2002). Investigators have reported that an apparent translocation
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of exogenously applied MTPs is detected in live cells by FACS analysis, but 
that treatment of cells with trypsin (Richard et al., 2003) or heparin (Lundberg et 
al., 2003) indicates that this protein is actually cell surface associated and not 
internalised. The cells examined in this study were subjected to a minimum of 8 
minutes treatment with trypsin, removing any protein that may have left 
expressing cells and merely become associated with the cell membranes of other 
cells.
Summary
Exploration of protein transduction mediated by the MTPs by direct and indirect 
visualisation of GFP, differentiation of transfected from non-transfected cells in 
co-culture, and by FACS analysis failed to confirm whether the transduction 
phenomenon had taken place. Different localisation characteristics exhibited by 
cells expressing EGFP-VP22 are as a result of attributes exhibited by the native 
VP22 protein. Identification of some GFP-positive cells in pTAT-EGFP and 
pDrome-EGFP transfected cell co-cultures that were probably not transfected 
was most likely an artefact introduced during fixation.
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CHAPTER 4 
LUCIFERASE AS A REPORTER FOR PROTEIN 
TRANSDUCTION
4.1 Introduction
The three approaches to detect translocation of MTP-EGFP fusion proteins 
yielded no definitive evidence that transduction had taken place. If the 
phenomenon were occurring in the cells it would be only to a very limited 
degree. To discern whether any transduction was being carried out by the MTPs 
a more sensitive method was required, enabling even low levels of translocated 
protein to be detected. The reporter chosen was luciferase, due to the ease with 
which the enzyme’s activity is assayed, and the sensitivity of the system.
The luc gene from the North American firefly Photinus pyralis encodes 
luciferase (LUC) which catalyses the ATP-dependent oxidative decarboxylation 
of beetle luciferin in a bioluminescence reaction, leading to light emission which 
can be quantified in a luminometer. The reaction is shown below:
Mg2+
luciferase + luciferin + ATP -------► luciferase • luciferyl-AMP + PPj
luciferase • luciferyl-AMP + oxygen ► luciferase + oxyluciferin + AMP
+ CO2 + hv
The luciferase cDNA sequence was originally isolated through screening of a P. 
pyralis lantern cDNA library, and cloned for expression in mammalian cells in 
1987 (Dewet et al., 1987). It has since become a very popular reporter gene, 
especially in the studies of promoters or regulation of gene expression. The 
already sensitive catalytic reaction has subsequently been improved with
9 0advances in detection technology allowing detection of as little as 10' moles of 
luciferase under optimal conditions (Wood, 1991). This is over 100 fold more 
sensitive than the popular chloramphenicol acetyltransferase reaction. It is 
possible to study the luciferase activity in individual cells using single photon 
imaging systems, but this equipment is not yet widely available.
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Luciferase activity can be detected in live or lysed cell samples, but the activity 
measured reflects the luciferase levels present for the whole sample, not the 
individual cells. It would therefore be necessary to develop a system in which 
transfected cells expressing the luciferase-MTP fusion proteins could be 
distinguished and separated from non-expressing recipient cells. This would 




4.2.1 Construction of the Luciferase Expression Vector pSAMl
4.2.1.1. Cloning Strategy
A vector was required that would express luciferase in mammalian cells under 
the control of a strong promoter. The ideal vector would contain a multiple 
cloning site (MCS) at the N-terminus of the luciferase gene that would allow the 
in-frame insertion of each MTP-encoding sequence into the vector to produce 
MTP-luciferase fusions. There were no commercially available vectors for 
generation and expression of luciferase fusion proteins in a eukaryotic system. 
As a result, the gene encoding luciferase had to be excised from a prokaryotic 
vector and inserted into a eukaryotic expression vector with a MCS. Following 
insertion of luciferase into the eukaryotic vector, sufficient restriction sites 
would have to be retained in the MCS to allow the subsequent insertion of the 
MTP-encoding sequences at the N-terminus of luciferase.
The vector pGEM-/wc was selected as the source of the firefly luciferase gene. 
The vector has a number of unique restriction sites at both ends of the gene, 
allowing its excision. The vector pcDNA3.1(+) was selected as the eukaryotic 
expression vector into which the luciferase gene would be inserted. It has a 
cytomegalovirus (CMV) enhancer-promoter for high level expression, and a 
MCS containing complementary restriction sites to those in pGEM-/wc.
4.2.1.2. Construction of pSAMl (pcDNA3.1(+)-luc)
The luciferase gene was removed from the pGEM-/wc vector on sequential 
digestions with the Bam HI and Xho 1 restriction enzymes. The luciferase gene 
was isolated by gel purification. The pcDNA3.1(+) vector was subjected to the 
same series of digests and purification procedures. A standard ligation reaction 
was then carried out to insert the luciferase gene into the linearised 
pcDNA3.1(+) vector, thus producing pcDNA3.1(+)-/wc vector that will be 
referred to as pSAMl. The orientation of the luc gene in pcDNA3.1(+) was 
known to be correct as a result of the non-identical sticky ends generated
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following restriction digestion of the two vectors. The presence of the luciferase 
gene within pcDNA3.1 (+) was confirmed by restriction analysis, see figure 4.1.
Figure 4.1. Bam YMXho I digest of pSAMl. Lane 1: Molecular weight 
markers, lane 2: digested pSAM, lane 3: pcDNA3.1(+) subjected to the same 
digests, and lane 4: uncut pcDNA3.1(+) plasmid DNA.
4.2.1.3 Activity Study o f the pSAMl Expression Product 
Having successfully inserted the luc gene into the pcDNA3.1(+) vector it was 
necessary to determine if cells transfected with the construct would express an 
active gene product. COS-7 cells were transiently transfected with different 
amounts of pSAMl using PEI as a transfection agent. A total of 2 pg of DNA 
was used in each transfection, and where less than 2 pg of pSAMl was used 
non-specific pcDNA3.1(+) DNA was added to make up the short-fall.
Luciferase activity was detected in the cytosolic extracts of cells 48 h post­
transfection using as little as 125 ng pSAMl (Fig. 4,2). Up to 2 pg pSAMl the 
luciferase activity exhibited by the cells increased in a linear manner as the 
amount of DNA used for the transfections was increased.
As the gene product of pSAMl was active the vector could act as a ‘parent’ 
vector for subcloning of MTPs, enabling generation of MTP-luciferase fusion 
products.
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Figure 4.2. Activity of COS-7 cells transfected with pSAMl. COS-7 cells 
were transfected with the amount of pSAMl DNA indicated and the luciferase 
activity in the cytosolic extract of cells measured 48 h post-transfection. 
Triplicate readings were taken and data represent the average of 3 experiments ± 
S.E.M.
4.2.2 Construction of MTP-Luciferase Expression Constructs 
As luciferase was to act as a reporter to quantify the protein transduction 
efficiency of each of the translocating sequences it was necessary to generate 
expression vectors that would allow the production of luciferase as a fusion 
protein with each of the MTPs. The vector pSAMl was to act as the ‘parent’ 
vector, and subcloning was undertaken to generate constructs coding for the 
MTP sequences in N-terminal fusions with luciferase.
4.2.2.1 Oligonucleotide Design
For the cloning of the peptides Tat PTD, wild-type penetratin, mutant penetratin 
and Drome oligonucleotide sequences were designed for the sense and antisense 
strands of each coding region. The sequences would be ordered (Sigma, 
Genosys, UK), and the complementary sense and antisense sequences 
phosphorylated and annealed to generate double-stranded DNA sequences 
coding for each short MTP. For successful generation of MTP-luciferase fusion
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protein it was necessary to include additional bases at the ends of the pairs of 
oligonucleotides to ensure the incorporation of:
a) a 5’ Hind III restriction site
b) a start codon preceding the peptide sequence
c) a 3’ Bam HI restriction site
d) additional bases between the peptide coding sequence and the Bam HI 
restriction site so that on ligation into pSAMl the luciferase gene was in the 
same reading frame as the start codon and coding sequence of the peptide.
The sense and anti-sense pairs of oligonucleotides designed for each of the short 
MTP sequences are shown in table 3, including the bases needed to satisfy the 
criteria above.
For the cloning of a vector containing the coding sequence for the VP22- 
luciferase fusion protein, a PCR product was required. Oligonucleotide primers 
were designed to amplify VP22 from the vector pGE155 (the plasmid coding for 
a EGFP-VP22 fusion protein referred to as pEGFP-VP22 in chapter 3). 
Additional 5’ bases were included to allow insertion into pSAMl. The sense 
primer contained a Hind III restriction site and a start codon. The antisense 
primer contained bases to ensure VP22 and luciferase would be in the same 
reading frame when VP22 was inserted into pSAMl, and a Bam HI restriction 
site. The oligonucleotide primers are shown in table 4.1.
4.2.2.2 Construction o f pSAMl-MTP Expression Vectors 
The pSAMl vector was subjected to sequential digests with the Bam HI and 
Hind III restriction enzymes, and the linearised vector isolated by gel 
purification. For the insertion of the TAT and Drome coding sequences the 
annealed and phosphorylated oligonucleotides were used in a standard ligation 
reaction with linearised pSAMl vector, thus producing pSAMl -Tat and 
pSAMl-Drome respectively. Transformed E. coli were screened for the 
presence of each construct by restriction analysis of their DNA. By using the 
Bam H\/Hind III double digest successful insertion of an MTP into pSAMl 
would result in the destruction of a Kpn 1 site. The correct inserted sequence 
was then confirmed by sequence analysis using the pSAMl sequencing primer 
(Appendix B12). The sequence traces can be seen in figure 4.3 A and B.
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Peptide (peptide sequence) Sense oligonucleotide Antisense oligonucleotide
HIV-Tat 5 ’ AgCTT AT GT AT ggC Agg 5 ’ g AT CCCT CTT CgT CgCT g
MYGRKKRRQRRR AagAAgCggAgACagCgAC TCTCCgCTTCTTCCT gCC A
gAAgAgg 3’ TACATA 3’
Wild-type Penetratin 5 ’ AgCTT AT gCgCC Ag AT 5 ’g AT CCCCTT CTT CC ACTT
MRQIKIWFQNRRMKWKK AAAgATTT ggTTCC AG A CAT gCgCCg ATT CT gg AAC
AT CggCgC AT g AAgT gg A C A AATCTTT AT CT ggCgC A
AgAAggg 3’ TA 3’
Mutant Penetratin 5 ’ AgCTT AT gCgCC Ag AT 5 ’gATCCCCTTCTT gAACTT
MRQIKIFFQNRRMKFKK AAAgATTTTCTTCCAgA CAT gCgCCg ATTCT ggAAgA
ATCggCgCAT gAAgTTCA AAATCTTTATCT ggCgCAT
AgAAggg 3’ A 3 ’
Drome 5 ’ AgCTT AT gg AAggT CgT 5 ’ g AT CCC ACgC AgC AggT C
MEGRRGKRDLLR CgT ggT A AACgT g ACCT g ACgTTT ACC ACgACg ACCT
CTgCgTgg 3’ TCCATA 3’
VP22 5 ’ ATTATAAgCTTATgAC 5 ’T AT gg ATCCgCT Cg ACggg
CTCTCgCCgCTCCgT gAA CgT CT ggggCg Ag A AgCgg Ag
gTCgggTCCgC 3’ 3’
Table 4.1. Sense and antisense oligonucleotides designed to produce 
MTP-coding sequences for insertion into pSAMl. The peptide sequences the 
oligonucleotides code for are shown in bold. The oligonucleotides given for 
VP22 are primers for the PCR amplification of VP22. For the mutated form of 
penetratin mutated codons and residues are underlined.
Due to failed attempts to generate the vectors pSAMl-WTPen and pSAMl - 
mPen, insertion of the sequences coding for wild-type penetratin and mutant 
penetratin required additional steps to purify the respective annealed and 
phosphorylated oligonucleotides. These steps were undertaken following 
vertical polyacrylamide gel electrophoresis to ensure successful phosphorylation 
and annealing of the primers had been achieved. Following successful isolation 
of the coding sequences, insertion into pSAMl was carried out in an identical 
manner to the insertion of the TAT and Drome sequences, and screening 
undertaken. The sequence traces confirming the presence of penetratin and 
mutant penetratin in pSAMl can be seen in figure 4.3 C and D, respectively.
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The VP22 coding sequence was amplified from the vector pGE155 by PCR, 
using primers from table 4.1. The following PCR reaction was set up, and the 




















* 100 ng ** 10 pmol
Following amplification, the VP22 fragment was gel purified, double digested 
with Bam HI and Hind III, and the DNA ready for insertion into pSAMl gel 
purified again. Following successful isolation of the coding sequences, insertion 
into pSAMl was carried out in an identical manner to the insertion of the other 
MTP sequences. Screening was undertaken by BamH\/Hind III digestion of 
pSAMl-VP22. Sequencing of the vector was undertaken using the pSAMl 
sequencing primers (Appendix B12) to check for mutations in the PCR product, 
and the sequence data is shown in figure 4.4 A and B. The data showed that an 
in-frame fusion of VP22 and luciferase had been generated, but a single point 
mutation was identified that resulted in a threonine to serine change-of-base 
mutation in residue 135. However, as transduction studies have been 
successfully undertaken using only a C-terminal fragment of VP22 (bases 159- 
301 (Kueltzo et al., 2000)) it appears that this base is not involved in the 
processes of VP22 translocation or protein transduction. For this reason no 
further attempt was made to generate a construct without mutation, and the 
vector described above was used for subsequent studies.
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Figure 4.3. Insertion of short MTP coding sequences into pSAMl. Sequence 
traces showing the insertion of the oligonucleotides encoding HIV Tat (A), Drome 
(B), wild type penetratin (C) or mutant penetratin (D) into pSAMl using the 
restriction sites Hind III and Bam HI. In-frame, N-terminal fusions of each sequence 
with luciferase were therefore generated (the start codon for each MTP is highlighted 
by an arrow, and the redundant start codon for luciferase, which is now a Met residue, 
is also highlighted in each case).
Qf>
A AAGCTTATGACCTCTCGCCGCTCCGTGAAGTCGGGTCCGC 
GGG AGGTTCCGCGCGAT G AGT ACG AGG ATCT GT ACT AC AC 
CCCGTCTTCAGGTATGGCGAGTCCCGATAGTCCGCCTGAC 
ACCTCCCGCCGTGGCGCCCTACAGACACGCTCGCGCCAGA 









GGCC AG A A AGCT GC ACTT
B CACTTT AGC ACCGCCCCCCC AAACCCC
GACGCGCCATGGACCCCCCGGGTGGCCGGCTTTAACAAGC 
GCGTCTTCTGCGCCGCGGTCGGGCGCCTGGCGGCCATGCA 
TGCCCGG ATGGCGGCGGTCC AGCT CTGGG AC AT GTCGCGT 
CCGCGC AC AG ACG AAG ACCT C A ACG AACT CCTT GGC ATC A 





Figure 4.4. Insertion of VP22 coding sequence into pSAMl. Sequence data 
demonstrating the insertion of VP22 cDNA into the MCS of pSAMl using the 
restriction sites Hind III and Bam HI (restriction sites underlined). An in-frame, 
N-terminal fusion of VP22 with luciferase is therefore generated (the start codon 
for VP22 is highlighted in bold type, and the redundant start codon for 
luciferase, which is now a Met residue, is also highlighted). (A) Sequence 
obtained using the pSAMl sequencing primer. (B) Reverse complementary 
sequence of the sequence obtained using the pSAMl reverse sequencing primer. 
Sequence shared between the two traces is indicated by linked black boxes. The 
point mutation within the sequence, A397C, which results in a threonine to 
serine change at residue 135, is highlighted in red.
Q7
4.2.3 Characterisation of the pS AM 1 Family of Expression Vectors 
Having successfully inserted each of the MTPs sequences into pSAMl to enable 
the expression of N-terminal fusions of the MTPs to luciferase it was necessary 
to confirm that the vectors produced active gene products. COS-7 cells were 
transfected with 1 pg vector DNA using GeneJuice and the activity of cytosolic 
cell extracts measured 24 and 48 hours post-transfection.
900
c
<D 800 - -♦— pSAMl 
-A— pSAM1-TAT 
pSAMl-Drome 




O  600 -Ph





28 32 36 40 48 5220 24 44
Time post-transfection (h)
Figure 4.5. Time course of luciferase activity. COS-7 cells were transiently 
transfected with pSAMl or each pSAMl-MTP fusion constructs. Luciferase 
activity of cytosolic extracts was measured 24 and 48 h post-transfection. 
Measurements were performed in triplicate, values are an average of two 
experiments ± S.D. (NB S.D. for pSAMl-mPen, no horizontal bar; S.D. for 
pSAMl-WTPen, broken line.) A pcDNA3.1(+) transfected control is not shown 
as background activity was > 104 fold lower than any of the other samples.
Each pSAMl-MTP construct generated an active luciferase fusion product, 
though the level of activity detected in transfected cells did vary considerably, 
depending on which vector was used in the transfections (Figure 4.5). With the 
exception of VP22 all the activity of all samples decreased from 24-48 h. To 
explore whether the differences in luciferase activity exhibited by the cells were
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due to differences in expression levels, or changes in the intrinsic activity of 
luciferase as a result of being expressed as a fusion protein, Western blot 
analysis directed against luciferase was performed on cytosolic extracts (Figure 
4.6). Analysis was performed 48 h post-transfection as the differences in 
activity were smaller at this time (a maximum difference of 12-fold between 
samples) than at 24 h post-transfection (a maximum difference of 50-fold).












1.00 0.39 0.087 0.89 1.18 0.057
Relative
expression
1.00 0.18 ---- 0.36 0.40
Table 4.2. Comparison of luciferase activity and expression. The luciferase 
activity and expression levels of the transiently transfected samples in figure 4.6 
are shown relative to that of pSAMl transfected cells. Lines indicate data that 
were not quantifiable.
The activities of the samples harvested for immunoblotting were consistent with 
those observed in figure 4.5, though the pSAMl-mPen transfected cells 
exhibited a higher activity than the pSAMl transfected cells (Figure 4.6 A). The 
relative activities of the samples can be seen in table 4.2. Western Blot analysis 
was undertaken with recombinant luciferase (Sigma) as a control. The control 
protein is visible at 66 kDa (Fig. 4.6 B). The samples expressing luciferase 
fusion proteins with the short MTP sequences (12 or 17 residues) would be 
expected to run only about 2 kDa heavier than luciferase when expressed alone. 
Bands were clearly visible for luciferase alone (luc) and the fusion proteins 
TAT-luc, WTPen-luc, and mPen-luc. No band was detected for Drome-luc. 
The fusion protein VP22-luc would have a molecular weight of about 104 kDa 
as the full length VP22 protein was used (38 kDa). However, no band was 
detected at this weight using Western blot analysis. The relative levels of 
expression, where determinable, are shown in table 4.2.
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Figure 4.6. Activity and expression of pSAMl-MTP products. COS-7 cells were 
transiently transfected with 1 pg of either pS AM 1 or a pS AM 1 -MTP fusion 
construct. (A) Forty eight hours post-transfections luciferase activity in cytosolic 
extracts was measured. Measurements were performed in triplicate and values show 
an average ± S.D. (B) To compare expression levels of the constructs Western 
blotting against luciferase was carried out on the same samples, using recombinant 
luciferase (rLuc) as a positive control. A sample of untransfected COS-7 cells is 
shown as a control (UT). The experiment was carried out three times and the 
samples presented here are representative of the data collected. The relative activity 
and expression levels for each sample is shown below in Table 4.2).
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The levels of activity detected in the samples seem to correspond to changes in 
the levels of expression of active fusion proteins. Cells transfected with the 
vectors pSAMl -Drome and pSAMl-VP22 give measurable activities of less 
than 10 % that of samples transfected using pSAMl, and Western blot analysis 
cannot detect any fusion protein within these samples. The samples TAT-luc 
and WTPen-luc, which have activities about 60 % and 10 % lower, respectively, 
than luciferase alone, are detected by Western blotting with expression levels 
lower than that of luciferase. Both samples have a second, lower molecular 
weight band detected by the blot, possibly representing an incomplete 
expression product. If this is the case, the product may have a limited activity 
that could account for the discrepancies in the differences observed between the 
relative activity and expression levels measured for the fusion proteins.
4.2.4 Quantification of Protein Transduction Using Luciferase as a Reporter 
Protein
4.2.4.1 Detection o f Protein Transduction
To harness the sensitivity potential of luciferase as a reporter protein it was 
necessary to develop a means by which cells expressing the luciferase fusion 
proteins could be distinguished and separated from non-transfected cells. 
Assessment of the latter sample of cells for luciferase activity would determine 
whether protein transduction had occurred. A comparison of the total activity of 
the cells with the activity exhibited by the non-expressing cells would allow 
quantification of the efficiency with which the transduction of the active protein 
had taken place.
Segregation of non-transfected cells from transfected ones was to be undertaken 
through cell sorting by FACS analysis. For this to take place a characteristic of 
the two cell samples must differ sufficiently to allow a population designation to 
be made. By creating one fluorescent population cells from this sample are 
easily distinguishable from non-fluorescent cells, and can be separated. This 
could be done by immunofluorescence directed against a cell-type specific 
epitope, as was undertaken in the transduction studies of GFP in co-cultures. 
However, unless the epitope is located on the outside of the cell some form of
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fixation must take place which may be deleterious to the activity of luciferase, 
or may introduce translocation artefacts, as discussed in the introduction.
The use of GFP expression to distinguish the cell populations would allow 
FACS analysis of live cells to be undertaken, and was thus chosen. However, 
rather than transiently transfect cells with a GFP expression vector a COS-7 cell 
line would be generated to constitutively express GFP. Co-culture experiments 
could then be undertaken utilising pSAMl -transfected COS-7 cells and non- 
transfected GFP expressing cells. Cell sorting to isolate the fluorescent cells 
would eliminate non-GFP-positive, and therefore transfected cells from the 
harvested population, and so activity within this population would be 
attributable only to protein transported to these cells.
4.2.4.2 Generation o f a Stable Cell Line Constitutively Expressing EGFP 
The vector pEGFP-Nl allows selection for transfected cells using the antibiotic 
G418. COS-7 cells were initially analysed to determine their susceptibility to 
G418 by growth in medium supplemented with different concentration of the 
antibiotic. Cells were seeded in non-supplemented medium at a density of 5 x 
104 cells per 35 mm dish. Growth medium was supplemented with different 
concentration of G418 24 h after seeding, and medium was changed every 48 h. 
Cell counts were performed 3 days after seeding, and then every 48 h. The 
growth of the COS-7 cells was monitored for two weeks in G418-supplemented 
medium to generate a ‘kill curve’ for the cells, which is shown in figure 4.7.
From the kill curve a concentration of 700 pg/ml was chosen to allow selection 
of pEGFP-Nl transfected cells over a time period of about 14 days. This 
concentration would ensure that non-transfected COS-7 cells were killed over 
the selection period, whilst the concentration was not too high to risk a toxic 
insult to transfected cells. Fourteen days would also allow formation of growth 
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Figure 4.7. Kill curve of COS-7 cells with G418. COS-7 cells were grown in 
medium supplemented with the antibiotic G418, at the concentrations indicated, 
for two weeks. Cell counts were performed every 48 h.
COS-7 cells in 35 mm dishes were transfected with 2 pg pEGFP-Nl using PEI. 
Twenty-four hours post-transfection growth medium was supplemented with 
700 pg/ml G418. Cells were washed and the supplemented medium changed 
every 48 h. Eighteen days post-transfection plaques of cells had formed that 
were not susceptible to G418. These plaques were individually harvested and 
cultivated in supplemented growth medium to increase the cell populations. The 
proliferation of the cells was monitored, and the expression levels of EGFP 
assessed by fluorescence microscopy. Potential stable cell lines for use in the 
co-culture experiments were then examined by FACS analysis to determine the 
number of cells exhibiting GFP expression. Of the cell populations examined, 
the cell line COS-EGFP6 was determined to have the most suitable 
characteristics for use in the co-culture experiments. Representative 







FL1-H = Fluorescence intensity (AU)
Figure 4.8. The stable cell line COS-EGFP6. COS-7 cells were transfected with the 
vector pEGFP-Nl and grown in growth medium supplemented with 750 jag/ml G418 for 
14 days to select cells constitutively expressing EGFP. (A and B) The cell line COS- 
EGFP6 shown under transmitted light and GFP expression viewed by excitation at 488 
nm, respectively. (D) FACS analysis of COS-EGFP6 shows the stable cell line to 
contain a significantly higher number of cells exhibiting GFP fluorescence compared 
with untransfected COS-7 cells (C) (percent events with fluorescence intensity 15- 
10,000 AU: COS-7 = 1.74, COS-EGFP6 = 64.00 ).
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4.2.4.3 Cell Sorting by FA CS
From the preliminary FACS data for the COS-EGFP6 cells the number of cell 
with a fluorescence intensity above background was found to be about 60 % (see 
figure 4.8 C vs. 4.8 D). Though this was not the ‘gold standard’ of 100 % of 
cells constitutively expressing EGFP it was determined that in a co-culture of 
COS-7 cells with COS-EGFP6 cells there would be sufficient cells to act as 
recipient cells for transduced luciferase fusion proteins. In a co-culture of 
transfected COS-7 cells with untransfected COS-EGFP6 cells, at a ratio of 1:1, 
about 30 % of the population would still act as recipient cells that exhibit a level 
of fluorescence sufficiently intense to allow sorting and collection of this 
population from the transfected cell population.
To determine the efficiency with which FACS analysis would allow separation 
and collection of cells trial sorting was undertaken using a population of COS- 
EGFP6 cells alone. The FACS machine was calibrated using a sample of non- 
fluorescent COS-7 cells. A region of fluorescence intensity was established 
whereby less than 1 % of the COS-7 cell population was detected within this 
gated region (figure 4.9 A and table 5), and settings applied that would allow 
collection of all cells occupying the region of high fluorescence intensity. A 
large sample of COS-EGFP6 cells (about 7 x 105) was then analysed by FACS, 
and cells detected in the high fluorescence region collected. Representative 
FACS data can be seen in figure 4.9 B and table 4.3. The harvested cells were 
concentrated by centrifugation prior to re-analysis. Figure 4.9 C shows 
representative FACS data of the collected sample of cells, and the percent events 
in both the low and high fluorescence intensity regions are presented in table 
4.3.






Table 4.3. FACS analysis and cell sorting of COS-EGFP6.
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Figure 4.9. Cell sorting of COS-EGFP6 cells. (A) COS-7 cells were analysed 
for GFP fluorescence (FL1-H) and a gate set so < 0.5% of the sample (10,000 
events) was detected in this region of fluorescence intensity (shaded area). About 
700,000 COS-EGFP6 cells were sorted, and cells in the gated, high-fluorescence 
region harvested. (B) A representative sample of COS-EGFP6 subjected to 
sorting. (C) Re-analysis of harvested COS-EGFP6 cells. Table 4.3 shows the 
percent of cells from the samples in the low and high-fluorescence regions.
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Three separate populations of COS-EGFP6 cells were analysed in this way, and 
these results are representative of the data collected.
From the FACS data it can be seen that, though the proportion of cells 
exhibiting high fluorescent intensity was enriched following sorting of COS- 
EGFP6 cells, there was still a significant percentage of the population (about 40 
%) displaying low levels of fluorescence intensity. For the planned luciferase 
transduction co-culture experiments this population of cells would include COS- 
7 cells transfected with the luciferase fusion constructs. The presence of 
luciferase expressing cells in the harvested population would result in detection 
of luciferase activity within the sample whether transduction had taken place or 
not.
In addition, the number of cells collected was very low relative to the total 
number of cells sampled. When the COS-EGFP6 cells were analysed as 
described above, only about 3 % of the total sample was collected for re­
analysis. As around 50 % of the initial population consisted of cells 
demonstrating high fluorescence, the 6 % of this sample harvested represents a 
very low sorting efficiency.
The combination of these two factors makes this particular approach impossible 
using the equipment available. Contamination of the harvested sample with 
cells expressing a luciferase fusion product raises the background levels of 
luciferase activity within the sample, decreasing the sensitivity of the method for 
detecting transduction. The low number of cells harvested, and the time 
required for this process, makes the sorting of co-cultured samples a very 
inefficient and time-consuming process.
107
4.3 Discussion
Though there have been no reports published with luciferase acting as a direct 
reporter for protein transduction, Ye et a l recently undertook work using 
luciferase expression to quantify the intercellular delivery of chimeric proteins 
containing either the Tat PTD or VP22 (Ye et al., 2002). The chimeric proteins 
comprised of the yeast Gal4 DNA-binding domain and the VP 16 transactivating 
domain with the MTP module. Purified bacterially-expressed fusion proteins 
were applied to “reporter” cells transfected with a luciferase gene that was 
regulated by upstream sites that bound the Gal4 DNA-binding domain. In this 
way, induction of luciferase expression would unambiguously confirm delivery 
of the proteins to the reporter cells. For the work reported here it was hoped that 
the use of luciferase as a reporter protein would provide a means by which 
quantitative comparisons of protein transduction could be accurately 
determined.
Luciferase was chosen because of the sensitivity that can be achieved by 
assaying cells expressing the protein. For GFP, even when using the mutant 
analogues with improved fluorescence intensities such as EGFP (Patterson et al., 
1997), it is estimated that to double the fluorescence of a typical cell (with a 
volume of about 1-2 pL) above endogenous autofluorescence levels somewhere 
in the region of 105 copies of the protein are required in that cell (representing a 
concentration of about 0.1 pM EGFP) (Niswender et al., 1995; Tsien, 1998). 
For luciferase, where current methods using luminometers allow detection of as
90little as 10' moles (Wood, 1991), the same number of enzyme copies is 
required per sample, and not per cell. This sensitivity is a result of both the 
enzymic nature of the system, allowing each copy of protein to amplify the 
signal, and because there are no endogenous substrates for luciferase in 
mammalian cells minimises background.
Luciferase is usually employed as a reporter for transcriptional activity, with 
levels of expression monitored in response to changes to promoter and enhancer 
regions. Luciferase can also be used in imaging studies of cells using low-light 
visualisation technology (see Greer and Szalay, 2002, for review), but this 
equipment is not widely available and equipment analogous to FACS systems
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does not exist for high-throughput quantitative analysis. The studies here were 
to be undertaken using luciferase fusion proteins to explore protein transduction, 
which can introduce additional problems due to an absence of research using 
such fusions. The addition of the MTP sequences could affect the expression or 
activity of luciferase.
The luc gene was successfully transferred from the pGEM-/wc vector, which is 
not intended for expression of luciferase, into the pcDNA3.1(+) vector. This 
vector is used specifically for expression in mammalian cells, and has enhancer- 
promoter sequences from the immediate early gene of human cytomegalovirus 
(CMV) for high-level expression, together with polyadenylation signal and 
transcription termination sequences from the bovine growth hormone to enhance 
mRNA stability. Expression of active luciferase product from the pcDNA-/wc 
vector was confirmed in COS-7 cells, and the remaining restriction sites within 
the MCS would then allow insertion of the MTP sequences to create C-terminal 
luciferase fusion proteins.
Insertion of the MTP sequences was next carried out, and sequencing confirmed 
that in-frame fusions of each sequence with luciferase had been accomplished. 
The VP22 sequence showed only a single point mutation leading to a change-of- 
residue mutation (T135S). However, previous demonstrations that 158 N- 
terminal residues can be removed with no discemable effect on the translocatory 
behaviour of VP22 (Kueltzo et al., 2000) prompted the decision to use this 
construct in the investigation. Cells transfected with each of the constructs 
demonstrated luciferase activity, which decreased between 24 h and 48 h post­
transfection (except in the case of VP22 where a marginal increase in activity 
was observed). Western blotting gave an indication that a difference in the level 
of expression between vectors could account for the observed variation in the 
activity exhibited by the samples. The same result would, however, also be 
observed if incomplete protein not detected by the Western blot was being 
expressed with diminished activity, or if the addition of the MTP sequence 
partially masked both the Western epitope and the active site. However, as all 
of the fusion proteins demonstrated luciferase activity over 4 orders of 
magnitude greater than that measured in cells transfected with the control vector
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pcDNA3.1(+), the system was determined to retain a sufficient level of 
sensitivity to continue with the luciferase reporter approach.
In order to distinguish cells expressing the luciferase fusion proteins from cells 
into which the reporter had been transported, an approach was adopted whereby 
FACS would be carried out to sort a co-culture of non-transfected, fluorescent 
cells with transfected, non-fluorescent cells. Detection of luciferase activity 
within the fluorescent sample of cells following their separation from the non- 
fluorescent cells would demonstrate translocation of the fusion proteins. So as 
not to introduce any fixation artefacts the analysis would be carried out on live 
cells, which negated the need for IF staining to differentiate two different cell 
lines in co-culture by use of cell line-specific antibodies, such as COS-7 cells 
from Rat-1 cells. Similarly, by using live cells the potential of fixative 
chemicals interfering with the activity of luciferase would be abrogated. 
Therefore, a cell line was to be generated to constitutively express EGFP, and 
direct measurements of this fluorescence exploited to sort the cells.
Having determined a suitable concentration of antibiotic to eliminate susceptible 
cells, COS-7 cells were transfected with pEGFP-Nl and the antibiotic G418 
used to select for resistant cells. A number of lines were established with 
promising attributes, but the line COS-EGFP6 was chosen for the proliferation 
and fluorescence characteristics it possessed. However, when a trial sort was 
carried out on these cells it was found that, though the population of cells 
collected was enriched with EGFP positive cells, about 40 % of the cells 
collected from the high fluorescence region exhibited fluorescence levels 
comparable to non-fluorescent COS-7 cells. This was not satisfactory as it was 
the non-fluorescent cells that would be transfected with the pSAMl luciferase 
expression vectors.
Luciferase was chosen because of the sensitivity the reporter offered. If, 
however, ‘contamination’ from expressing cells occurred at the level 
demonstrated by the test sort, detection of low-level transduction, implicated by 
the GFP transduction studies, would not be possible. The high levels of activity 
displayed by the transfected cells would instead reduce the sensitivity of the
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system by increasing the background activity observed, and thus mask the signal 
attributable to the fluorescent cells. In addition to this the number of cells 
harvested by FACS was very low in proportion to the number of cells sampled. 
Of a sample of about 7 x 105 cells processed for sorting it was only ever possible 
to collect about 6 % of the theoretical maximum (around 50 % of those sampled 
were in the high fluorescent region), just 3 % of the cells analysed. This is a low 
sorting efficiency, and is reduced further still as only 60 % of the collected cells 
were from the desired population.
Summary
Constructs for the expression of C-terminal fusions of each MTP sequence with 
luciferase were successfully generated, and cells transfected with the constructs 
expressed active protein. A cell line constitutively expressing the reporter 
protein EGFP was established with about 60 % of the cells exhibiting 
fluorescent intensities above background. Examination of this cell line by 
FACS demonstrated that inefficient and inaccurate sorting would result in a low 
number of harvested cells contaminated with cells not expressing EGFP.
I l l
CHAPTER 5 
PRO-LESS CASPASE-3 AS A REPORTER FOR 
PROTEIN TRANSDUCTION
5.1 Introduction
As neither GFP nor luciferase could be utilised to quantify protein transduction 
using the protocols developed a new reporter was required. A reporter was 
sought that would allow the amplification of a signal following intercellular 
transport from expressing cells to maintain a system with high sensitivity. If the 
effect of this amplification could be visualised through microscopy, in addition 
to being quantified by means of an assay, the system would have a combination 
of the attributes offered by the other two reporters.
5.1.1 Intracellular Signalling Pathways
Cells have a number of pathways to amplify signals, allowing weak or low level 
signals to be increased into a distinctive response by a cell. These pathways 
operate through signalling cascades whereby a single member is able to exert its 
effect on a number of molecules of a downstream mediator, whilst it remains 
active. As each of these components is in turn able to interact with its own 
substrate molecules the amplitude of the signal can be greatly increased. An 
example of this is the amplification in the light-induced catalytic cascade in 
vertebrate rods where the absorption of a single photon of light by a single 
rhodopsin molecule leads to the hydrolysis of more than 105 cyclic GMP 
molecules in a cascade lasting for about 1 second (Lagnado and Baylor, 1992). 
This is a very specific example of a signalling pathway that operates in only one 
cell type. However, there are other pathways familiar to many different cell 
types, and one that is ubiquitous to mammalian cells is that of apoptosis.
5.1.2 Programmed Cell Death
Multicellular animals have a requirement to eliminate cells that are in excess, in 
the way, or potentially dangerous. For this purpose there is dedicated molecular 
machinery that allows the removal of specific cells in a tightly regulated 
manner. Programmed cell death has been observed for two centuries (Vaux and
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Korsmeyer, 1999), but it was in 1972 that Currie and colleagues coined the term 
apoptosis to describe cells undergoing cell death in a manner that was 
morphologically different from necrosis. The term was taken from the Greek 
word that describes the falling off of leaves from trees (Kerr et al., 1972).
Apoptosis is a form of cellular suicide that can be triggered by a variety of 
stimuli, including cytokines, hormones, viruses, and toxic insults. The initial 
definition of apoptosis from Kerr et al was purely morphological, with 
apoptotic cells exhibiting characteristic membrane blebbing, cell shrinkage, 
chromatin condensation and formation of membrane-enclosed vesicles 
(apoptotic bodies). It took over 20 years for the break-through to be made in 
identifying the driving force behind the terminal morphological changes 
associated with apoptosis (Lazebnik et al., 1994). The biochemical alterations 
within apoptotic cells were found to be a result of the cleavage of a specific 
subset of cellular polypeptides by a family of cysteine-dependent aspartate- 
directed proteases that have consequently been termed caspases (Alnemri et al.,
1996). Caspases act on polypeptides by cleaving them at specific sites on the 
carboxyl side of an aspartate residue. The specific cleavage sequence, 
determined by the three residues preceding the required aspartate residue, is 
particular for each caspase, and therefore determines the substrates for the 
enzyme (Talanian et al., 1997; Thomberry et al., 2000; Thomberry et al., 1997). 
There is a huge amount of interest in the area of apoptosis and caspases, and 
consequently there is a vast wealth of material available on the topic. A simple 
literature search will reveal over 135 reviews encompassing the term ‘caspase’ 
in the title alone (source: Web of Science, September 2003). Rather than an 
account detailing the mechanisms of apoptosis, outlined below is a synopsis of 
programmed cell death, with the role of some specific caspases within it, in 
order to consider candidates suitable for use as ‘reporters’ in the study of protein 
transduction. For a comprehensive description of apoptosis see Refs. Cohen, 
1996; Eamshaw et al., 1999; Wyllie, 1997.
5.1.3 Caspases and the Initiation of Apoptosis
Caspases are constitutively and ubiquitously synthesised as precursor proteins, 
zymogens, with little or no activity. To date 14 known mammalian caspases
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have been cloned. Caspase activation requires cleavage to produce a mature 
protein with full enzymic activity (Eamshaw et al., 1999). This cleavage usually 
occurs through the action of another, previously activated, caspase. It appears
Figure 5.1. The intrinsic and extrinsic cell death pathways. In this 
simplified scheme, exogenous ligand, binding to a death receptor, initiates the 
extrinsic pathway by recruitment of an adaptor protein, e.g. FADD. Through 
the interaction death effector domain (DED) modules pro-caspase-8 is recruited, 
and, when a critical concentration is reached, active caspase-8 is generated 
through autocatalytic cleavage of internal sites. The intrinsic pathway, generally 
initiated as a result of an insult to the cell, involves the translocation to the 
mitochondria of pro-apoptotic Bcl-2 family members, such as Bax. In the 
presence of dATP or ATP, the resultant release of mitochondrial cytochrome c 
into the cytosol allows the generation of the apoptosome through 
oligomerisation with Apaf-1 and pro-caspase-9, leading to subsequent activation 
of caspase-9. Activation of these ‘initiator’ caspases activates downstream 
‘effector’ caspases, exemplified by caspase-3, which carry proteolytic cleavage 
of numerous substrates leading to diverse results which culminates in the 
controlled execution of the cell.
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that there are at least two mechanisms by which the most upstream caspases can 
be activated and the cascade initiated: induced proximity and association with a 
regulatory subunit. Simplistically, these methods of initiation correspond, 
respectively, to stimuli resulting in two distinct, but convergent, cascade 
pathways -  extrinsic and intrinsic (summarised in figure 5.1).
The extrinsic pathway begins outside the cell with a ligand binding to its 
respective so-called death-receptor, resulting in activation of the receptor. This 
growing family of receptors all share a conserved cytoplasmic protein-protein 
interaction module termed the death domain (DD). Activation of the receptor 
results in recruitment of DD-containing adaptor proteins, forming the death- 
induced signalling complex (DISC). The adaptor proteins present allow the 
recruitment of upstream caspases (pro-caspase-8 and/or pro-caspase-10) via 
interaction of another module, the death effector domain (DED). These pro- 
caspases possess minimal, but discemable, proteolytic activity, and recruitment 
to the DISC increases the concentration in the local microenvironment to levels 
where autoactivation is possible (Muzio et al., 1998; Salvesen and Dixit, 1999). 
Once activated, these initiator or instigator caspases directly, or indirectly, 
activate downstream effector caspases responsible for execution of the cell.
The intrinsic pathway is responsible for integrating stress, such as DNA 
damaging agents, and some developmental apoptotic stimuli. Such an insult to 
the cell triggers translocation into the mitochondria of a pro-apoptotic Bcl-2 
family member, such as Bax, and subsequent release of mitochondrialy 
compartmentalised cytochrome c. Once in the cytoplasm, cytochrome c can 
bind to the pro-apoptotic regulatory subunit Apaf-1, and in the presence of 
dATP or ATP an oligomeric assembly is formed (Liu et al., 1996; Zou et al.,
1997). It is likely that the conformation of Apaf-1 is altered through this 
association making its amino-terminal caspase recruitment domain (CARD) 
more readily available, consequently allowing binding to pro-caspase-9 through 
a reciprocal CARD domain, generating the ‘apoptosome’ (Li et al., 1997). Once 
bound to pro-caspase-9, Apaf-1 triggers caspase-9’s proteolytic self-activation 
(Srinivasula et al., 1998a) and subsequent activation of downstream effector 
caspases.
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These convenient descriptions of intrinsic and extrinsic pathways are 
undoubtedly simplified, as is demonstrated by the involvement of the 
mitochondrial pathway in receptor initiated cell death through the intermediate 
Bid (Cheng et al., 2001a; Ruffolo et al., 2000). However, it is clear that both 
pathways converge at the point of the effector caspases. In particular, caspase-3 
is activated from its zymogen by both caspase-8 (Muzio et al., 1998; Srinivasula 
et al., 1996; Stennicke et al., 1998) and caspase-9 (Deveraux et al., 1998; Li et 
al., 1997; Srinivasula et al., 1998a). Caspase-3 is often referred to as the ‘point 
of no return’ for cells following the onset of apoptosis. Once caspase-3 is 
activated cells are generally seen as terminally committed to suicidal destruction 
due to the nature and number of substrates on which the active enzyme acts. 
Exceptions to this rule have been observed, but only where other factors have 
altered the normal course of apoptosis progression (Racke et al., 2002; Wright et 
al., 1997). Targets for caspase-3 include pro-caspases (for reviews see Fraser 
and Evan, 1996, and Nicholson and Thomberry, 1997), which serve to act as an 
amplification loop for the apoptotic signal (Slee et al., 1999). With apoptosis 
resulting in a well-characterised change in morphological and biochemical 
features, it is an easily identifiable and measurable event; indeed there is a wide 
range of products available for its quantification. As caspase-3 acts at such an 
important juncture during this process, and with amplification of the apoptotic 
signal occurring through this point, the feasibility of using this enzyme as a 
reporter molecule for protein transduction was explored.
5.1.4 Caspase-3
As with the other caspases, caspase-3 (CPP32, apopain, Yama) is synthesised as 
a single-chain inactive zymogen with an N-terminal prodomain plus a large and 
small catalytic subunit (Cohen, 1997; Nicholson et al., 1995; Nicholson and 
Thomberry, 1997). Caspase-3 comes from a family of caspases known as the 
effector or executioner caspases which act downstream in the caspase pathway 
and that are activated, at least in part, by initiator caspases. In contrast to the 
initiator caspases, the executioner caspase zymogens contain short prodomains 
with neither DED nor CARD motifs (the prodomain of the executioner caspases 
6 and 7 number only 23 amino acids (aa), whereas caspase-1, an activator
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caspase, has a 119 aa prodomain, and caspase-10, another activator caspase, has 
the longest prodomain of the known caspases at 219 aa). Mature caspase-3 is 
generated from a 32-kDa zymogen by a sequential two-step mechanism. The
initial cleavage occurs to produce the small pl2 subunit and a p20 peptide. p20
is further processed, whereby the prodomain is removed, resulting in generation 
of the mature large pl7 subunit (Han et al., 1997). The active enzyme is 
composed of two heterodimers of the pl2 and p i7 subunits generated (Rotonda 
et al., 1996), see figure 5.2.
Figure 5.2. Maturation of
caspase-3. The caspase-3
zymogen is composed of a short 
prodomain, a large subunit and a 
small subunit. Proteolytic cleavage 
at two internal sites by upstream 
caspases and subsequent
rearrangement of subunits results in 
the formation of the mature
heterotetramer caspase-3 enzyme. 
The residues present in the active site of caspase-3 are shown, and their location 
within the mature molecule indicated by blue squares.
Over-expression of the long prodomain initiator caspases in mammalian cells 
results in apoptosis-induced cell death as a result of their activation, probably
through autocatalysis (Kumar et al., 1994). In contrast, overexpression of
caspase-3 was not shown to result in activation of the enzyme, and apoptosis 
was not evident in the expressing cells (Colussi et al., 1998b). Because of the 
processing requirement of procaspase-3 its use as a reporter molecule would 
necessitate treatment of cells with pro-apoptotic stimuli in order to generate the 
mature, active enzyme capable of eliciting a measurable effect. However, this 
would also result in activation of the pool of the ubiquitously expressed 
zymogen. More desirable would be a caspase-3 analogue with intrinsic activity, 
by-passing the requirement of processing for activation. However, investigation 
into the factors influencing caspase-3 activation have resulted in the generation
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of vectors capable of expressing constitutively active forms of the enzyme 
(Meergans et al., 2000; Srinivasula et al., 1998b), see figure 5.3. In the first of 
these reports the order of the proteins subunits was swapped so the coding 
sequence for the small subunit preceded that of the large subunit (Srinivasula et 
al., 1998b). The recombinant molecule was capable of autoprocessing and 
inducing apoptosis in vivo independent of the upstream caspases. In the second 
report the coding sequence for the 28 amino acids of the prodomain were 
omitted from the expression vector (Meergans et al., 2000). Again, 
autoprocessing was observed prior to activation in transiently expressing cells. 
The implication of these reports is that the short prodomain suppresses the 
spontaneous activation of the inactive zymogen, with this restraint removed 
when a pro-less variant is expressed, or masked when there is a rearrangement 
of the subunit order. Either of these variants fulfills the criterion of an active 
caspase-3 analogue, and so could potentially be used as a reporter. However, 
further complications remain: Can potential apoptosis of expressing cells, 
induced by active MTP fusion protein, be delayed or prevented in order to allow 
a pool of transducible protein to build up? Will generation of chimeric fusions 
of the enzymes impair activity?
Figure 5.3. Analogues of procaspase-3 
exhibiting intrinsic activity. Representation of 
the two different strategies used to generate 
analogues of procaspase-3 (A) with intrinsic 
activity with no requirement for processing by upstream caspase. (B) 
Rearrangement of the p20 subunit, containing the pro-domain (red) and the pl7 
large subunit (dark green), with the small p i2 small subunit (light green). (C) 
Removal of the 28 residues corresponding to the pro-domain.
The first of these questions is answered thanks to the work of Nicholson Qt al. 
(Nicholson et al., 1995). This research originally identified caspase-3 as the 
heteromeric apopain enzyme composed of a large and small subunit, derived 
from the proenzyme CPP-32. One of the potential substrates for this enzyme 
was poly (ADP-ribose) polymerase (PARP), which had a known internal site of 
cleavage corresponding to DEVD/G. Through the generation of a tetrapeptide
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aldehyde based on this sequence (Ac-DEVD-CHO) it was possible to prevent 
both camptothecin-induced apoptotic cell death of osteosarcoma cells and to 
inhibit completely the activity of apopain by addition of this peptide to cultured 
cells or purified enzyme. Currently, there are a number of products available for 
the inhibition of caspase-3 with differing properties of specificity, permeability 
and reversibility (see Oncogene catalogue (CNBiosciences, UK) for a detailed 
list).
The effect of generating fusion proteins with either of the intrinsically active 
forms of caspase-3 would be unknown until the proteins were examined. Little 
work has been published on caspases expressed as fusion proteins. GFP fusions 
have been generated to study subcellular localisation of the both full-length 
caspases and of the long prodomains of the initiator caspases (Colussi et al., 
1998a; Shikama et al., 2001). Where the activity of the enzymes was examined 
it was not perturbed by N- or C-terminal fusions. Caspase-3 fusion proteins 
have also been generated to study the influence of long prodomains on 
autoactivation of the enzyme (Colussi et al., 1998b; Racke et al., 2002). In these 
reports replacement of the short prodomain of caspase-3 with the prodomain of 
either caspase-2 or caspase-1 resulted in activation of the caspase, probably 
through the induced proximity model previously described. The only other 
examples of fusion proteins reported have been generated through the addition 
of targeting sequences to the full-length protein to determine the effect on intra- 
and inter-cellular localisation (Harada et al., 2002; Vocero-Akbani et al., 1999). 
The activity of these proteins was unaffected by the addition of short peptide 
sequences preceding the prodomain, most likely as their small size did not 
interfere with the processing of the native protein at the internal cleavage sites.
Selection of the intrinsically active caspase-3 used required consideration of the 
potential influence that the addition of a peptide sequence could have on the 
activity of the enzyme, directly or otherwise. Examination of the structure of 
the active caspase-3 heterodimer shows that rearrangement of the large and 
small subunits occurs in a manner whereby the active site is formed by residues 
situated near the C-terminus of the large subunit (Eamshaw et al., 1999). By 
using the Srinivasula et al model for active caspase-3 (Srinivasula et al.,
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1998b), addition of a sequence to the C-terminus of the protein would put the 
additional residues in a region close to the active site residues. Screening of the 
fusion products would have to be undertaken in order to assess the effect on 
activity the MTP sequences had. As there are not usually residues at the N- 
terminus of the small subunit following processing in the wild-type caspase-3 
protein, the addition of residues here could interfere in someway with the 
formation of the heterodimer necessary for full enzyme activity. The addition of 
any sequence to the N-terminal of the Meergans et a l pro-less variant 
(Meergans et al., 2000) may prevent processing by acting in a manner analogous 
to the wild-type pro-domain. By generating C-terminal fusions this inhibitory 
potential would be removed. However, the possibility of the sequences 
interfering with the dimerisation or activity of caspase-3 would remain, and 
activity assays would have to be undertaken to examine this.
Due to potential processing problems associated with the N-terminal fusions 
(the additional sequences acting to interfere with oligomerisation or as a pro­
domain for the rearrangement or pro-less models, respectively) neither strategy 
was explored. Instead, a strategy was proposed to generate C-terminus fusions 
with the pro-less caspase-3 model. This region is not in the immediate vicinity 
of the active site, unlike a C-terminal fusion with the rearrangement model, and 




5.2.1 Generation of an Expression System for Pro-Less Caspase-3
Work previously undertaken by Meergans et al to characterise a pro-less 
caspase-3 variant (PLCasp3) used a Tet-Off tetracycline-regulated expression 
system and vectors that simultaneously co-express the luciferase reporter protein 
to monitor and normalise the expression levels between different transfections 
(Meergans et al., 2000). A regulated expression system was attractive to enable 
suppression of PLCasp3 fusion protein expression. In addition, co-expression of 
a reporter protein such as luciferase would allow normalisation of expression 
levels between transfections with fusion constructs. Co-expression of a reporter 
such as GFP would allow differentiation of transfected from non-transfected 
cells, and visualisation of the cellular morphologies exhibited by those cells 
expressing the PLCasp3 fusion proteins.
The strategy adopted was to use the expression vector pBI (Clontech). This is a 
bi-directional expression vector allowing the simultaneous expression of two 
genes under the control of a single tetracycline-response element. By using Tet- 
Off cells (Clontech) expression of both genes would be down regulated in 
response to treatment with tetracycline (Tc) or Tc derivatives, such as 
doxycycline (dox). The PLCasp3 sequence would be inserted into one MCS of 
pBI, and another reporter gene (luciferase or EGFP) would be inserted into the 
other MCS. The aim would be to then insert each of the MTP sequences in such 
a way as to form in-frame fusions with PLCasp3. As PLCasp3 exhibits intrinsic 
activity, with no pro-enzyme processing requirement, it is able to process 
caspase-3 target proteins, and detection of such activity in non-transfected cells 
would indicate transduction of the protein from transfected cells.
5.2.2 Regulation of Expression in Tet-Off Cells
To develop a protocol to quantify protein transduction using the PLCasp3 
approach outlined above it was necessary to determine methods to control 
expression in Tet-Off cells.
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5.2.2.1 Regulation o f Expression ofpBI-3K
In order to study regulation of expression in Tet-Off cells, the expression vector 
pBI-3K was used. This vector was a generous gift from Thomas Meergans, 
University of Konstanz, Germany, and was the construct described in his pro- 
less caspase-3 paper (Meergans et al., 2000). In this paper the vector was used 
for the regulated co-expression of PLCasp3 and luciferase in HeLa Tet-Off 
cells. However, examination of the expression of these proteins in the HeLa 
Tet-Off cells used in these studies yielded no caspase-3 activity above 
background. The same cells did, however, express active luciferase, and so 
luciferase activity was monitored during the regulation studies.
Figure 5.4 shows HeLa Tet-Off cells transfected with 1 pg pBI-3K, and grown 
in medium supplemented with different concentrations of Tc at the time of 
transfection. Twenty-four hours post-transfection the cytosolic extract of the 
transfected cells was assayed for luciferase activity. The activity of samples is 
shown relative to a sample of transfected cells grown in medium without Tc. 
The expression of luciferase in cells treated with lpg/ml Tc is about 7-fold 
lower than in the untreated sample.
Regulation of luciferase expression was next examined using a Tc analogue 
doxycycline (dox). Dox is more stable than Tc and the protocol recommends 
supplementation of growth medium every 48 h, compared with every 24 h with 
Tc. This would make the use of dox preferential in expression studies, 
providing it was still able to control tightly expression of the target gene.
Figure 5.5 shows the luciferase activity in the cytosolic extracts of HeLa Tet-Off 
cells transfected with 1 pg pBI-3K, with growth medium supplemented with 
different concentrations of dox at the time of transfection. The extracts were 
harvested 24 h post-transfection. Down regulation of expression is observed 
with dox concentrations as low as 2 pg/ml, with full repression occurring at 
about 0.2 ng/ml. The concentrations necessary for down regulation are lower 
than those required when Tc is used, which is preferential as this will limit any 
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Figure 5.4. Regulation of expression by tetracycline. HeLa Tet-Off cells were 
transfected with pBI-3k. Tetracycline was added at the concentrations indicated at 
the time of transfection. Luciferase activity was measured in cytosolic extracts from 
transfected cells 24 h after transfection. Measurements were performed in triplicate, 
values are an average of two experiments ± S.D. Values are presented in terms of 
activity relative to a transfected sample not supplemented with tetracycline, with a 
sample of untransfected cells (UT) shown as a control.
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Figure 5.5. Regulation of expression by doxycycline. HeLa Tet-Off cells were 
transfected with pBI-3k. Doxycycline was added at the concentrations indicated at 
the time of transfection. Luciferase activity was measured in cytosolic extracts from 
transfected cells 24 h after transfection. Measurements were performed in triplicate, 
values are an average of three experiments, and error bars indicate S.E.M. Values 
are presented in terms of activity relative to a transfected sample not supplemented 
with doxycycline, with a sample of untransfected cells (UT) shown as a control.
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its preparation. Therefore, where regulation of expression was required, dox 
was used.
5.2.2.2 Recovery o f Expression in Doxycycline Down-Regulated HeLa Cells 
With down regulation of expression achieved it was necessary to determine the 
period of time necessary for expression to be recovered following removal of 
the regulatory antibiotic. HeLa Tet-Off cells were transfected with pBI-3K and 
growth medium supplemented with 200 pg/ml dox. Twenty-four hours post­
transfection cells were washed and fresh, supplemented growth medium applied. 
At various times over a 12 h time course cells were again washed and the 
growth medium replaced with non-supplemented medium. The luciferase 
activity in the cytosolic extracts of the cells was measured either 36 h or 48 h 
post-transfection, allowing luciferase activity to be determined up to 24 h 
following removal of dox from the growth medium.
As shown in figure 5.6 the recovery of luciferase expression is dependent on the 
time cells are exposed to dox-free medium. The data up to 12 h following 
removal of dox represent the activity of cells 36 h post-transfection (filled 
circles and solid line), whereas the data from 12-24 h represent activity 
measured 48 h post-transfection (circles and broken line). As was found 
previously (see figure 4.5) luciferase activity decreased when measured at 24 h 
and 48 h. This was observed here as the two samples measured 12 h following 
the removal of dox demonstrate.
Though the activity within the cells does not appear to have reached a maximum 
12 h following the removal of dox, a longer incubation in dox-free medium may 
result in a lower measured activity due to the observed decrease in luciferase 
activity with time. This would not be detected, however, if all of the samples 
were harvested at the same time, as in the protocol undertaken here, since the 
activity of each sample would decrease to the same extent. For studies where 
the measurement of activity was necessary following removal of the regulatory 
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Figure 5.6. Recovery of luciferase expression following removal of doxycycline.
HeLa Tet-Off cells were transfected with pBI-3K and cells supplemented with 200 
pg/ml doxycycline (dox). Twenty four hours post-transfection cells were washed 
twice with PBS, and fresh dox-supplemented growth medium applied as before. At 
the time intervals 0, 3, 6, 8, 10, 11, 11.5 and 12 h (filled circles and solid line), or 0, 
3, 6, 9 and 12 h (circles and dashed line) cells were washed as before and fresh, 
unsupplemented growth medium applied. Luciferase activity in the cytosolic 
extracts of cells was measured 36 h post-transfection (filled circles and solid line) or 
48 h post-transfection (circles and broken line). Measurements were performed in 
triplicate, values are an average of three experiments, and error bars indicate S.E.M.
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5.2.3 Regulation of Caspase-3 Activity
As discussed previously, PLCasp3 exhibits capase-3-like activity and is capable 
of cleaving caspase-3 substrates. Production of PLCasp3 or PLCasp3 fusion 
proteins could therefore result in apoptosis of expressing cells, preventing an 
accumulation of protein for transduction. To protect against this, caspase-3 
activity would require inhibiting with a reversible inhibitor to enable recovery of 
reporter activity subsequent to inhibition.
As there was no discemable caspase-3 activity in pBI-3K transfected cells an 
alternative method was required to follow caspase-3 inhibition and activity 
recovery. Staurosporine (STS) is a well-known inducer of apoptosis, and 
treatment of cells with STS results in increased levels of caspase-3 activity. 
STS-induced apoptosis was, therefore, used as a mechanism to study caspase-3 
inhibition.
5.2.3.1 Inhibition o f Caspase-3 Activity
As it was necessary to inhibit caspase activity within the cultured cells, initial 
studies were undertaken using a cell-permeable inhibitor. The sequence Asp- 
Glu-Val-Asp represents the site of caspase-3 cleavage in poly (ADP-ribose) 
polymerase (PARP). This sequence is capable of binding to the active site of 
caspase-3, and inhibitors have been designed around the affinity of caspase-3 to 
the tetrapeptide. The inhibitor N-acetyl-AAVALLPAVLLALLAP-DEVD-CHO 
(cp-DEVD-CHO) consists of this sequence preceded by a peptide corresponding 
to the hydrophobic region of the Kaposi fibroblast growth factor added to 
increase the cell permeability of the inhibitory sequence (Lin et al., 1995), and 
the aldehyde nature of the peptidyl mimetic results in reversible rather than 
irreversible binding to caspase-3.
Confluent monolayers of HeLa Tet-Off cells were pre-incubated with different 
concentrations of cp-DEVD-CHO for 2 h. STS was added to the cells to a 
concentration of 1 pM and the cells were incubated for a further 3 h. Cytosolic 
extracts were harvested and caspase-3 activity was measured as the rate of 
change in absorbance at 405 nm by cleavage of the substrate N-acetyl-Asp-Glu- 
Val-Asp p-nitroanilide (Ac-DEVD-pNA).
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Figure 5.7 shows the caspase-3 activity measured in STS treated cell pre-treated 
with 0-50 pM cp-DEVD-CHO. A sample of cells not subjected to STS 
treatment shows the background level of Ac-DEVD-pNA cleavage, which is due 
to non-specific processing of the substrate by other proteases. Though some 
inhibition of caspase-3 activity is observed at 20-50 pM cp-DEVD-CHO, the 
activity was never reduced below 65 % the activity of a sample with no pre­
incubation treatment with cp-DEVD-CHO.
A second inhibitor was examined to determine whether the inhibition 
demonstrated by cp-DEVD-CHO could be improved upon. The inhibitor N- 
acetyl-DEVD-CHO (Ac-DEVD-CHO) lacks the cell permeable sequence of the 
cp-DVD-CHO inhibitor, but has been shown to inhibit caspase-3 activity when 
added exogenously to cells subsequently treated with STS (Gurtu and Zhang, 
1997).
HeLa Tet-Off cells were treated as before, but with just a one hour pre­
incubation with Ac-DEVD-CHO. Figure 5.8 shows the caspase-3 activity 
measured in cells pre-treated with 0-100 pM Ac-DEVD-CHO. Pre-incubation 
with only 1 pM Ac-DEVD-CHO resulted in a 50 % reduction in measurable 
caspase-3 activity, and as the inhibitor concentration was increased the activity 
was decreased further. Total inhibition to background levels was experienced at 
100 pM inhibitor, though very little observable Ac-DEVD-pNA cleavage was 
observed at 50 pM.
The studies have shown that the inhibitor Ac-DEVD-CHO was able to inhibit 
caspase-3 activity, induced by treatment with STS, when added exogenously to 
cells in culture to a greater extent than its cell-permeable analogue, cp-DEVD- 
CHO. To achieve a similar level of inhibition pre-incubation for 1 h with only 1 
pM Ac-DEVD-CHO was necessary compared with pre-incubation for 2 h with 
50 pM cp-DEVD-CHO. This made the inhibitor Ac-DEVD-CHO the lead 
candidate for the studies using PLCasp3. However, the degree to which the 
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Figure 5.7. Effect of a cell permeable inhibitor on the caspase-3 activity in 
staurosporine treated cells. HeLa Tet-Off cells were pre-incubated with varying 
concentrations of the inhibitor cell permeable-DEVD-CHO (cp-DEVD-CHO) for 2 
h. After this period cells were treated with staurosprorine (STS) to allow induction 
of apoptosis. Caspase-3 activity was then measured in cytosolic extracts of treated 
cells. Measurements were performed in triplicate, values are an average of two 
experiments ± S.D. Values are presented in terms of activity relative to a sample not 
supplemented with cp-DEVD-CHO, with a sample of cells not treated with STS 
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Figure 5.8. Effect of an inhibitor on the caspase-3 activity in staurosporine 
treated cells. HeLa Tet-Off cells were pre-incubated with the indicated 
concentrations of the inhibitor acetyl-DEVD-CHO (Ac-DEVD-CHO) for 1 hour. 
After this period cells were treated with staurosporine (STS) to allow induction of 
apoptosis. Caspase 3 activity was then measured in cytosolic extracts of treated 
cells. Measurements were performed in triplicate, values are an average of three 
experiments, and error bars indicate S.E.M. Values are presented in terms of 
activity relative to a sample not supplemented with Ac-DEVD-CHO, with a sample 
of cells not treated with STS (UT) shown as a control.
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5.23.2 Recovery o f Caspase-3 Activity
HeLa Tet-Off cells were pre-incubated for 1 h with 100 pM Ac-DEVD-CHO. 
The inhibitor was removed by thorough washing of the cells with PBS, and 
fresh growth medium added. At different times following the removal of the 
inhibitor growth medium was supplemented with STS to a concentration of 1 
pM. Cytosolic extracts were harvested after 3h treatment with STS, and 
caspase-3 activity measured as before.
As figure 5.9 shows, full caspase-3 activity, as demonstrated by the sample with 
no inhibitor pre-incubation (w/o Ac-DEVD-CHO), was recovered 6 h following 
removal of Ac-DEVD-CHO from cells. This recovery was from total inhibition 
to background levels, represented by Ac-DEVD-pNA cleavage evident in a 
sample of cell subjected to no treatment. As a result, it should be possible to use 
Ac-DEVD-CHO to inhibit the caspase-3 activity of PLCasp3, providing the 
inhibitor retained functionality against the enzyme, allowing expression to occur 
within transfected cells without compromising cell viability. This would allow 
time for the formation of a pool of PLCasp3-MTP fusion protein to accumulate, 
and for translocation of the protein to neighbouring, non-expressing cells to take 
place. Removal of the inhibitor by washing the cells would then enable the 
activity of PLCasp3 to return to normal over a 6 h period, and observations 
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Figure 5.9. Recovery of caspase-3 activity in staurosporine treated cells 
following removal of the inhibitor Ac-DEVD-CHO. HeLa Tet-Off cells were 
treated with 100 pM Ac-DEVD-CHO for 1 h. Cells were washed to remove the 
inhibitor, and at the time intervals indicated growth media was supplemented with 
staurosporine (STS) to induce apoptosis, applied. After 3 hours, caspase-3 activity 
was measured in cytosolic extracts of treated cells. Measurements were performed 
in triplicate, values are an average of three experiments, and error bars indicate 
S.E.M. Values are presented in terms of activity relative to a sample not 
supplemented with Ac-DEVD-CHO (w/o Ac-DEVD-CHO), with a sample of cells 
not treated with STS shown as a control.
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5.2.4 Strategy and Construction of Pro-Less Caspase-3 Expression Vectors 
Once the reagents necessary to regulate expression in HeLa Tet-Off cells and to 
control caspase-3 activity in cells had been determined, it was necessary to 
generate a system for the expression of PLCasp3. As discussed previously, the 
vector chosen was pBI, and outlined below is the cloning strategy undertaken to 
generate vectors enabling the co-expression of luciferase or EGFP with 
PLCasp3 or PLCasp3-MTP fusion proteins. A schematic of the strategy is 
shown in figure 5.10
5.2.4.1 Generation o f pBI-GFP andpBI-luc
Both the luciferase gene and the GFP gene were to be inserted into the MCS II 
site of pBI. Both sequences would be excised from vector already used during 
the course of this work, luciferase from pGEM-/wc and EGFP from pEGFP-Nl. 
Excision of the genes would take place through Sal I/Not 1 and Not l/Pst 1 
double digests for luciferase and EGFP, respectively, with insertion taking place 
following digestion of pBI with the same two restriction enzymes. The pairs of 
enzymes have compatible restriction buffer requirements and all digests were 
undertaken simultaneously. Fragments were inserted through simple ligation 
with the linearised vector, and transformed E. coli screened for the presence of 
constructs containing the insert by restriction analysis of their DNA with the 
same pair of inserts. Figure 5.11 A shows the successful insertion of EGFP into 
pBI, and figure 5.11 B the successful insertion of luciferase. The vectors will be 
referred to as pBI-GFP and pBI-luc.
5.2.4.2 Generation o f Vectors for the Co-Expression ofPLCasp3
The sequence coding for PLCasp3 was to be inserted into MCS I of each of pBI- 
GFP and pBI-luc. This insertion was limited to only 2 restriction enzymes, 
Mlu 1 and Nhe 1. However, as MTP sequences were to be added to produce 
constructs able to express PLCasp3-MTP fusion proteins it would be necessary 
to introduce an additional restriction site for these insertions to take place. In 
order to do this, the reverse primer designed for the amplification of PLCasp3 
would contain additional bases to include the restriction site for Bel 1. 
Restriction sites were incorporated in the primers in addition to the 
complementary annealing bases. These would allow insertion of the PLCasp3
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Figure 5.10. Schematic demonstrating the cloning strategy for the 
generation of PLCasp3 expressing vectors. Either the EGFP or the 
luciferase coding sequence would be inserted in to the second multiple cloning 
site of pBI (MCS II), generating pBI-GFP and pBI-luc, respectively. Pro-less 
caspase-3, amplified from pBI-3K by PCR, would then be inserted into MCS I 
to generate the bi-expression vectors pSAM2 and pSAM3.
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Figure 5.11. Restriction analysis of pBI-GFP and pBI-luc. (A) Restriction 
analysis of pBI-GFP. Lanes 1 and 2 show Pst MNoi I double digests of pBI and 
pBI-EGFP, respectively. Lane 2 shows insertion of the EGFP cassette into 
MCS II of pBI. (B) Restriction analysis of pBI-luc. Lane 1, Sal I/Not I double 
digest of pBI. Lane 2, Pst I/Not I double digest of pBI. Lane 3, Sal I /Not I 
double digest of pBI-luc showing insert of luciferase cassette into MCS II of 
pBI. Lane 4, Pst I /Not I double digest of pBI-luc.
sequence into pBI MCS I, and then permit subsequent insertion of MTPs to 
form C-terminal fusions with PLCasp3. The additional bases were as follows:
a) 5 ’ Mlu 1 restriction site immediately preceding a start codon on the forward 
primer.
b) 5’ Nhe 1 restriction site immediately preceding a stop codon on the reverse 
primer.
c) Codons for a tri-glycine repeat separating the stop codon from downstream 
Bel 1 restriction site on the reverse primer.
d) Additional 5’ bases preceding both the Mlu 1 and Nhe 1 restriction sites to 
allow successful digestion of the PCR fragment.
Insertion of PLCasp3 into pBI-GFP and pBI-luc would therefore take place on 
an Mlu MNhe 1 double digest. The inserted sequence would be that of PLCasp3 
with a C-terminal tri-glycine repeat. Insertion of each MTP sequence would 
then take place using a Bel MNhe 1 double-digest, forming C-terminal fusions
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with PLCasp3. Primers for the amplification of PLCasp3 from the vector pBI- 
3K are shown in table 5.1.




GAT C AGT GAT AAAA AT AG AGTT CTT 
TTG 3’
Table 5.1. Primers for amplification of PLCasp3.
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Following amplification, the PLCasp3 fragment was gel purified, digested by 
Mlu MNhe 1 double digest, and the DNA ready for insertion into pSAMl gel 
purified again. The vector pBI-GFP was prepared to accept the fragment by 
sequential digests with the same enzymes as simultaneous digestion was not 
possible due to the close proximity of the two restriction sites. Ligation of 
PLCasp3 and pBI-GFP was undertaken, and transformed E. coli screened to 
determine the presence of the inert in pBI-GFP by restriction analysis of their 
DNA using the same 2 restriction enzymes. Where an insert was detected DNA 
was sent for sequencing, using the pBI sequencing primer shown in appendix 
B12, to check for mutations within the PLCasp3 sequence.
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The sequence data obtained for pBI-GFP-PLCasp3 is shown is figure 5.12. The 
M m  1 and Nhe 1 sites are underlined, and the start codon for PLCasp3 is 
highlighted in bold. The sequence for PLCasp3 was without mutation. 
However, the sequence for the Bel 1 restriction site, highlighted in red, 
contained a single point mutation, underlined, which resulted in destruction of 
the restriction site.
ACGC GT AT GT CT GG AAT ATCCCT GG AC AAC AGTT AT AAAA 
T GG ATT AT CCT GAG AT GGGTTT ATGT AT AAT AATT AAT AAT 
A AG A ATTTT CAT A AA AGC ACT GG A AT G AC AT CTC GGT CTG 
GT AC AG AT GTCG AT GC AGC AAACCTC AGGG A AAC ATTC AG 
AAACTT G AAAT AT GAAGTC AGG A AT AAAAAT G ATCTT AC A 
CGT G AAG AAATT GT GG A ATT GAT GCGT GAT GTTTCT AAAG 
A AG ATC AC AGC A AA AGG AGC AGTTTT GTTT GT GT GCTTCT 
GAGCC AT GGT G AAG AAGG A AT AATTTTTGG AAC AAAT GG A 
CCT GTT GACCT G AAAA AAAT A AC A AACTTTTTC AG AGGGG 
ATCGTT GT AG AAGT CT AACT GG AA AACCC AAACTTTT C ATT 
ATTC AGGCCT GCCGT GGT AC AG A ACTGG ACT GT GGC ATT G 
AG AC AGAC AGT GGT GTT GAT GAT G AC AT GGCGT GT CAT AA 
AAT ACC AGT GG AGGCCG ACTT CTT GT AT GC AT ACTCC AC A 
GCACCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTC 
CTGGTTCATCCAGTCGCTTTGTGCCATGCTGAAACAGTATG 
CCGAC AAGCTTG AATTT AT GC AC ATTCTT ACCCGGGTT AAC 
CG A A A GGT GGC AAC AG AATTT G AGT CCTTTT CCTTT G AC G 
CT ACTTTT CAT G C AAAG A AAC AG ATT CC AT G T ATT G TTT CC 
ATGCTCACAAAAGAACTCTATTTTTATCACTGATCCGG/4G 
GAGGATAAGC TAGC
Figure 5.12. Insertion of pro-less caspase-3 into pBI-GFP. Sequence data 
showing insertion of pro-less caspase-3 cDNA into MCS1 of pBI-GFP using the 
restriction sites Mlu 1 and Nhe 1 (restriction sites underlined). The start codon 
for the coding sequence is highlighted in bold. Additional bases coding for a C- 
terminal tri-glycine repeat and a stop codon, in frame with pro-less caspase-3, 
are shown in italics. The mutated Bel 1 site is highlighted in red, where an A to 
C point mutation (underlined) has destroyed the restriction site.
The mutation resulted in a vector that would co-express EGFP and PLCasp3, but 
that could not be used for subsequent subcloning to make PLCasp3-MTP fusion 
proteins. The vector pBI-GFP-PLCasp3 with the redundant Bel 1 restriction site
m
will be referred to as mpSAM2 (pSAM2 would refer to a vector that subcloning 
could take place in).
Further attempts at generating an insert without mutation yielded no results, and 
so site-directed mutagenesis was used to correct the mutation in the restriction 
site, allowing insertion of the MTP sequences between that site and the 
downstream Nhe 1 site. However, to simplify future subcloning, rather than 
correct only the point mutation in mpSAM2, the Bel 1 site would be replaced 
with a site for restriction with the enzyme Age 1. Bel 1 cleavage of DNA is 
blocked by Dam methylation, requiring preparation of DNA from a bacterial 
strain devoid of Dam methylase, such as strain GM2163. As with the other 
restriction enzymes used in the cloning in these studies, Age 1 is unaffected by 
the methylation state of DNA, enabling the normal JM109 strain to be used for 
the preparation of DNA.
The primers in table 5.2 were used for the site directed mutagenesis, following 
the manufacturers protocol.
Forward Primer Reverse Primer
5’ GAACTCTATTTTTATCACACCGG 





Table 5.2. Primers for site directed mutagenesis of mpSAM2. Forward and 
reverse primers to replace the mutated Bel 1 site in mpSAM2 with an Age 1 
restriction site (Age 1 recognition sequence highlighted in bold).
Screening of colonies from the site directed mutagenesis was undertaken by 
restriction analysis using Age 1. Figure 5.13 shows a mutagenesis product that 
has been successfully digested using Age 1, with mpSAM2 failing to digest.
Sequencing of the product using the pBI (MCS I) sequencing primer (see 
appendix B12) showed PLCasp3 with no mutations. The Mlu 1, Nhe 1, and 
Age 1 restriction
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Figure 5.13. Restriction analysis of mpSAM2 site-directed 
mutagenesis product. Lanes 1 and 2 show Age I digests of 
mpSAM2 and of its mutagenesis product, respectively. The 
pair of bands in lane 1, highlighted by arrow, show undigested 
vector. The single band in lane 2 is a result of a single Age I 
restriction site within the mutagenesis product
m Bel 1
800 810 820 f K 8^0 840 850
Age 1
940 950 960 f  9 7 0  980 990
Figure 5.14. Sequence comparison of mpSAM2 and mutagenesis product.
(A) Trace of C-terminal pro-less caspase-3 sequence from mpSAM2. Mutated 
Bel I restriction site is highlighted. (B) Corresponding trace of product from 
site-directed mutagenesis of mpSAM2. As highlighted, mutagenesis was 
successful in changing the mutated Bel I site to an Age I restriction site. Stop 
codons are underlined. A silent, change-of-base point mutation in the 
mutagenesis product is underlined.
n o
sites were also present without mutation. Figure 5.14 is a comparison of the 
traces from the sequencing of mpSAM2 (A) and the product of the site directed 
mutagenesis performed using this vector as a template (B). The only mutation 
identified from the sequencing was a silent point mutation in the stop codon of 
PLCasp3 (underlined).
However, neither caspase-3 activity, nor EGFP expression was detected in cells 
transfected with the mutagenesis product (data not shown). The vector was 
subjected to RFLP analysis, and as figure 5.15 shows, digestion did not take 
place with the enzyme Pst 1.
Pst 1/ Not 1 Not 1 Pst 1 undigested
 ^ JL ^_____ _^_______A- ^ ^ A  ^ A
1 2 3 4 5 6 7 8
Figure 5.15. Restriction analysis of the mpSAM2 site-directed mutagenesis 
product. RFLP analysis of mpSAM2 (lanes 1, 3, 5, and 7) and its site-directed 
mutagenesis product (lanes 2, 4, 6, and 8) was undertaken. The restriction 
analysis showed the destruction of the Pst I site from the MCS II of pBI in the 
mutagenesis product.
The Pst 1 site is located in proximity to (about 10 bp distant from) the start of 
the CMV promoter site that drives expression of inserts in MCS II, and to the 
Tet responsive element for the vector. It is possible that a loss-of-function 
mutation, caused by a large deletion in either/both of the regions was 
unintentionally introduced during site-directed mutagenesis of mpSAM2.
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5.2.5 Characterisation of PLCasp3 Expression Vectors
Though mpSAM2 could not be utilised for the generation of PLCasp3 fusion 
proteins it could be used to characterise the viability of the caspase-3 approach 
to study protein transduction. In addition to this vector, the PLCasp3 sequence, 
shown in figure 5.12, was excised and inserted into the vector pBI-luc on an 
Mlu \/Nhe 1 double digest, generating pBI-luc-PLCasp3, which will be referred 
to as mpSAM3.
5.2.5.1 Characterisation o f mpSAM3
The vector mpSAM3 was studied to determine the conditions necessary to 
regulate expression of the vector, and to control the activity of the PLCasp3 
protein expressed. From the previous studies on luciferase expression using 
pBI-3K, dox-regulated co-expression of PLCasp3 and luciferase was examined. 
Figure 5.16 shows that both proteins were expressed in HeLa Tet-Off cells 
transfected with mpSAM3. Both the luciferase and the caspase-3 activity 
exhibited by the cells decreased as the concentration of dox was increased. Both 
activities were reduced to background levels when the cells were subjected to 
200 pg/ml dox.
It was necessary to determine whether the caspase-3 activity exhibited by the 
mpSAM3 transfected cells could be controlled in the same manner as the 
activity in staurosporine-treated cells. Cells transfected with mpSAM3 were 
treated with doxycycline and/or the inhibitor Ac-DEVD-CHO. Figure 5.17 
shows that, as determined above, treatment with dox results in decreased 
caspase-3 and luciferase activities. Treatment with Ac-DEVD-CHO does not 
affect the luciferase activity exhibited in transfected cells, but does decrease the 
caspase-3 activity of the cells. This is, therefore, due to inhibition of the 
PLCasp3 protein rather than a decrease in the amount of protein expressed. The 
caspase-3 activity can be recovered, however, by removal of the inhibitor by 
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Figure 5.16. Regulation of expression in mpSAM3 transfected cell by 
doxycycline. HeLa Tet-Off cells were transfected with expression construct 
mpSAM3. Doxycycline (dox) was added at the time of transfection at the 
concentrations indicated. Luciferase and caspase-3 activity was measured in 
cytosolic extracts from transfected cells 24 h after transfection. Measurements were 
performed in triplicate, values are an average of two experiments ± S.D. Values are 
presented in terms of activity relative to a transfected sample not supplemented with 
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Figure 5.17. Regulation of activity exhibited by cells transiently transfected 
with mpSAM3. HeLa Tet-Off cells were transfected with mpSAM3, and growth 
media supplemented with 200 pg/ml doxycycline (dox) and/or 100 pM Ac-DEVD- 
CHO. Eighteen hours post-transfection cells were washed, where indicated, and 
fresh growth medium applied. Luciferase and caspase-3 activity was measured in 
cytosolic extracts of transfected cells 24 h post-transfection Measurements were 
performed in triplicate, and values are an average of two experiments ± S.D. Values 
are presented in terms of activity relative to a transfected sample with no medium 
supplementation, with a sample of untransfected cells shown as a control
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5.2.5.2 Characterisation o f mpSAM2
With regulation of mpSAM3 determined, mpSAM2 was assessed for PLCasp3 
and EGFP expression. Figure 5.18 A shows that expression of PLCasp3 in 
mpSAM2 transfected cells is also regulated by dox. Examination of the 
transfected cells confirmed that the cells also expressed EGFP (figure 5.18 C 
and D). It was anticipated that apoptosis would occur in the cells expressing 
PLCasp3 as a result of the intrinsic activity exhibited by the pro-less caspase-3 
variant. Figure 5.18 A shows the nuclear morphologies of cells treated with 
staurosporine. Apoptosis has been induced in the cells, and this is characterised 
in the micrographs by chromatin condensation. A representative sample of non- 
apoptotic cells is shown in figure 5.18 E for comparison. However, the 
mpSAM2 transfected cells, identified by EGFP expression, were visible 
exhibiting the morphologies of both apoptotic and non-apoptotic nuclei, 
represented by the images captured in figure 5.18 C and D, respectively. This is 
an indication that though the pro-less caspase-3 variant does exhibit caspase-3 
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Figure 5.18. Regulation of activity exhibited by cells transiently transfected with
mpSAM2. HeLa Tet-Off cells were transfected with mpSAM2. Doxycycline (dox)
was added at the concentrations indicated at the time of transfection. (A) Caspase-3
activity was measured in cytosolic extracts from transfected cells 24 h after
transfection. Measurements were performed in triplicate, values are an average of
two experiments ± S.D. Values are presented in terms of activity relative to a
transfected sample not supplemented with dox. A sample of untransfected cells
(UT) is shown as a control. (B-E) Representative fluorescent microscope images of
DAPI stained cells (blue) to study nuclear morphology. (B) HeLa Tet-Off cells
treated for three hours with staurosporine (STS) prior to harvesting. (E) Untreated
HeLa Tet-Off cells. (C and D) Images of mpSAM2 transfected HeLa Tet-Off cells,
untreated with dox, harvested prior to lysis for caspase-3 activity determination,
expressing EGFP (green). (C) Transfected cell exhibiting apoptotic nuclear
morphology. (D) Transfected cells exhibiting normal nuclear morphology.
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5.3 Discussion
A number of investigations have been undertaken exploring the potential of 
protein transduction for use in relation to apoptosis, both for protection against 
apoptosis (Denicourt and Dowdy, 2003; Dietz et al., 2002; Embury et al., 2001; 
Gustafsson et al., 2002; Ribeiro et al., 2003), and to eliminate cells either 
directly of indirectly through induction of apoptosis (Bandara et al., 1997; Chen 
et al., 1999; Cheng et al., 2001c; Giorello et al., 1998; Harada et al., 2002; 
Herbert et al., 2000; Holinger et al., 1999; Kanovsky et al., 2001; Kim et al., 
1999; Li et al., 2002; Phelan et al., 1998; Schimmer et al., 2001; Tasciotti et al., 
2003; Vocero-Akbani et al., 2000; Vocero-Akbani et al., 1999; Zender et al., 
2002). However, only two studies have examined direct transport of a caspase 
in fusion with an MTP, and both focused on transport of caspase-3 analogues 
mediated by the Tat PTD (Harada et al., 2002; Vocero-Akbani et al., 1999). The 
proteins in question were modified to alter the conditions under which they were 
activated. Vocera-Akbani et al modified the internal cleavage sites of capsase- 
3 to those recognised by the HIV protease, instigating processing and activation 
of the analogue in HIV infected cells only (Vocero-Akbani et al., 1999). Harada 
et a l included an oxygen-dependent degradation domain in the fusion protein 
studied, leading to degradation of the caspase in cells not subjected to hypoxic 
conditions whilst inducing increased levels of apoptosis in cells under oxygen- 
limited conditions (Harada et al., 2002). In contrast to these investigations the 
approach that was adopted for the work undertaken here was to generate an 
intrinsically active analogue of caspase-3 and utilise the activity of this protein 
to directly quantify protein transduction.
5.3.1 Regulation of Expression of pBI Vectors
Meergans et al had previously developed a system for the regulated expression 
of an active caspase-3 analogue, using a coding sequence that omitted the pro­
domain (Meergans et al., 2000). The Wendel group generously donated the 
vector characterised in this paper, pBI-3K, and a methodology exploiting the 
group’s findings was adopted. Unfortunately, when the HeLa Tet-Off cells used 
for this study were transfected with pBI-3K they failed to exhibit caspase-3 
activity. However, luciferase activity was detected, and this enabled 
characterisation of expression regulation in this cell line to be investigated.
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The pBI expression vectors (Clontech), from which pBI-3K was derived, allow 
the simultaneous expression of two genes under the control of a single 
tetracycline-response element. Examination of luciferase expression in pBI-3K 
transfected cells demonstrated that doxycycline (dox) conferred a much tighter 
means of regulation than tetracycline (Tet) at 104 fold lower concentrations. 
Dox has the additional benefit of improved stability over Tet, allowing repeat 
applications every 48 h rather than 24 h. These findings made dox the analogue 
of choice for regulation of expression in these cells. Meergans et al. report Tet 
concentrations of 25 ng/ml for full repression of expression of activity from 
pBI-3K transfected HeLa Tet-Off cells (Meergans et al., 2000). Though this 
concentration is around 100 fold higher than the dox concentration required to 
limit expression in the HeLa Tet-Off cells used for the results reported here, it is 
substantially lower than the maximum Tet concentration used (1 |ig/ml), where 
luciferase activity about 100 fold that of the negative control cells was still 
measured. The differences observed demonstrate the variation in samples of 
cells from the same cell line (all experiments were carried out in HeLa Tet-Off 
cells), and this natural variation may account for the absence of caspase-3 
activity in the transfected pBI-3K cells. It may be that the HeLa Tet-Off cell 
line used by Meergans et al had a slightly altered expression profile whereby 
the cells were less sensitive to the antibiotics regulating their expression, but that 
they expressed higher levels of the proteins when transfected with the pBI 
vector, enabling detection of caspase-3 activity from the pro-less caspase-3 
analogue.
Having determined that expression could be controlled by dox it was necessary 
to determine whether expression and activity could be recovered in cells treated 
with dox. In cells harvested 36 h post-transfection a large increase in activity 
was measured 6-9 h following removal of dox from the cells, and a slightly 
smaller increase 9-12 h. However, cells harvested 48 h post-transfection 
demonstrated a markedly lower activity in samples incubated for 12 h in dox- 
free medium. An increase in activity was observed in these cells 12-24 h 
following dox removal, but the maximum levels exhibited were still lower than 
those in cells incubated for 9 h without dox and harvested 36 h post-transfection.
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Theoretically, the two samples grown without dox for 12 h should exhibit the 
same levels of activity, yet the samples harvested 48 h post-transfection had an 
activity less than 20 % that measured for the samples harvested 36 h post­
transfection. As the age of a culture of cells appears to influence the maximum 
level of expression recovery achievable, careful consideration would have to be 
given to the stage at which cells were harvested following repression of their 
expression with dox, with longer periods of incubation without the repressor not 
necessarily leading to higher levels of expression.
5.3.2 Inhibition of In Vivo Caspase-3 Activity
Though it was now possible to regulate the expression of proteins in a pBI 
vector, the expression of the desired protein, an active caspase-3 analogue, may 
have the terminal effect of killing the cells expressing the protein. This was not 
desirable for quantification of protein transduction as accumulation of 
insufficient protein within the donor cells would be inhibited, thus analysing 
translocation of the fusion proteins would be difficult. Two caspase-3-specific, 
reversible inhibitors, cp-DEVD-CHO and Ac-DEVD-CHO, were examined to 
explore the extent to which the caspase-3 activity could be abrogated. In order 
to test the inhibitors cells were treated with staurosporine, which activates 
caspase-3 and results in apoptosis, as caspase-3 activity was not exhibited in 
cells transfected with the pBI-3K vector. The sole difference between the two 
inhibitors was that one, cp-DEVD-CHO, carried a 16 residue peptide 
corresponding to the hydrophobic region of the Kaposi fibroblast growth factor. 
Like the MTPs, this sequence is reported to enhance the cellular uptake of 
proteins to which it is attached (Lin et al., 1995). However, a greater degree of 
inhibition was observed in cells pre-treated with the inhibitor Ac-DEVD-CHO 
than with the cell permeable analogue cp-DEVD-CHO, and with a shorter pre­
incubation time. Reversibility studies showed that full caspase-3 activity was 
recovered 6 h following removal of Ac-DEVD-CHO from cells pre-treated with 
the inhibitor. This inhibitor could therefore be used to inhibit the caspase-3 
activity of the expressed fusion proteins, extending the period over which the 
protein could be synthesised without unnecessarily compromising the 
transfected cells’ viability, optimising the amount of protein available for 
translocation. Reversal of inhibition following removal of Ac-DEVD-CHO
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would allow PLCasp3 to act on its natural cellular substrates, and transduction 
could then be quantified.
5.3.3 Generation and Characterisation of PLCasp3-Exnressing Vectors 
Before this could be accomplished it was necessary to generate vectors to 
express PLCasp3 and the MTP fusion proteins. Two systems to co-express 
either EGFP or luciferase with PLCasp3, or the MTP fusion proteins, were 
chosen in order to increase the number of options available for measurement of 
transduction. It was hoped that the presence of PLCasp3 within cells would be 
sufficient to induce apoptosis. Determination of the number of cells in a 
transfected sample exhibiting apoptotic morphologies, but not expressing EGFP, 
would allow quantification of the transduction efficiency of a particular MTP. 
Similarly, measurements of the activity of downstream caspase-3 substrates 
could be normalised between samples by co-expression of luciferase, and 
thereby comparative quantification of the MTPs be undertaken. As a result of 
the feed-back loops existing in the caspase cascade it would even be possible to 
measure the caspase-3 activity of samples as one of the caspase-3 ‘downstream’ 
substrates.
The two co-expression reporters were successfully inserted into the pBI vector, 
and amplification of PLCasp3 from pBI-3K undertaken, and due to the 
restrictive nature of pBI MCS I, with only 3 restriction sites, an additional 
restriction site, Bel 1, had been inserted after the PLCasp3 coding sequence to 
allow the insertion of the MTPs. Sequencing of this vector showed that, though 
the correct coding sequence for PLCasp3 was present, a point mutation had 
destroyed the Bel 1 site, rendering any further subcloning with the vector 
impossible. As the vector pBI-GFP-PLCasp3 was to be termed pSAM2, this 
vector was named mpSAM2.
Correction of the mutation was undertaken by site-directed mutagenesis to 
change the restriction site from a Bel 1 site to an Age 1 site, which would 
simplify further subcloning. Though restriction analysis with Age 1 and 
sequencing of the mutagenesis product showed the mutation had been 
successfully undertaken, activity studies showed transfected cells demonstrated
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neither PLCasp3 activity, nor did they exhibit EGFP fluorescence. Further 
restriction analysis was undertaken, and a Pst 1 RFLP was identified. This site 
is in close proximity to the CMV promoter site that drives expression of inserts 
in MCS II, and to the Tet responsive element for the vector. It appears that a 
deletion mutation in this region has destroyed the ability of the vector to express 
either of the proteins to any measurable degree.
Though the mpSAM2 vector was unsuitable for further subcloning, it was used 
to verify the viability of the pro-less caspase-3 approach for measuring protein 
transduction. To extensively investigate this potential the PLCasp3 sequence 
with the mutated Bel 1 site was excised from mpSAM2 and inserted into pBI-luc 
to generate pBI-luc-PLCasp3, or mpSAM3. This vector was then used to 
confirm the regulation of expression by dox. Regulation of both luciferase and 
caspase-3 activity was substantiated, and the concentration of dox required for 
‘full’ repression of expression was found to be the same as that used in the pBI- 
3K studies. PLCasp3 activity was also found to be inhibited by Ac-DEVD- 
CHO in a similar way to caspase-3 in staurosporine treated cells, whilst 
luciferase activity was unaffected by the inhibitor. As with the studies using 
staurosporine to activate caspase-3, removal of the inhibitor led to return of 
PLCasp3 activity in the transfected samples. In these samples the measured 
PLCasp3 activity was in excess of the levels exhibited by untreated transfected 
cells, as was the luciferase activity. This is probably a consequence of cells 
undergoing apoptosis where PLCasp3 is not inhibited by Ac-DEVD-CHO. As 
the cells expressing PLCasp3 are also expressing luciferase, death of these cells 
would reduce the luciferase activity measured. For samples incubated with Ac- 
DEVD-CHO PLCasp3 activity is repressed until the inhibitor is removed. 
Activity is subsequently recovered and peaks 6 hours following removal of the 
inhibitor. Inhibition of the PLCasp3 actvitity provides a period during which 
cells can produce the protein without being subjected to the protein’s potentially 
lethal effects, enabling these samples to have an activity greater then samples 
where the intrinsically active enzyme is able to carry out its normal function. In 
terms of the MTP-PLCasp3 fusion proteins, this period would allow protein to 
be expressed and translocate to other cells without the integrity of the expressing 
cells being compromised.
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Having demonstrated that the luciferase-PLCasp3 co-expression vector would 
respond to the regulatory agents previously tested the EGFP-PLCasp3 co­
expression vector was examined for expression of the proteins. Cells 
transfected with mpSAM2 exhibited caspase-3 activity, which, like mpSAM3 
transfected cells, was regulated by altering the concentration of dox. The cells 
expressed EGFP as examination by fluorescence microscopy demonstrated. 
Cell counts were not performed to determine if the number of cells exhibiting 
EGFP fluorescence was also regulated by the presence of dox, but as the coding 
gene had been inserted into the same MCS as luciferase this would be expected 
to be so. Examination of the nuclear morphology of EGFP expressing cells 
showed that they demonstrated diffuse chromatin associated with viable cells, 
but also condensation of chromatin associated with cells undergoing apoptosis 
(Kerr et al., 1972). Meergans et al reported that, despite high caspase-3 
activity, only about 15 % of cells transfected with a EGFP-pro-less caspase-3 
co-expression vector showed typical signs of apoptosis-like membrane blebbing 
or chromatin condensation (Meergans et al., 2000). Determination of the 
number of apoptotic cells expressing EGFP in a sample of mpSAM2-transfected 
cells was not undertaken here, but it was apparent that cells expressing EGFP 
were undergoing apoptosis. Even if only a relatively low percentage of cells 
harbouring PLCasp3 undergo apoptosis it may be possible to use this to quantify 
transduction efficiencies for the MTPs.
Summary
Attempts to generate constructs for the expression of an intrinsically active form 
of caspase-3, pro-less caspase-3, in fusion with the MTP sequences proved 
unsuccessful. However, constructs were generated that allowed the expression 
of PLCasp3 with either luciferase or EGFP. These constructs allowed the 
viability of a PLCasp3 approach to quantify protein transduction to be assessed.
Repression of co-expressed luciferase or EGFP with PLCasp3 in HeLa Tet-Off 
cells was possible through the use of dox, and recovery of expression of was 
possible by removing the regulatory antibiotic. The expressed PLCasp3 
exhibited caspase-3 activity, which could be inhibited by treatment of
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expressing cells with the caspase-3 inhibitor Ac-DEVD-CHO. This inhibition 
was reversible, and full activity was observed 6 h following removal of the 
inhibitor. Measurement of luciferase and PLCasp3 activity 24 h post­
transfection showed cells transfected with mpSAM3 demonstrated higher levels 
of luciferase and PLCasp3 activity where PLCasp3 activity was inhibited for 18 
h post-transfection than in untreated samples. This was probably a result of 
PLCasp3-induced apoptosis in the untreated samples. Cells transfected with 
mpSAM2 exhibited both PLCasp3 activity and EGFP fluorescence, with 




CONCLUDING REMARKS AND FUTURE WORK
Gene therapy approaches for the treatment of disease have inherent 
complications associated with the introduction of genetic material into target 
cells. Where a condition does not require prolonged or regulated expression of a 
gene for correction, a realistic approach may be to deliver the gene product 
itself, circumventing a number of the problems associated with gene therapy. 
However, the plasma membrane of the target cells remains a significant 
obstacle, as it is naturally impermeable to peptides and proteins that lack 
specialised membrane receptors or transport proteins. In recent years a number 
of proteins have been reported to possess the innate ability to freely enter cells, 
and further investigation has led to the discovery of short peptide regions from 
some of these proteins, which govern this process. Included in this family are 
two peptide sequences and one full-length protein that have been shown to be 
able to transport a biologically active cargo with them as they travel into cells. 
These are the HIV Tat protein transduction domain (PTD) (Schwarze et al., 
1999), penetratin peptide (Theodore et al., 1995), and VP22 (Elliott and O'Hare, 
1997). The identification of these protein transducing sequences has opened 
new possibilities not only for the study of intracellular functions, but more 
strikingly as a means for delivering trans-gene products to cells for the 
treatment of disease.
With these and other proteins identified as possible vectors for protein delivery 
it is important to have some way by which their transport ability can be 
quantified and directly compared. The work discussed in this thesis focused on 
an investigation to develop a means to quantify the process of protein 
transduction. The three MTPs mentioned above were used as model vectors, 
which would enable the utility of a developed quantitation system to be 
assessed, and also allow comparative studies of the different MTPs to be 
undertaken.
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Although addition of exogenously expressed recombinant proteins would allow 
application of known doses of the MTPs and their cargo to cells, such 
approaches introduce time-consuming and technically demanding components 
to any system developed. As the aim of the study was to develop a means by 
which not only these, but potentially novel MTPs could be quantitatively 
assessed for protein transduction efficiency it was important to develop a system 
where new vectors could be tested with ease. The recombinant approach would 
require protein purification steps, which would require tailoring for each new 
MTP tested. Instead, it was decided that a system of de novo synthesis would be 
employed, whereby cells would be transfected with constructs coding for each 
MTP and a cargo, and spread of the cargo throughout the cells quantified. Such 
a system allows simple introduction of new MTP sequences into the test vector, 
and testing can immediately be undertaken. Further testing using an exogenous, 
recombinant protein approach could be continued once the best candidate MTPs 
had been determined by this approach, limiting the number of samples for which 
purification protocols would have to be determined. As protein therapy would 
perhaps be the ultimate application for protein transduction technology the cargo 
to be examined throughout the course of this investigation was to be full-length 
proteins. By exploring the ability of the MTPs to transport reporter proteins 
between cells, and for the reporter to retain measurable activity, it was hoped 
that the transport would be representative for other proteins including 
therapeutic ones. The three MTPs studied here have all been shown to transport 
numerous cargo molecules, and a recent review covers many of the transported 
cargoes (see Leifert and Whitton, 2003).
The first part of this investigation, discussed in chapter 3, focuses on the use of 
GFP as a reporter for transduction. Three different approaches were employed 
in order to account for factors that may have influenced detection of protein 
translocation, for example denaturation of the protein, dilution of signal through 
diffusion of protein, identification of cells harbouring translocated protein, and 
inefficient transduction. However, with the exception of some apparent limited 
translocation by the TAT-EGFP and Drome-EGFP fusion proteins (figures 3.10 
and 3.11), the approaches failed to confirm the transduction effect observed by 
other groups. A number of studies have been undertaken using GFP as a
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reporter to study protein translocation, most commonly utilising full-length 
VP22 as the transducing peptide (Aints et al., 1999; Brewis et al., 2000; Elliott 
and O'Hare, 1999a; Elliott and O'Hare, 1999b; Lai et al., 2000; Wybranietz et 
al., 1999). However, a number of reports have disputed these findings, with 
Fang et a l initially questioning the findings in 1998 (Fang et al., 1998), and 
recently concerns have been raised that the methods employed to visualise 
protein transduction, focusing on the use of GFP as a reporter in particular, may 
introduce artefactual translocatory effects (Leifert et al., 2002; Lundberg et al., 
2003; Richard et al., 2003). Where fixation was used to analyse fluorescent 
samples a PFA/methanol fixation protocol was followed. Redistribution of 
MTP-EGFP fusion proteins has been identified using fixation with each of these 
agents alone, yet no apparent spread of the fusion proteins throughout the 
sample cells in this study was recognised. There was no need to explore the 
effect of different fixation conditions on the distribution of the fusion proteins as 
no definitive translocation was observed.
As GFP had proved to be an inadequate reporter of protein transduction it was 
necessary to explore other avenues in order to firstly identify the translocation 
process, and to then quantify it. Chapter 4 introduces a novel reporter for 
protein transduction, luciferase. By using this highly sensitive system it would 
be possible to recognise even very minor incidences of translocation, and the 
nature of the assay would allow direct quantification of the process. Constructs 
were successfully generated allowing expression of chimeras of each MTP with 
luciferase, providing the tools with which transduction could be analysed. The 
approach adopted employed a co-culture system, and relied upon having a 
means by which transfected, expressing donor cells could be identified and 
isolated from untransfected recipient cells. Cells constitutively expressing 
EGFP were chosen to act as recipient cells as they would provide a distinctive 
parameter by which transfected, non-fluorescent cells could be sorted and 
removed from the co-culture sample by means of flow cytometry. However, 
when the sorting efficacy of the FACS apparatus was examined it was found 
that, though the cell sample exhibiting high levels of fluorescence intensity was 
enriched following sorting and collection of the cells, there was a high level of 
contamination from cells demonstrating only autofluorescence. In addition the
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sorting procedure was very time consuming, and a large initial sample would 
yield only a relatively low number of assayable cells.
The low number of recipient cells collected, and the potential contamination 
within this sample by donor cells would negate the sensitivity provided by 
luciferase as a reporter using this approach. If the degree of separation of donor 
and recipient cells could be improved, through the use of an alternative flow 
cytometer or alternatively by using a different factor to distinguish and segregate 
the two samples, luciferase provides an attractive system by which 
quantification of protein transduction may be achieved.
A third system for quantification of protein transduction was explored, and 
chapter 5 outlines an approach employing an endogenous protein, caspase-3, for 
this purpose. An intrinsically active pro-less caspase-3 analogue (PLCasp3) 
(Meergans et al., 2000) was used to obviate the requirement of processing 
usually associated with activation of caspase-3. Characterisation of the 
regulation of the vector chosen to express the reporter, and studies into 
inhibition of staurosporine-activated endogenous caspase-3 provided 
information on the most favourable compounds to use. These were tested on 
vectors generated to co-express PLCasp3 with either luciferase or EGFP, and 
both the expression regulator dox, and the caspase-3 inhibitor Ac-DEVD-CHO 
were found to act as expected, providing a means to control the amount and 
activity of expressed PLCasp3. Interestingly, during this work an inhibitor was 
examined that contained a peptide sequence to enhance cellular uptake of the 
molecule, the hydrophobic region of the Kaposi fibroblast growth factor (Lin et 
al., 1995), a type of MTP. This inhibitor was, however, shown to reduce the 
caspase-3 activity around 50 fold less successfully than the same peptide 
inhibitor lacking this sequence.
The PLCasp3 expression vectors characterised in order to assess the viability of 
using this protein as a reporter were not suitable for insertion of additional 
sequences to generate fusion proteins with the MTPs. Attempts to correct the 
mutated restriction site responsible for this were unsuccessful, and so no work 
was undertaken using proteins with any translocatory sequences. However,
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from the constructs produced throughout the course of this part of the 
investigation it would be possible to generate a vector that would allow further 
subcloning to create plasmids for the co-expression of EGFP or luciferase and 
PLCasp3-MTP fusion proteins. The preliminary data obtained from this work 
demonstrate that PLCasp3 has the potential to act as a reporter for protein 
transduction as it possesses an intrinsic activity. Under normal culture 
conditions active caspase-3 is synonymous with apoptosis, and this well-defined 
process should provide a means to quantify the transduction ability of MTPs 
using PLCasp3 as a reporter. By generating constructs that allow the expression 
of the PLCasp3-MTP fusion proteins it would be possible to test this using the 
data presented here to control the activity of the protein.
Of the three approaches developed to assess protein transduction, successful 
investigation of the process was only possible using EGFP as a reporter. In 
contrast to many early reports on protein transduction (Aints et al., 1999; Brewis 
et al., 2000; Elliott and O'Hare, 1999a; Elliott and O'Hare, 1999b; Lai et al., 
2000; Wybranietz et al., 1999), but in agreement with more recent ones (Leifert 
et al., 2002; Lundberg et al., 2003; Richard et al., 2003) no definitive evidence 
of protein translocation was identified for any of the MTPs tested. Using 
luciferase as an active reporter was a novel approach, and the biological tools 
now exist to study this. However, the equipment available at the time of the 
investigation hindered the approach. If more suitable apparatus becomes 
available than this system is a very real means by which protein transduction 
could be quantified. In contrast to this, the final approach was impeded by 
difficulties in generating the constructs to test. All of the components necessary 
for creation of the constructs now exist - through digestion of mpSam2 or 
mpSam3 it would be possible to remove the PLCasp3 element, and this could be 
replaced by the PLCasp3 element from the mpSAM2 mutagenesis product, 
which has an intact Age I site, and would therefore permit future insertion of 
MTP sequences. The activity exhibited by the mutated PLCasp3 expression 
vectors, and control with which PLCasp3 expression and activity can be 
moderated by dox and Ac-DEVD-CHO, demonstrate that there is potential for 
this system to be utilised in an attempt to study protein transduction efficiencies.
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Whether protein transduction is a noVel system by which protein can gain access 
to the intracellular environment or not, the evidence suggests that proteins can 
be successfully delivered to cells using the protein transduction sequences (see 
chapter 1.3 for pharmacological evidence). As such it is necessary to investigate 
lead sequences to understand and improve factors influencing the process. A 
method is required by which comparative quantification of protein transduction 
mediated by MTPs can be undertaken. The biological tools for a novel 
approach using luciferase now exist, and a second methodology using pro-less 
caspase-3 has been characterised. In the future this knowledge may provide a 
means by which these essential comparisons can be carried out.
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Abstract: Protein translocation domains: an investigation of the
influence of VP22, Penetratin, and HIV Tat translocation peptide fusion 
constructs on translocation of enhanced green fluorescent protein (EGFP).
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Calibration Curve for Soluable Protein Content of Cell Extract 
Calibration curve for protein concentration by Bradford assay using bovine 
serum albumin (BSA) as a standard. A one to ten dilution of a 10 mg/ml stock 
solution of BSA (New England Biolabs) was prepared and 100 pi samples were 
prepared in Milli-rho water containing 0, 4, 8, 12, 16 and 20 pg of protein. The 
following is representative of the linear regression analyses obtained:














1 Phosphorylation and Annealing of Insert DNA
DNA inserts were constructed from complementary single stranded 
oligonucleotides purchased from Sigma Genosys, UK, on a 3 OD scale. The 
oligonucleotides were annealed prior to annealing using the following reaction 
mix:
DNA oligonucleotide (100 pmol/pl) 1 p,l
ATP, 100 mM (Boehringer) 1 pi
Kinase lOx buffer 4 pi
T4 Polynucleotide Kinase (lOU/pl) 1 pi
Nuclease free water up to 40 pi
The mix was incubated at 37 °C for 2 hours. Following incubation the two 
complementary strands were combined in a single tube and the tubes placed in a 
500 ml beaker containing water. The water bath was heated to boiling and held 
at this temperature for 2 minutes. The water bath was then placed on ice and 
allowed to cool to 30 °C. The insert DNA was then ready for insertion into the 
desired vector.
2 Polymerase Chain Reaction
Polymerase chain reactions (PCRs) for the amplification of VP22 and PLCasp3 
were undertaken using ReadyMix Taq PCR reaction mix (Sigma Aldrich, UK), 
according to the manufacturers instructions. The primers and specific 
conditions for the amplification reactions are detailed in the respective chapters.
3 Site-Directed Mutagenesis
Site-directed mutagenesis of the mpSAM2 vector was undertaken using the 
QuikChange Site-Directed Mutagenesis kit (Stratagene, UK) according to the 
manufacturers instructions. The primers used for the reaction are detailed in 
chapter 5.
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4 Restriction of DNA using Restriction Endonucleases
Plasmid DNA restrictions were performed using New England Biolab (NEB) 
restriction enzymes. One of the two following reaction mixes was used for 
digests. The first mix was used if the restriction enzyme had been shown to 
exhibit ‘star’ activity. The second reaction mix was used if there was no ‘star’ 
activity associated with the enzyme of choice.
Reaction Mix 1
pDNA 1 |ig
Buffer (1 Ox) 3 |iil
Milli-Q water up to 30 pi
Restriction enzyme 1 in 3 dilution (normally 10 U/pl) 1 pi
Reaction Mix 2
pDNA 1 pg
Buffer (1 Ox) 3 pi
Milli-Q water up to 30 pi
Restriction enzyme (normally lOU/pl) 2 pi
The restriction enzyme was always added last to the reaction. The reaction tube 
was then mixed by ‘flicking’ and the contents collected at the bottom of the tube 
by a quick spin-down in a microcentrifuge. The reactions were carried out at 37 
°C for three hours. Rather than use temperature or EDTA to stop the reaction in 
most cases the digested DNA was simply ethanol precipitated. Double digests 
were never used; instead the DNA was sequentially digested with an ethanol 
precipitation stage between the two digests. Restriction was confirmed by 
adding 2 pi loading buffer to 3 pi of digest and making up to 15 pi with water. 
This was then loaded on a 1 % agarose gel alongside undigested vector and a 
ladder. The gel was run at 90 V for 90 minutes. Where larger quantities of 
DNA were required the above reactions were either scaled up or altered to 
include more DNA in the reaction. However, a high ratio of restriction enzyme
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to DNA was always maintained to ensure that the presence of undigested vector 
following the digestion reaction was minimalised.
5 Purification of DNA by Ethanol Precipitation
One tenth of the reaction volume of 3 M Sodium Acetate, pH 7.0, and two 
reaction volumes of ice cold 100 % ethanol were added to the reaction solution 
and mixed by vortexing briefly. The solution was incubated for one hour at 
-20 °C and centrifuged for 15 minutes at 4 °C. The supernatant was removed by 
pipetting, and 200 pi of 70 % ethanol was added. The sample was centrifuged 
for 5 minutes at 4 °C and the supernatant was removed. Washing was repeated 
and the DNA pellet air dried for 15-20 minutes. The purified DNA was 
dissolved in the desired volume of Milli-Q water.
6 Ligation
The concentration of the vector DNA was estimated by running an aliquot (the 
volume was dependant on the final volume in which the DNA was eluted using 
the purification kit) of the gel-purified DNA on a 1 % agarose gel alongside a 
known standard. A volume between 3 and 7 pi was used in each ligation 
reaction. The ligation reaction mixture was as follows:
Vector DNA
Insert DNA/annealed oligonucleotides 
Ligase lOx buffer 
Milli-Q water up to 
T4 DNA ligase (Boehringer 1 U/pl)
Two controls were included in every ligation:
1. Plasmid, no insert DNA, no enzyme, buffer, Milli-Q water
2. Plasmid, no insert DNA, plus enzyme, buffer, Milli-Q water
The reaction mixes were incubated under one of the following conditions:
1. 4 °C overnight (16 hours)







3. Room temperature for 2 hours, followed by 37 °C for 2 hours
No single condition worked for every ligation, and a number of conditions were 
generally tried for each before successful ligation. The ligated DNA was 
transformed into JM109 cells using the protocol below and the entire ligation 
mix. In addition to the tubes of competent cells for each of the ligations two 
additional controls were added. The first, a negative control, involved 
transformation with no DNA, just water, and the second, a positive control, 
involved transformation using the original unrestricted vector.
7 Preparation of Competent E. coli JM109 Cells 
Tfbl Buffer
30 mM KC1 3 ml of 1 M stock
lOOmMRbCl 1.209 g
10 mM CaCh 12.5 ml of 80 mM stock
50 mM MnCb 5 ml of 1 M stock
15 % (v/v) Glycerol 15 ml
Water to 100 ml
Adjust to pH 5.8 with 0.2 M Acetic acid. And filter sterilise.
Tfbll Buffer
10 mM MOPS 0.209 g
75 mM CaCl2 1.100 g
lOmMRbCl 0.121 g
15 % (v/v) Glycerol 15 ml
Water to 100 ml
Adjust to pH 6.0 with 1 M KOH and filter sterilise.
A single colony of E. coli JM109 was picked from a fresh agar plate and 
inoculated into 10 ml of LB medium and incubated at 37 °C overnight in a 
shaking incubator. The following morning, 1 ml of the culture was used to 
inoculate 100 ml of LB medium and this culture was grown under standard 
conditions until the optical density (ODssonm) of the solution reached 0.48 (about
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2-3 hours). The cell suspension was then chilled on ice for 5 minutes and 
centrifuged in sterile Greiner tubes for 5 minutes, 6000 rpm (Beckman J2-MC) 
at 4 °C. The supernatant was discarded and each of the two pellets re-suspended 
in 20 ml Tfbl buffer and chilled on ice for 5 minutes. The cells were centrifuged 
as before and the supernatant discarded. The cells were subsequently re­
suspended in 2 ml Tfbll buffer and chilled on ice for 15 minutes. The 
suspensions were then mixed by vortexing and 300 pi aliquots distributed into 
1.8 ml cryotubes. The cells were snap frozen in a dry-ice/ethanol bath and 
stored at -80 °C until required.
8 Transformation of Competent E. coli JM109 Cells
Competent cell suspensions were thawed on ice, and 100 |il added to each 
ligation mixture, 2 pi unrestricted plasmid (positive control) or to 2 pi water 
(negative control). Cells were mixed by gentle pipetting using a Gilson pipette 
tip followed by incubation on ice for at least 30 minutes. The cells were 
shocked by incubating at 43 °C for 45 seconds and then returned to ice for 2 
minutes. The cell suspension was transferred to 1 ml LB medium and incubated 
at 37 °C for 90 minutes. After this time 200 pi was plated out on a LB-plate 
containing ampicillin at a concentration of 125 pg/ml. Plates were incubated at 
37 °C overnight.
9 Colony Picking and Small Scale Plasmid Purification
After checking the controls, a sterile Gilson pipette tip was used to transfer 
single colony forming units from the LB plates into 3 to 5 ml LB medium 
containing the appropriate antibiotic. The cultures were incubated at 37 °C 
overnight in a shaking incubator. The next morning the 1.5 ml of this culture 
was transferred to a sterile microcentrifuge tube and centrifuged at 13,000 rpm 
for 5 minute in a MicroCentaur (MSE, UK). The supernatant was decanted 
from the tube, so as not to disturb the cell pellet. The plasmid DNA was 
isolated from the pellet using the Wizard Plus SV Minipreps DNA Purification 
System and Vac-Man vacuum manifold (Promega, UK) according to the 
manufacturers instructions. The miniprep DNA samples were then screened
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using restriction digest followed by gel electrophoresis. If required, samples 
were stored at -20 °C.
10 Horizontal Agarose Gel Electrophoresis
Routinely, 1 % agarose gels were produced by dissolving 1 g electrophoresis 
grade agarose (Gibco BRL, UK) in 100 ml lx TAE buffer (0.04 mM Tris- 
acetate, 0.01 M EDTA) at a high temperature in a microwave oven. The 
solution was cooled to about 60 °C, 4 jllI ethidium bromide added and the gel 
poured into a casting tray and allowed to set at room temperature for about 30 
minutes. The gel tray was then mounted in an electrophoresis tank (BioRad, 
UK) and submersed in lx TAE. Electrophoresis was carried out at 90 V for 
sufficient time to produce separation of bands (normally 90 minutes). All gels 
were run with suitable ladders. The DNA bands were visualized using a UV 
transilluminator. Photographs were taken using a Polaroid MP4 camera and 
Polaroid 637 film.
11 DNA Preparation from Agarose Gel
DNA bands on an agarose gel were visualised on an UV transilluminator. The 
desired band(s) was (were) excised from the gel using a stainless steel razor 
blade. Each sample was weighed and the DNA isolated using the Qiaex II DNA 
Extraction Kit (Qiagen, UK) following the manufacturer’s instructions. DNA 
was eluted with either TE buffer, pH 8.0, or Milli-Q water, pH 8.0, and stored at 
-20 °C.
12 DNA Sequencing
DNA sequencing was carried out at the automated DNA sequencing facility in 
the Department of Biology and Biochemistry, University of Bath using d- 
Rhodamine terminator dye chemistry (labelled dNTPs) and FS Taq polymerase 
(PE Applied Biosystems). The ABI377 DNA sequencer and cycle sequencer 
used were both from PE Applied Biosystems. The DNA samples for sequencing 
were supplied in 200 pi PCR tubes and contained 3 pi of miniprep DNA (200- 
500 ng) template, 10 pmol of primer and were made up to 6 pi with Milli-Q 
water.
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The sequencing primers used for sequencing of oligonucletides and the VP22 
PCR product inserted into pSAMl, and for confirming insertion of PLCasp3 
into pBI-GFP (and checking the mpSAM2 mutagenesis product) are shown in 
the table below:
Primer name Primer sequence
pSAMl sequencing primer 5 ’ -CCC ACT gCTT ACT ggC-3 ’
pSAMl reverse sequencing primer 5 ’-gC AgTTCTCTCCAgCgg-3 ’




The 1 kb GeneRuler ladder (Fermentas, UK) was run for about 90 minutes 
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